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Neuronal maturation requires precise gene regulation to trigger pro-survival 
pathways for proper neuronal structure and function. Amongst the numerous 
types of brain cells, the neurons are crucial for synaptic transmission and 
hence brain function, but are also the most vulnerable. Hence, ischemic stroke, 
which cuts off the supply of oxygen and nutrients to an area of the brain, 
causes rapid dysregulation of neuronal function, leading to neuronal death and 
loss of brain function.  This accounts for severe morbidity and high mortality. 
There is currently only one approved therapy for the treatment of ischemic 
stroke, recombinant tissue plasminogen activator, but its use is limited. 
Therefore, there is an urgent need to explore for other neuroprotectants that 
can salvage neurons post-ischemia. The endogenous regulators of gene 
expression, long non-coding RNAs and microRNAs, could serve therapeutic 
potential by preventing pro-apoptotic dysregulation of gene expression after 
ischemic injury. It was hypothesized that non-coding RNA profiles during 
neuronal differentiation and survival would be altered upon exposure to 
ischemic injury, which would allow identification of a neuroprotective non-
coding RNA. To identify neuroprotective non-coding RNAs, it was imperative 
that primary neuronal cultures with the highest purity be used. Hence, the 
optimal embryonic day to harvest mouse cortices was determined to achieve 
pure neuronal cultures for the study of neuronal maturation and ischemic 
injury. After having established a primary neuronal culture comprising pure 
post-mitotic neurons, expression profiling of coding (messenger RNA) and 
regulatory non-coding (long non-coding RNAs and microRNAs) RNAs was 
carried out in maturing neurons and neurons subjected to ischemic insult. This 
 xviii 
 
served to elucidate genes and their associated regulatory non-coding RNAs 
crucial to neuronal survival but dysregulated during ischemic injury. Of the 
genes identified, neuronal growth regulator 1 (Negr1), a neurite-outgrowth 
promoting, cell adhesion molecule, and its associated non-coding RNAs 
displayed the most pronounced changes during neuronal maturation and 
ischemia. Hence, these were followed-up to characterize the associated long 
non-coding RNAs and microRNAs and determine their effects on Negr1 gene 
expression as well as neuronal structure and function. It was found that the 
expression of Negr1 was co-regulated by both non-coding RNAs for precise 
expression during neuronal development. Furthermore, dysregulation of their 
expression during ischemia contributed to neuronal cell death. Another 
molecule found to be crucial to neuronal development but altered in ischemic 
injury was the truncated isoform of tropomyosin receptor kinase B (TrkB T1), 
a negative regulator of the pro-survival, brain-derived neurotrophic factor 
signalling pathway. Hence, the use of microRNAs as post-transcriptional 
regulators of TrkB T1 and potential neuroprotectants in ischemia were 
explored. Furthermore, since TrkB T1 is derived as a splice variant of the 
neurotrophic tyrosine kinase receptor, type 2 (Ntrk2) gene, the possibility of 
microRNAs regulating alternative splicing was also investigated. Therefore, 
this study provides evidence of non-coding RNAs that could serve as potential 
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1.1 The brain  
The nervous system controls all sensory and motor functions of the body [1]. 
Its master control is the brain which is responsible for analysis and integration 
of sensory and motor information from the surroundings to instigate a 
response [1]. These complex operations of the brain depend on intricate and 
precise interconnections between billions of neurons, the basic functional unit 
of the nervous system [1,2]. 
 
Brains of different species vary greatly in size and shape [3]. The human brain 
has a mass of about 2,700 times greater than that of the mouse brain [4] 
(Figure 1.1). The increased size particularly affects the cerebral cortex, the 
largest brain structure and base of most higher cognitive functions [5]. The 
cortex is smooth in rodents, but comprises convoluted folds in humans  
(Figure 1.1), allowing more cortex to squeeze into the limited volume of the 
head [4,5]. Cerebral sections show that there is a relative small increase in the 
thickness of the cortex compared with the large increase in surface area that 
results in an approximately 1000 fold increase in surface area (Figure 1.1) [6]. 
This highly elaborate human cerebral cortex contributes to the extraordinary 
human cognitive abilities [4,6]. Nevertheless, the cerebral cortex does not 
function alone - it is closely interconnected with subcortical structures that are 
well conserved across mammalian species. The brains of vertebrates have a 
common structural organization comprising of the cerebral hemispheres, 
midbrain, cerebellum, pons and medulla. Among mammals, the neural 
structures within these divisions and the circuits that interconnect them have 
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distinct similarities. Furthermore, there are many fundamental physiological 




Figure 1.1: The mouse and human brain. In the top panel, the cerebral 
hemispheres of a mouse and a human brain are drawn to approximately the 
same scale to convey the overall difference in the size of the cerebral cortex in 
these species. The human brain has a mass approximately 2,700 times greater 
than that of the mouse brain and has convoluted folds of an extensive cerebral 
cortex that distinguish the human brain from the mouse brain. In the middle 
panel, diagrams of cerebral sections are shown for these species to illustrate 
that there has is a relative small increase in the thickness of the cortex (dark 
purple outline) compared with the large increase in surface area (1: 1000 X in 
mouse and human, respectively). The last panel shows the subcortical 
structures that are well conserved across mammalian species. Figure is 
adapted from Rakic et al. and Cryan et al. [4,6] with modifications. 
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1.1.1  The neocortex 
The neocortex is the outer covering of the cerebral hemispheres unique to 
mammals and responsible for higher cognitive function such as sensory 
perception, speech and spatial reasoning [7,8]. The neocortex is comprised of 
a six-layered structure whereby each layer possesses a specific cell density and 
neuronal morphology [9,10]. Neurons in each layer must form appropriate 
connections with other neurons within the layer as well as with cells in other 
layers and distal parts of the brain [11]. Proper neocortex function is therefore 
dependent on timely production and positioning of neurons during 
development [12].  
 
1.1.2  Cortical neuronal development 
A tightly regulated, multi-step neurogenesis process is required to achieve the 
6-layer cortical structure with a large, integrated neural network. During 
neurogenesis, neural stem cells proliferate, differentiate, and thereafter mature 
to give rise to a neuronal morphology and fully functional neurons [13]. At the 
same time, neurons in each part of the brain form appropriate connections with 
other neurons in both proximal and distal parts of the brain [11].  
 
The developing mouse telencephalon is composed of a pseudostratified layer 
of neuroepithelial cells, also known as neural progenitors, that line the lateral 
ventricle, known as the ventricular zone (VZ; Figure 1.2) [9]. During 
neurogenesis, various subtypes of projection neurons are generated 
sequentially through consecutive asymmetric divisions of neural progenitors 
[14]. Neurons destined for the marginal zone, a cell sparse layer identified as 
 4 
 
L1 (Layer 1) of the postnatal cortex [9], and the subplate are generated first 
(Figure 1.2). This is followed by generation of neurons destined for L6 and 
L5, and then formation of the upper layers, L4, L3 and L2 [14]. Therefore, the 
cortical layers are sequentially generated in an ‘inside-out’ fashion [9,14]. 
During migration to establish the 6-layered structure, neurons mature to give 
rise to their characteristic neuronal phenotype (Figure 1.2) [15]. Immature 
post-mitotic neurons mature by developing axonal projections to targets, 
extending their dendrites, forming synapses and releasing neurotransmitters 






Figure 1.2: Projection neuron generation and migration from progenitors located in the VZ and SVZ of the mouse neocortex. To form 
the 6 layers of the cerebral cortex, various types of projection neurons are generated sequentially through proliferation and asymmetric divisions 
of neural progenitors in the VZ and SVZ. These then move out to the different layers during development. Neurons destined for layer 1 (L1, 
marginal zone) and the subplate (SP) are generated first. This is followed by formation of L6, L5, L4, L3 and L2. During the migration process, 
these progenitors differentiate into neurons. Maturation processes such as axonal projection, dendritic extension and synaptogenesis cause 
immature postmitotic immature neurons to become mature mitotic neurons. VZ: ventricular zone, SVZ: subventricular zone, PP: preplate, SP: 







1.1.3  Neuron structure and function  
Santiago Ramón y Cajal, the “father” of neuroscience and Nobel Prize winner, 
was the first to propose in the late 19th century that the neuron is the basic 
anatomical and physiological unit of the nervous system [2]. He was also the 
first to describe neurons as polarized cells with distinct inputs (dendrites) and 
an output (axon) extending from opposite poles of a cell body, known as the 
soma (Figure 1.3) [17]. This became known as the neuron doctrine [2,17,18].  
 
The soma comprises the nucleus where all neuronal proteins and membranes 
are synthesized [19]. Some proteins are also synthesized in dendrites, but none 
are made in the axon. Usually, a neuron has one axon which originates from 
the axon hillock as a thread and can range from a length of 1 µm to 1 m or 
even longer so that signals can be transmitted over long distances (Figure 1.3) 
[1,18,19]. Axons mediate conduction of an action potential, a type of electric 
impulse, away from the cell body and in the direction of the axon terminus. An 
action potential is characterized by a spike in electric potential across the 
plasma membrane. Following depolarization of the membrane, rapid 
repolarization occurs which returns the membrane potential to the resting 
value. The action potential begins at the axon hillock and moves down the 
axon into the axon terminals which are small branches of the axon that form 
synapses (cell-cell junction) with other cells (Figure 1.3) [1,18,19]. One axon 
can synapse on dendrites of several neurons and trigger a response in all them 




Neurons usually possess multiple dendrites, with complex branches, that 
receive chemical signals from the axon termini of neighbouring neurons 
(Figure 1.3). These chemical signals are converted to electric impulses which 
are transmitted towards the cell body [19]. In addition to dendrites, synapses 
can also be formed with cell bodies. Electric impulses generated in the 
dendrites or cell body spread to the axon hillock, which, if sufficient, can 
result in an action potential that moves down the axon and is passed on to 
adjacent neurons (Figure 1.3) [19].  
 
Neurons therefore communicate by transmitting electrochemical signals via 
the synapse (cell-cell junction) that is formed between long projecting axons 
and highly branched dendrites (Figure 1.3) [2]. The number of synapses of a 
single neuron varies between 1 to about 100 000 [1], which indicates the 
complexity of the human brain. Signal transmission at the synapse occurs only 
from the axon terminus of the presynaptic cell to the postsynaptic cell which 
can be a dendrite or cell body of another neuron (Figure 1.3) [19]. Upon 
arrival of an action potential in the axon terminal of the presynaptic cell, 
localized calcium levels in the cytosol rise. This triggers the fusion of 
neurotransmitter filled vesicles with the plasma membrane, causing the release 
of neurotransmitters into the synaptic cleft, the space between the cells. The 
neurotransmitters diffuse across the synaptic cleft and bind to receptors on the 
postsynaptic cell [19]. This causes alterations in the ion permeability of the 
postsynaptic membrane, which mediates changes in the membrane’s electric 
potential. Generation of this electric disturbance in a neuron might induce an 
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action potential whereas in the case of a muscle, the change in membrane 
potential may cause contraction [19]. 
  
Timely formation of these neuronal structures during neuronal maturation 
coupled with modulation of neurotransmitter sensitivities and myelination 
determines neuronal connections with extraordinary precision [20-23]. 
Synaptic and neuronal pruning is also part of this delicate process to remove 
extra synapses and neurons, thereby, refining mature neuronal networks. 
These culminate into a large, integrated neural network of synapses with 


























Figure 1.3: Schematic representation of a neuron and detailed view of the 
synapse. The arrow indicates the direction of conduction of action potential in 
the axon which originates at the axon hillock. The neuron has multiple 
branched dendrites that receive signals at synapses made with neighbouring 
neurons. A single axon also branches laterally and at its terminus. At the 
synapse, the plasma membrane of the presynaptic and postsynaptic cell is 
separated by a narrow space called the synaptic cleft.  Transmission of electric 
impulses requires the release of neurotransmitters (red circles) from synaptic 
vesicles by the presynaptic cell, diffusion across the synaptic cleft, and 
binding to specific receptors on the plasma membrane of the postsynaptic cell. 










1.1.4  Neuronal dysfunction in ischemic injury  
Amongst the many cells in the brain, the neurons are crucial for synaptic 
transmission and hence brain function. However, neurons are also more 
vulnerable than glial cells to ischemia, hypoxia or hypoglycemia, with the 
cortex and cerebellum being affected to a greater extent than the brainstem 
[24]. This is attributed to their high energy requirement and mitochondrial 
activity, dependence on long-distance axonal transport and large surface area 
for increased exposure to toxicants in the extracellular environment [25]. 
Moreover, the problem is aggravated by no direct access to blood-borne fuels, 
and most importantly, the lack of energy storage [26]. Therefore, depletion of 
vital nutrients to an area of the brain for a minute period of time causes 
dysregulation of neuronal function resulting in neuronal cell death and loss of 
brain function. This accounts for the severe morbidity and high mortality 
observed in cerebrovascular diseases such as ischemic stroke, the focus of this 
thesis. 
 
Stroke occurs when a blood vessel that carries oxygen and nutrients to the 
brain is either blocked or ruptured [27]. Eighty seven percent of stroke cases 
are due to ischemic stroke whereas the remaining are a consequence of 
hemorrhagic stroke [28]. The occluded region of the brain can be segmented 
into the core and the penumbra regions (Figure 1.4). Within the core region, 
the primary neurons die rapidly by necrosis [29]. Neurons in the penumbral 
region undergo apoptosis either due to early events like excitotoxicity and 
acidosis or late stage events in favour of apoptotic gene expression (Figure 
1.4) [30,31]. This chain of downstream events triggered by a perfusion deficit 
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is known as the ischemic cascade [31,32]. This results in loss of activity and 
function which is controlled by the affected region of the brain.  
 
There are two therapeutic approaches used to treat ischemic stroke upon onset, 
insult limitation and neuroprotection [33]. Insult limitation involves removing 
the blood clot as soon as possible. This is mediated by recombinant tissue 
plasminogen activator (rt-PA), currently the only approved treatment for acute 
ischemic stroke therapy. However, its use is limited due to the risk of cerebral 
hemorrhage and the narrow therapeutic window of 4.5 hours [34]. This limited 
time frame results in only less than 5% of stroke patients being eligible for 
treatment upon arrival in the hospital  [35]. The second therapeutic approach, 
neuroprotection, is aimed at salvaging or protecting the neurons in the 
penumbral region by arresting any stage in the ischemic cascade to minimize 
the effect of ischemic stress and prevent the neurons from progressing to 
apoptosis [29,36]. Several different types of neuroprotectants targeting the 
processes in the ischemic cascade have shown therapeutic potential in 
preclinical trials, such as calcium antagonists, glutamate antagonists, AMPA 
antagonists, glutamate modulators, free radical scavengers, anti-inflammatory 
agents, membrane stabilizers, apoptosis inhibitors and hypothermia. However, 
the positive results could not be replicated in clinical trials [36]. The most 
recent example is that of NXY-059, a free-radical scavenger, which showed 
promise as a therapeutic agent in phase I trials [37]. However, follow-up trials 
and analyses showed lack of efficacy and an inability of the drug to cross the 




Therefore, there is an urgent need to explore for other therapeutic targets to 
arrest the ischemic cascade in the penumbra for stroke therapy [39]. Recently, 
it has been reported that genes are dysregulated during ischemia injury which 
could contribute to cell death [40]. Identification of these genes can provide a 
better understanding of the pathways involved in cell death and hence, 
pinpoint potential targets for stroke therapy [41]. In addition, exploiting 
intrinsic neuroprotective mechanisms could prove to be effective with less 
likelihood of adverse effects as compared to synthetic drugs.  
 
1.1.5 Potential mechanisms of neuroprotection  
To identify gene targets for neuroprotection, it is first necessary to determine 
the survival mechanism of normal maturing neurons. Molecules crucial for 
neuronal survival and their dysregulation during ischemic injury would 
identify the most promising targets for manipulation for neuroprotection.  
 
1.1.5.1  Restriction of apoptotic pathway 
In the fully developed nervous system, the long term survival of post-mitotic 
neurons is imperative for proper function throughout an organism’s life.  
Furthermore, given their limited regenerative potential, neurons cannot afford 
to be vulnerable to apoptosis. Therefore, the cell death pathway is tightly 
regulated during the neuronal maturation process [42]. Neurons utilize 




Figure 1.4: Brain damage during ischemia and the ischemic cascade. During ischemia, blockage of a blood vessel results in a perfusion 
deficit which causes neurons to die rapidly by necrosis in the core region. Surrounding this, neurons in the penumbral region undergo apoptosis 
either due to early events like excitotoxicity and acidosis or late stage events in favour of apoptotic gene expression. This chain of downstream 
events triggered by a perfusion deficit is known as the ischemic cascade. This results in loss of activity and function which is controlled by the 










The typical mitochondrial intrinsic pathway of apoptosis is triggered by mixed 
lineage kinase (MLK) and c-Jun N-terminal kinase (JNK) proteins which 
phosphorylate the c-jun transcription factor (Figure 1.5) [42]. This induces the 
transcription of pro-apoptotic members of the Bcl-2 homology 3 (BH3)-only 
family of proteins such as Bim, resulting in the activation of pro-apoptotic 
BAX protein. Oligomerization of BAX results in translocation to the outer 
mitochondrial membrane, mitochondrial permeabiliation and release of 
cytochrome c from the mitochondrial intermembrane space. Cytochrome c, 
with apoptotic protease activating factor-1 (Apaf-1) and caspase-9, forms the 
apoptosome complex which cleaves and activates caspase-3, which in turn 
cleaves other cellular targets, causing cell death (Figure 1.5) [42].  
  
To reduce apoptotic susceptibility of neurons, every step of the intrinsic 
mitochondrial pathway is restricted. The availability of pro-apoptotic proteins 
is firstly reduced. This is mediated by repressing the induction of several BH3-
only pro-apoptotic proteins at once by increasing expression of their common 
inhibitor, microRNA-29 [43]. Secondly, BAX protein remains cytoplasmic in 
mature neurons [44] and Apaf-1 expression is also repressed [45]. Finally, 
caspase-3 levels are significantly reduced in mature neurons [46]. Hence, 
implementation of apoptotic brakes at several points along the apoptotic 
pathway results in favourable survival of mature neurons [42].  
 






Figure 1.5: Intrinsic mitochondrial pathway of apoptosis in immature 
developing neurons. Apoptosis is triggered by mixed lineage kinase (MLK) 
and c-Jun N-terminal kinase (JNK) proteins which phosphorylate the c-jun 
transcription factor. This induces the transcription of pro-apoptotic members 
of the Bcl-2 homology 3 (BH3)-only family of proteins, resulting in the 
activation of pro-apoptotic Bax. Bax oligomerizes and translocates to the outer 
mitochondrial membrane, making it permeable. Cytochrome c is released from 
the mitochondrial intermembrane space, which with apoptotic protease 
activating factor-1 (APAF-1) and caspase-9, forms the apoptosome complex. 
This complex then cleaves and activates caspase-3, which in turn cleaves other 
cellular targets, causing cell death. Figure is adapted from Kole et al. [42] with 











However, during neuronal injury or neurodegeneration, restriction of these 
apoptotic mechanisms is lost, causing mature neurons to resemble their 
immature phenotype [42]. Likewise is observed in ischemic injury during 
which neuronal gene expression is dysregulated [34,47].  Hence the ability to 
salvage neurons during ischemic injury, or neuroprotection, can be achieved 
by identifying genes important for neuronal maturation, but dysregulated 
during ischemic injury. The dysregulation of the target genes could be 
prevented and even reversed to bring about a favourable outcome. 
 
1.1.5.2 Neurotrophins 
In addition to restriction of apoptotic pathways during neuronal maturation, 
the maturation process itself is mediated by neuron-specific molecules. The 
most important and well-characterized molecules that regulate neuronal 
survival, development and function belong to a family of growth factors 
known as neurotrophins [48-51]. Four neurotrophins have been described till 
date, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) [48]. Amongst these, 
BDNF and its receptor, TrkB, are the most highly expressed in the cerebral 
cortex and hippocampus [52]. 
 
Administration of BDNF immediately or days after ischemia has been 
reported to confer neuroprotection [53]. Conversely, inhibition of BDNF 
activity exacerbates ischemia [54]. However, systemic administration requires 
very large amounts of BDNF, with repeated peripheral administration 




enters the brain and the range of adverse effects after administration of high 
doses and continuous delivery have yet to be determined in animal models 
[55]. Hence, alternative means of triggering the pro-survival pathway 
downstream of BDNF post-ischemia need to be explored.  
 
BDNF mediates its biological effects by binding to the full length TrkB 
receptor (TrkB FL) which results in dimerization and auto-phosphorylation at 
tyrosine residues in the cytoplasmic kinase domains [56]. These activate 
mitogen-activated protein kinase/extracellular signal-regulated protein kinase 
(MAPK/ERK), phospholipase Cγ (PLCγ), and phosphoinositide 3-kinase 
(PI3K) pathways [57] that promote differentiation, neuronal survival as well 
as regulate neuronal structure and function in developing and mature nervous 
systems [58].  
 
In addition to the full-length isoform (TrkB FL) encoding the active receptor, 
alternative splicing of the neurotrophic tyrosine kinase receptor, type 2 (Ntrk2) 
gene yields a truncated receptor, TrkB T1. TrkB T1 lacks the kinase domain 
and negatively modulates the activity of TrkB FL [59]. TrkB FL is present 
only in neuronal cells while TrkB T1 is present in both neuronal as well as 
non-neuronal cells such as astrocytes and oligodendrocytes [60,61]. The 
expression of each isoform is also specifically regulated during development 
[52,62,63]. TrkB FL is expressed from the early development period of the 
central nervous system and is maintained into adulthood. On the other hand, 
TrkB T1 is expressed at a very low level in the early and mid developmental 




TrkB T1 level then remains constant throughout adulthood. Interestingly, the 
increased expression of TrkB T1 takes place with down-regulation of BDNF 
expression and correlates with axonal and synaptic pruning, the elimination of 
excessive synapses [52].  
 
The homeostasis of the TrkB FL and TrkB T1 isoforms is crucial to neuronal 
survival [62]. During ischemic injury, excitotoxicity perturbs this balance by 
reducing TrkB FL expression and increasing TrkB T1 expression, resulting in 
neuronal death [64,65]. TrkB T1 therefore acts as a dominant inhibitor of the 
neuroprotective TrkB FL-BDNF signalling cascade [64-66]. It has also been 
reported that transgenic mice overexpressing TrkB T1 in neurons showed 
significantly larger infarct upon ischemic injury [67]. In addition,                  
Fryer et al.[68] reported that up-regulation of TrkB T1 on astrocytes following 
lesions in the central nervous system sequesters BDNF at the site of reactive 
gliosis. This prevents regeneration of axons from TrkB FL expressing neurons 
by depleting BDNF from the region. Thus, blocking the induced expression of 
TrkB T1 during ischemic injury could be a therapeutic approach to mediate 
neuroprotection by facilitating BDNF:TrkB FL pro-survival signaling.  
 
1.1.5.3 Cell adhesion molecules 
Another family of molecules important to development of neuronal circuits are 
the neurite-associated members of the immunoglobulin (IgLON) super family, 
the cell adhesion molecules [69]. These molecules mediate connections 
between presynaptic and postsynaptic neurons for axonal extension, neuronal 




Communication between neurons provide proper growth signals to the axon 
which then mediate downstream survival and maturation signals to the 
neuronal cell body [72-74]. There are 4 well-characterized IgLON proteins 
belonging to this superfamily, LAMP (limbic system-associated membrane 
protein), OPCML/OBCAM (opioid-binding cell adhesion molecule), 
neurotrimin/CEPU-1, and NEGR1 (neuronal growth regulator 1). Amongst 
these, Negr1 gene expression is altered upon cerebral ischemia [75] and so is 
worth studying to investigate new avenues for neuroprotection. 
 
Negr1 (Neuronal growth regulator 1) is expressed at high levels in the cerebral 
cortex, hippocampus, and cerebellum with increasing expression during 
postnatal development which stabilizes in adulthood [69,76]. It is localized at 
postsynaptic sites of dendritic synapses [76] and determines neurite outgrowth 
[77,78] as well as synapse number [70] during neuronal development. 
Recently, Pischedda et al.[79] reported that reduced expression of Negr1 
resulted in lower numbers and length of neuronal processes in mature neurons, 
signifying tight control over Negr1 expression levels during neuronal 
maturation to regulate neuronal morphology.  
 
Interestingly, three independent human genome-wide association studies have 
identified Negr1 as an obesity-associated locus [80-82]. Furthermore, ablation 
of Negr1 function resulted in a reduction in body mass [83]. Schäfer et al.[69] 
also reported that after entorhinal cortex lesion, expression of NEGR1 protein 
is induced on reactive astrocytes, which in turn promotes neurite outgrowth of 




growth-promoting factor for outgrowing axons following hippocampal 
denervation [69]. Studies to determine modulators of Negr1 could serve as a 
therapeutic approach for cerebral ischemia.  
 
1.2  Non-coding RNAs 
Non-coding RNAs are fast rising as mediators, biomarkers as well as potential 
therapeutic targets in disease [84,85]. These endogenously produced 
molecules were initially thought to be “transcriptional noise” due to lack of 
evidence of their functionality, but were later found to regulate gene 
expression [86]. These RNA transcripts vary in size and are derived from 
different regions of the genome inclusive of untranslated regions, seemingly 
untranscribed regions as well as from introns [86]. These are generally 
referred to as non-coding RNAs (ncRNAs) that have a myriad of regulatory 
effects ranging from transcriptional regulation, posttranscriptional processing, 
translation and even chromatin remodeling [87,88].  
 
The functional importance of these uncharacterized regions of the human 
genome are beginning to surface, including regulation of brain function. 
ncRNAs were found to show brain specific expression and function [89-91]. 
These ncRNAs are regulated during neuronal development [92,93] and are 
also shown to be associated with neurological diseases [94,95]. Distinct 
temporal and spatial expression of specific ncRNAs has been observed during 
cerebral ischemia in in vivo models as well [34,96]. These studies support the 
notion that reversing the dysregulation of gene and ncRNA expression in 




1.2.1   Types of ncRNAs  
ncRNAs comprise of a wide range of transcripts, with various sizes and 
functions associated with each subtype. The 2 well-known subclasses of 
ncRNAs are the “housekeeping” ncRNAs (ribosomal RNA, transfer RNA, 
small nuclear RNA, small nucleolar RNA) and the recently characterized 
regulatory ncRNAs (e.g., microRNA, long ncRNA. Table 1.1). Regulatory 
ncRNAs can be further classified based on their sizes as short (<200 bp) or 
long (>200 bp) ncRNAs. microRNAs (miRNAs) are the most well-
characterized and widely-studied group of short ncRNAs in ischemic brain 
injury whereas the functions of the long non-coding RNAs (lncRNAs) are just 
beginning to be unraveled. The focus of this thesis will be on these 2 non-
coding RNAs as their role in gene regulation is better characterized. 
 
 
Table 1.1: Classification and functional roles of non-coding RNAs 
(ncRNAs) in humans. 
ncRNA Function 
House-keeping ncRNAs 
transfer RNA (tRNA) mRNA translation [97] 
ribosomal RNA (rRNA) mRNA translation [97] 
small nucleolar RNA (snoRNA) rRNA modification [97] 
small nuclear RNA (including 
spliceosomal RNA) 
RNA splicing, polyadenylation [97] 
Regulatory ncRNAs: Short ncRNA (<200 nt) 
microRNA (miRNA) 
degradation of mRNA or repression of translation 
[98,99] 
piwi-interacting RNA (piRNA) 
regulation of transposon activity and chromatin state 
[100] 
repeat-associated short 
interfering RNA (rasiRNA) 
regulate germline transposition activity [101] 
tRNA-derived RNAs Translational repression [102] 
Telomere small RNAs (tel-
sRNAs) 
Telomere maintenance [103] 
Centrosome-associated RNAs 
(crasiRNAs) 




Circular RNAs (circRNAs)  miRNA sponge [105] 
Competing endogenous RNA 
(ceRNAs) 
Compete with mRNAs for common miRNAs [106] 
Regulatory ncRNAs: Long ncRNA (>200 nt) 
Intergenic ncRNA 
Epigenetic regulators of transcription in cis/in trans 
[107] 
Intronic ncRNA 
Transcriptional, posttranscriptional regulation, 
precursors for small ncRNAs [108] 
Antisense transcript 
mRNA stability of its homologous coding gene 
[109] 
Pseudogene transcript 
Generation of natural antisense transcripts or 
competing endogenous RNAs, stabilization of its 




Cell cycle and proliferation by unknown 
mechanisms [112] 
Repeat-associated ncRNA Regulation of repeat silencing [113] 
Satellite ncRNA 
Involvement of formation and function of 
centromere-associate complexes [114] 
Repetitive RNAs Epigenetic regulation? Other mechanisms? [114] 
Tiny transcription initiation 
RNAs (tiRNAs) 
Chromatin modifications and protein recruitment for 
transcriptional initiation [115] 
Promoter upstream transcripts 
(PROMPTS) 
Chromatin changes [116] 
Transcripts of unknown 
function (TUFs) 
Stem cell differentiation [117] 
Regulatory ncRNAs: Diverse sizes 
Promoter-associated RNAs 
(PARs) 
Gene repression in cis via interacting with PRC2 
[118] 
Enhancer-like ncRNA (eRNA) 








1.2.2  miRNAs  
1.2.2.1 Biogenesis 
miRNAs are highly conserved small (17–24 nucleotides) endogenous 
molecules that mediate post-transcriptional gene silencing of mRNA in a 
sequence-dependent manner [98,99]. Transcription of miRNAs is mediated by 
RNA polymerase II (Figure 1.6). miRNAs can exist as an independent gene or 
be located in introns of protein-coding genes (mirtrons) to give rise to primary 
miRNA transcripts (pri-miRNAs) (Figure 1.6). The folded pri-miRNA 
hairpins are cleaved by Drosha in the nucleus, exported into the cytoplasm and 
cleaved by Dicer to produce ~20nt miRNA/miRNA* duplexes. The strand 
with a less thermodynamically stable 5′ end usually acts as the mature miRNA 
whereas the other strand is degraded. In some cases, both strands are viable 
and become functional miRNAs. Thereafter, a mature miRNA is incorporated 
into a multiprotein complex known as the RNA-induced silencing complex 
(RISC), which also contains Argonaute (AGO) proteins, to form miRISC 
(Figure 1.6). In the miRISC formation, miRNAs base pair to target mRNAs, 
generally on the 3′ untranslated region (UTR) and induce their translational 
repression or deadenylation and degradation [120].  
 
1.2.2.2  Mechanism of action 
miRNAs primarily function to repress translation of messenger RNA (mRNA) 
in the cytoplasm. The mature miRNA binds to the 3’ untranslated region 
(3’UTR) of a target mRNA to form a duplex [121]. Multiple mismatches 
between the miRNA and miRNA are acceptable but high complementarity in 




recognition of the target mRNA [121]. High sequence complementarity results 
in cleavage of the target mRNA by AGO2 whereas low complementarity leads 
to gene silencing via other mechanisms such as packaging of the mRNA in 
Processing-bodies (P-bodies) [122].  
 
A miRNA can regulate the expression of hundreds of genes simultaneously, 
and several miRNAs can regulate a single mRNA cooperatively [123]. 
Moreover, Mukherji et al. [124] reported that miRNAs can act as a switch as 
well as fine-tuner of gene expression. The switch is regulated by miRNAs to 
establish a threshold level of target mRNA to repress protein production. Fine-
tuning is determined near this threshold where protein expression responds 
sensitively to target mRNA input. 
  
Recent findings demonstrate that miRNAs are present in the nucleus with 
some being nuclear-enriched in primary neurons as well [125]. Post-
transcriptional gene silencing may also be mediated by the nuclear RNA 
Induced Silencing Complex (nRISC) whereby the target nuclear transcript is 
sliced by AGO2 [121,126]. Transcriptional gene silencing can also be 
mediated by miRNAs that direct the RNA-induced transcriptional silencing 
complex, comprising chromatin modifiers such as DNA-methyltransferase, to 
promoter transcripts [121,127]. Promoter-associated lncRNAs recruit 
transcriptional repressors to mediate gene-silencing. miRNAs can disturb the 
recruitment of these silencing factors resulting in activation of the locus [128]. 
miRNAs could possibly also influence alternate splicing decisions at specific 




polymerase II procession, resulting in exon inclusion [121,129]. Hence, 
miRNAs function as regulators of gene expression at the transcriptional, post-
transcriptional as well as translational level [120,130-132].  
 
 
Figure 1.6: miRNA biogenesis and function. Transcription of miRNAs is 
mediated by RNA polymerase II (RNAP II) from independent genes or from 
introns of protein-coding genes (mirtrons) to give rise to primary miRNA 
transcripts (pri-miRNAs). The folded pri-miRNA hairpins are cleaved by 
Drosha in the nucleus, exported into the cytoplasm and cleaved by Dicer to 
produce ~20 nt miRNA/miRNA* duplexes. The less thermodynamically stable 
5′ end usually acts as the mature miRNA whereas the other strand is degraded. 
Thereafter, a mature miRNA is incorporated into the RNA-induced silencing 
complex (RISC), which contains Argonaute (AGO) proteins, to form miRISC. 
In the miRISC formation, miRNAs base pair to target mRNAs, generally on 
the 3′ untranslated region (UTR) and induce their translational repression 
[120]. The mature miRNAs can also be channeled back into the nucleus to 




1.2.3  Long non coding RNAs  
1.2.3.1  Biogenesis 
LncRNAs are RNA transcripts longer than 200 nucleotides that make up the 
largest portion of the transcriptome [133]. LncRNAs are transcribed by RNA 
polymerase II, and some lncRNAs are processed in a similar manner to 
mRNAs, undergoing splicing, polyadenylation and 5′-capping [97,134]. 
lncRNAs originate from intronic, exonic, intergenic, promoter regions, 
3′UTRs and 5′UTRs (Figure 1.7). Some lncRNAs can be transcribed as 
bidirectional transcripts (derived from divergent transcription within 1000 bp 
of a promoter) [135] and can also be derived from pseudogenes.  
 
1.2.3.2  Mechanism of action 
Like miRNAs, lncRNAs have a range of functions and hence mechanisms of 
action in the cell. However, unlike the miRNAs, the detailed mechanism of 
action of lncRNAs has yet to be determined. In the nucleus, lncRNAs guide 
and hold together chromatin-modifying complexes to result in tissue-specific 
gene expression (Figure 1.7) [136]. LncRNAs can also sequester transcription 
factors thereby preventing them from binding to target DNA sequences. 
Hence, lncRNAs can modulate gene expression in cis (genes near the site of 
synthesis on the same chromosome), or in trans (genes on a different 
chromosome or homologous chromosome from which it is transcribed) in the 
nucleus [136,137]. In the cytoplasm, lncRNAs may act as scaffolds for protein 
complexes that lack protein-protein domains thereby modulating protein 
activity, structure and localization [136,137]. LncRNAs can also compete with 




[136]. Hence, lncRNAs coordinate gene expression through epigenetic 
modification, mRNA splicing, control of transcription or translation and 
genomic imprinting which is determined by their structure and association 
with the gene loci [136]. 
 
A handful of lncRNAs are conserved [107] while other well-characterized 
functional mammalian lncRNAs, such as myocardial infarction associated 
transcript (Gomafu) [138], Dlx6 antisense RNA 1 (Evf-2) [139] and HOX 
transcript antisense RNA (HOTAIR) [140] exhibit poor sequence conservation 
across species. Nevertheless, lncRNAs have shown important implications in 











Figure 1.7: LncRNA biogenesis and function. LncRNAs are transcribed by 
RNA polymerase II from intronic, exonic, intergenic and promoters of genes. 
Some lncRNAs can be transcribed as bidirectional transcripts (derived from 
divergent transcription within 1000bp of a promoter). Some lncRNAs are 
processed in a similar manner to mRNAs, undergoing splicing, 
polyadenylation and 5′-capping. The lncRNA can have functions ranging from 
modulation of alternative splicing and transcriptional interference in the 
nucleus to modulation of protein activity and location in the cytoplasm. Figure 




1.3  Non-coding RNAs in neuronal development and ischemic injury 
Both miRNAs and lncRNAs are vital regulators of gene expression for 
neuronal function associated with synaptic plasticity, neurogenesis and disease 
[92,142-144]. Several studies have also demonstrated that ncRNAs that direct 
neuronal gene expression are dysregulated in ischemia [34,40,96]. Modulation 
of certain miRNAs has also been shown to confer neuroprotection in cerebral 
ischemic models [145-147].  
 
1.3.1  Non-coding RNAs in neuronal development 
1.3.1.1 miRNAs in neuronal development 
miRNAs have been reported to be crucial for neuronal development. Deletion 
of Dicer in forebrain and hippocampal neurons results in changes in dendrite 
morphology, spine length, apoptosis, microcephaly, ataxia, and lethality 
within three weeks after birth [148]. Studies on neuron-enriched miRNAs 
have shed light on some mechanisms during neuronal development, which 
involve neuronal stem/progenitor cells proliferation and differentiation, 
neuritogenesis and outgrowth, synapse formation and plasticity. 
 
Brain-enriched miR-124 is well-conserved from worms to humans and is 
estimated to be the most abundant miRNA in the brain [91]. miR-124 may 
contribute to maintaining neuronal identity by suppressing non-neuronal gene 
expression in neurons [149]. Furthermore, miR-124a-1 knockout mice showed 
severe consequences for neuronal survival and axonal outgrowth [150]. miR-
124 is highly expressed in differentiating and mature neurons and exhibits 




highly conserved, brain specific miRNA, with its expression largely confined 
to the nervous system [152,153]. Several studies suggest that miR-9/miR-9* 
suppresses neuronal progenitor proliferation and promotes neural 
differentiation via nuclear receptor subfamily 2, group E, member 1 
(Nr2e1/TLX), REST, and REST corepressor 2 (CoREST) [154,155]. In 
differentiated neurons, miR-9 controls axonal extension and branching by 
regulating translation of microtubule-associated protein 1B (Map1b), an 
important factor for microtubule stability [156]. Other neuron- and brain-
specific miRNAs such as miR-128, -29b have also been identified that are 
crucial to neuronal differentiation and function (Table 1.2).  
 
1.3.1.2 LncRNAs in neuronal development 
Similar to miRNAs, lncRNAs have also been implicated in neuronal 
development [93,157]. Inducible nitric oxide synthase (NOS2A) is upregulated 
during neurogenesis in the mammalian brain. This profile was observed to be 
opposite to that of an ncRNA antisense to the gene (anti-NOS2A RNA) during 
differentiation of human embryonic stem cells. This suggests involvement of 
human anti-NOS2A RNA in regulation of neuronal differentiation by 
suppressing NOS2A gene expression [158].  
 
Brain-derived neurotrophic factor (BDNF) is a crucial determinant of neuronal 
outgrowth and survival. A conserved transcript antisense to BDNF has 
recently been characterized to negatively modulate transcription as well as 
translation of the BDNF mRNA [159]. Likewise, several sense and antisense 




calcium/calmodulin-dependent protein kinase II inhibitor 1 (Camk2n1) loci 
during cerebral corticogenesis [160]. Several other lncRNAs such as tie-1 AS 
and Tsx have specific functions in neuron development which are listed in 
Table 1.2. 
 
1.3.2  Non-coding RNAs in ischemic injury 
Recent reports have shown that gene dysregulation leading to apoptotic events 
during ischemia could be attributed to the derailment of ncRNAs [30,31]. 
Several ncRNAs described to date have been shown to either cause cell death 
or protect neurons from ischemic death [145-147].  
 
1.3.2.1 miRNAs in ischemic injury  
Temporal regulation of miRNA expression has been shown in the brain of rat 
models subjected to middle cerebral artery occlusion (MCAo) [126]. In 
addition, biphasic expression of miRNAs has also been demonstrated in the 
same animal models. The temporal and biphasic regulation of these miRNAs 
have been proposed to play a crucial role either in the acute injury phase or the 
late recovery phase [127]. An upregulation of the anti-apoptotic miR-21 has 
been shown to protect neurons from death in cerebral ischemic model. miR-21 
was demonstrated to  target FASLG, a member of the tumour necrosis factor-α 
family and cell death inducing ligand [128]. In an in vitro model of cerebral 
ischemia, increase of miR-497 expression following oxygen-glucose 
deprivation, correlated with increased cell death and downregulation of its 
antiapoptotic targets, Bcl2 and Bclw [129]. Down-regulation of miR-9 and 




ischemia, indicated dysregulation of neuronal function [161]. Several other 
studies [145-147] have reported dysregulation of miRNAs during cerebral 
ischemia and that modulating these during cerebral ischemia could protect 
neurons from ischemic injury.  
 
1.3.2.2 LncRNAs in ischemic injury  
Similar to miRNAs, ischemic insult can also give rise to dysregulation of 
lncRNAs essential to neurogenesis, affecting the neuronal machinery, thereby 
resulting in neuronal death. Dharap et al. [96] reported the dysregulation of 
lncRNAs in rats subjected to focal ischemia. The group identified lncRNAs 
which showed > 90 % sequence homology with exons of protein-coding 
genes. The authors reported that the stroke-responsive lncRNAs were 
homologous to protein-coding genes involved in ribosomal complex 
formation, splicing, translation initiation, and nuclear import of mRNAs, 
possibly stabilizing those mRNAs to restore the protein synthesis inhibited 
during the acute phase after stroke. The stroke-responsive lncRNAs might also 
control chromatin modifications, transcription factor activity, and apoptosis 
[162-164]. However, further studies are needed to characterize specific 
lncRNAs in ischemic injury. 
 
Since neuronal cell death is the main effect brought about by ischemic brain 
injury resulting from a multitude of molecular events and processes (the 
ischemic cascade), ncRNAs involved in the main processes hypoxia, oxidative 




demise of neurons during cerebral ischemia [29]. The list of known ncRNAs 
implicated in these processes are listed in Table 1.2.  
 
Thus far, various miRNAs and lncRNAs implicated in neuronal development, 
ischemic disease and its major processes have been identified. Amongst these, 
the miRNAs have been the most extensively studied and well characterized. 
Preliminary studies on lncRNAs have shown their importance in neuronal 
development and ischemic disease. Further in-depth studies are imperative to 
uncover the significance of these ncRNAs as potential targets for therapy in 








Table 1.2: List of miRNAs and lncRNAs involved in neuronal development and the different processes in ischemic injury. 





miR-124 SCP1 Promotes neurogenesis [165] Anti-NOS2A NOS2A 
Possibly downregulate NOS2A 
expression, regulate neuronal 
differentiation [158] 








Posttranscriptional regulation of  
differentiation [160] 
 
BAF53a Promotes neuronal differentiation [167] Tie-1AS Tie-1 
Regulation of vascular development 
[168] 
 SOX9 Promotes neuronal differentiation [92] Tsx Unknown Learning and behavior [169] 
 Jag1 
Promotes neural progenitor cells 
proliferation [161] 
Malat-1 SR proteins 
Synapse formation and/or 
maintenance [170,171] 
miR-9* BAF53a Promotes neuronal differentiation [167] FGF-AS FGF 
Downregulates proliferation of neural 
progenitor cells [172,173] 
 CoREST Promotes neuronal differentiation [154] ANRIL Unknown Risk and recurrence of stroke [174] 
 TLX Promotes neuronal differentiation [155] Evf2 Dlx5/6 
GABAergic interneuron development 
[175] 
 STMN1 Promotes neuronal differentiation [176] Sox2ot Sox2 
Expressed concurrently with Sox2 
[177] 
miR-9 REST Promotes neuronal differentiation [154] asOct4-pg5 Oct4 
Downregulates transcription of Oct4 














miR-134 Dcx, Chrdl-1 Promotes neuronal differentiation [179] BDNF-AS BDNF 
Downregulates transcription of 
BDNF and BDNF mRNA [159] 
miR-29b 
Bim, Bmf, Hrk, 
and Puma 
Promotes neuronal differentiation [43] 
   miR-137 Mib1 
Dendritic morphogenesis, neuronal 
maturation, spine development [73] 
miR-34a 
SIRT1 
Promotes neuronal differentiation and 
neurite elongation [180] 




Integration of newborn neurons into adult 
brain synaptic circuitry [182] 
   
miR-338 COXIV 
Regulates axonal respiration and  
function [183] 
   





Regulates spine morphology and synaptic 
plasticity [185] 
   
miR-138 APT1 Regulates size of dendritic spines [186]    
miR-138 Lypla1 
Regulates synaptic plasticity and spine 
morphology [187] 
   
miR-219 CaMKIIγ 
Regulates fast neurotransmission and 
synaptic plasticity [188] 
   














miR-199a-5p HIF-1a Inhibits apoptosis [190] 5′aHIF-1α HIF-1α 
Prevents export of HIF-1α mRNA 
into cytoplasm [191] 
miR-17-92 
cluster 
HIF-1a Inhibits cancer cells proliferation [192] 3′aHIF-1α HIF-1α Downregulates HIF-1α mRNA [193] 
miR-155 HIF-1a Inhibit hypoxia [194] aHig-1 Hig-1 Inhibits translation of Hig-1 [195] 
miR-138 HIF-1a Inhibits apoptosis and migration [196] H19 IGF-2 
Induced upon hypoxia, regulates 
expression of IGF-2, precursor for 
miR-675 [197,198] 
miR-107 
HIF-1β Inhibits differentiation [199] PTENP1 PTEN 
Sequesters miRNAs acting on PTEN 
mRNA, cell death [200] 
miR-20b VEGFA Inhibits tumor growth [201]    
miR-15a/-16 VEGFA Inhibits angiogenesis [202]    
miR-519c HIF-1a Promotes angiogenesis [203]    
miR-93 VEGFA Inhibits angiogenesis [204]    
miR-126 VEGFA Inhibits angiogenesis [205]    
miR-200a Flt-1 Inhibits tumour invasion [206]    
miR-145 BNIP3 Inhibit apoptosis [207]    
miR-221/222 PUMA Inhibits apoptosis [208]    
Excitotoxicity 




Represses CCND1 expression, cell  

















miR-146a/b IRAK1, TRAF6 Inhibits inflammation [212] 17A GPR51 Induced upon inflammation [213] 
miR-146a TLR4 Inhibits inflammation [214]    
miR-181c TNF-α Inhibits inflammation [215]    
miR-125b TNF-α Inhibits inflammation [216]    
miR-17 ICAM1 Inhibits recruitment of immune cells [217]    
miR-126 VCAM1 Inhibits recruitment of immune cells [218]    
miR-130a AQP4 Reduces edema [132]    
miR-320a AQP4 Reduces edema [146]    
Oxidative stress 
miR-145 SOD2 Inhibits anti-oxidant defense [219] MSUR1 Unknown 
Reduces ROS and oxidative damage 
[220] 
miR-101 COX2 Reduces ROS production [221] Gadd7 Unknown 
Induced upon oxidative stress, cell 
death [222] 
Apoptosis 
miR-15a BCL2 Promotes cell death [223] TUG1 
Cell cycle 
genes 
Induced by p53 upon DNA damage, 
cell death [164] 
miR-29b BCL2L2 Promotes cell death [224]    
miR-497 BCL2, BCL2L2 Promotes cell death [147]    












Epigenetics refers to heritable alterations that are not due to changes in DNA 
sequence [225]. Rather, changes such as DNA methylation, histone 
modification, chromatin conformation, and non-coding RNAs [226] regulate 
patterns of gene expression by altering DNA accessibility and chromatin 
structure.  
 
Chromatin is the complex of chromosomal DNA associated with proteins in 
the nucleus. DNA in chromatin is packaged around histone proteins, in units 
known as nucleosomes. Each nucleosome comprises 147 base pairs of DNA 
associated with an octomeric core of histone proteins, that consist of 2 H3-H4 
histone dimers surrounded by 2 H2A-H2B dimmers each. N-terminal histone 
tails protrude from nucleosomes into the nuclear lumen. H1 histone associates 
with the linker DNA located between the nucleosomes. Spacing between the 
nucleosome determines chromatin structure, which can be broadly divided into 
heterochromatin and euchromatin. Chromatin structure and gene accessibility 
to transcriptional machinery are regulated by modifications to both the DNA 
and histone tails [225,226]. 
 
1.4.1 DNA methylation 
DNA methylation at the cytosine in CpG dinucleotides is initiated de novo by 
the DNA methyl transferases (DNMT) 3A and 3B. After replication, DNMT1 
plays a primary role in maintaining the methylation state in the daughter 
strands. This CpG methylation ensures repression of transcription of repeat 




chromosome inactivation [227]. Transcriptional gene silencing by CpG 
methylation also restricts the expression of some tissue-specific genes during 
development and differentiation by repressing them in nonexpressing cells 
[225]. Demethylation is thought to occur by reduction of DNMT1 activity or 
by excision repair mechanisms after deamination of methyl cytosine (
me
C) to 
create a T:G mismatch [225]. DNA methylation can also suppress the binding 
of transcription factors to gene promoters, allow binding of repressor proteins 
to result in transcriptional repression, contribute to developmental events such 
as X-chromosome inactivation and genome stability [228] as well as control 
the transcription network of cells [229]. Failure to maintain correct 
methylation patterns leads to abnormal DNA methylation, usually observed in 
human diseases such as neurodevelopmental defects and cancers [226,230] 
 
1.4.2 Histone modification 
Histone modification is another mode of epigenetic regulation. The protruded 
NH2-tails of histones in the nucleosomes can be modified in several ways, for 
instance, lysine and arginine methylation, lysine acetylation, serine, threonine 
and tyrosine phosphorylation, and lysine ubiquitination and sumoylation 
[231]. These modifications can alter the charge of chromatin leading to a more 
condensed or open state. This structure then dictates the accessibility of 
regulatory proteins including transcriptional regulators [226]. 
 
Histone acetylation at the ε-amino group of lysine residues in H3 and H4 tails 
is most consistently associated with promotion of transcription. However, this 




chromatin structure may also allow access of transcriptional repressors [225]. 
Histone lysine methylation patterns and their effects on transcription are more 
complex than acetylation in that some methylation sites are associated with 
transcriptionally permissive chromatin (euchromatin) and some are repressive, 
which fosters heterochromatin formation. In addition, ε-amino groups of 
lysine residues can be monomethylated, dimethylated, or trimethylated. In 
general, the H3K27me3 and H3K9me states are associated with silencing, 
whereas the H3K4me3 and H3K36me3 states are transcriptionally permissive 
modifications. Importantly, methylation marks recruit effector proteins that 
play essential roles in maintaining the transcriptional state of the chromatin; 
for example, H3K9me recruits HP1, which contributes to heterochromatin 
formation [225]. 
 
The histone code hypothesis suggests that different combinations of histone 
modifications may regulate chromatin structure and transcriptional status 
[231]. Details, such as the location of nucleosomes relative to the 
transcriptional start site of a gene, together with specific combinations of sites, 
types, and extents of histone modifications, add to the complexity of the 
histone code [225]. 
 
1.4.3 Non-coding RNAs 
The recently discovered non-coding RNAs such as miRNAs and lncRNAs 
also contribute to epigenetic regulation. These RNAs play many important 
roles in transcriptional repression and activation, including 




[233] and other biological processes. Extensive cross-talk between epigenetic 
regulators upholds and modulates intricate transcriptional networks in cells 
[226]. 
 
For instance, the lncRNA HOTAIR in the human homeobox loci recruits 
remodelling complexes that mediate inhibitory H3K27me3, resulting in gene 
silencing [140]. Furthermore, lncRNAs can also mediate transcriptional 
suppression by mechanisms such as recruitment of RNA-binding proteins that 
interfere with histone deacetylation or that prevent exclude association of 
transcription factor II D with the promoter [225,234]. 
 
Small inhibitory RNAs are also reported to be involved in RNA-mediated 
DNA methylation and transcriptional gene silencing [235]. Furthermore, 
synthetic small inhibitory RNAs and endogenous microRNAs that target gene 
promoters may also direct transcriptional gene silencing by recruiting specific 
argonaute proteins and forming epigenetic remodeling complexes that 
suppress gene expression by fostering DNA methylation, histone deacetylation 
and histone methylation (H3K9 and H3K27) [127,225,236,237]. 
 
1.5  Objectives of this study 
Thus far, it has been established that the neuronal maturation process involves 
precise gene regulation to trigger pro-survival pathways for proper neuronal 
structure and function. However, dysregulation of these pathways upon 
exposure to ischemic injuries could be contributing to neuronal death. These 




endogenous regulators of gene expression, miRNAs and lncRNAs. These non-
coding RNAs show potential as neuroprotectants in ischemic injury which 
currently lacks efficacious clinical treatment. Furthermore, ncRNAs can target 
several genes at a time and hence identification of a neuroprotective ncRNA 
that favours neuronal survival by regulating several genes could serve as a 
good therapeutic approach as compared to targeting a single mRNA. Further 
in-depth studies are therefore necessary to identify neuroprotective ncRNAs 
and their mechanism of action in ischemic injury, thereby providing new 
avenues for therapeutic intervention.  
 
It was hypothesized that ncRNA profiles during neuronal differentiation and 
survival would be altered upon exposure to ischemic injury, which would 
allow identification of a neuroprotective ncRNA. To identify neuroprotective 
ncRNAs, studying them in neurons, the basic functional unit of the nervous 
system, would serve as the most appropriate and accurate in vitro model. 
Hence, primary neuronal cultures are used as these neurons in culture undergo 
distinct stages of differentiation and maturation and can replicate the ischemic 
response upon exposure to oxygen and glucose deprivation. For this purpose, 
it is imperative that neuronal cultures with the highest purity with no 
contamination from glial cells be used. To ensure this, primary cultures of 
cortical neurons were established from E15 embryos, when neurogenesis 
peaks, as well as an earlier (E14) and a later (E16) embryonic day to 
determine the optimal embryonic day to achieve pure neuronal cultures to 
study neuronal maturation. In vitro maturation of these cultures from Day 2 to 




characterized by immunostaining with cell-type specific markers. Cultures 
with the highest neuronal purity served as the in vitro model for all primary 
cortical neuronal culture experiments performed in this thesis thereafter. 
 
Having established the most relevant model to study neuronal maturation and 
injury, expression profiling of coding (mRNA) and regulatory non-coding 
(lncRNAs and miRNAs) RNAs was carried out in maturing neurons and 
neurons subjected to ischemic insult. Bioinformatics analyses and comparison 
between the 2 models would identify genes and their associated regulatory 
ncRNAs crucial to neuronal survival but dysregulated during ischemic injury. 
This part of the study allowed the identification of ncRNAs that can modulate 
expression of their target gene(s) for neuroprotection against ischemic injury.  
 
Having shortlisted potential neuroprotective ncRNAs and their associated 
genes, the next aim of the study was to determine the effect of the identified 
ncRNAs on gene expression as well as their neuroprotective potential in 
ischemia. Amongst the genes identified in the previous study, the cell 
adhesion molecule Negr1 and its associated ncRNAs displayed the most 
pronounced effects during neuronal maturation and ischemia and hence were 
selected for further characterization. Two lncRNAs associated with Negr1 
were characterized by under-expression, over-expression and functional 
studies. The miRNA, miR-203, also associated with Negr1, was characterized 
by interaction studies, under-expression, over-expression and functional 





Apart from Negr1, the neurotrophic tyrosine kinase receptor, type 2 (Ntrk2), 
belonging to the neurotrophin signalling pathway, was also identified as 
crucial to neuronal maturation and dysregulated during ischemia. The link 
between dysregulation of expression of the truncated isoform of this receptor, 
TrkB T1, and ischemic death has recently been reported. As no lncRNAs were 
found to be associated with Ntrk2, this part of the study aimed to determine 
miRNAs as regulators of TrkB T1 expression both at the level of post-
transcriptional regulation and alternative splicing. Specific assays were 
employed to study putative miRNAs and their mode of action. This was 
followed up with studies in primary neuronal cultures to determine if the 
interaction could be replicated in vitro. The neuroprotective potential of 






2  MATERIALS AND METHODS  
2.1  Materials  
2.1.1  Secondary cell lines and culture reagents  
SH-SY5Y (CRL-2266) and HeLa (CCL-2) cells were obtained from the 
American Type Cell Culture (ATCC, USA).  
  
2.1.1.1  Phosphate buffer saline (PBS) (1 L) 
NaCl          8 g  
KCl          0.2 g  
Na2HPO4·2H2O        1.4 g  
KH2PO4         0.24 g  
The solutes were dissolved in 1 L of sterile deionised water and autoclaved.  
 
2.1.1.2  Trypsin  
10 X trypsin (PAA, The Cell Culture Company, Austria) was diluted to 1 X 
with PBS, filtered with a 0.22 μm filter and stored at 4 °C.  
 
2.1.1.3 Dimethyl sulfoxide (DMSO) 
DMSO (MP Biomedical, USA) was sterile-filtered with a 0.22 μm filter and 









2.1.1.4  Basal Dulbecco’s Modified Eagle’s medium (DMEM) (1 L) 
Dulbecco’s Modified Eagle’s Medium      17.4 g 
(Invitrogen, Carlsbad, CA, USA)  
L-glutamine (Gibco, USA)      0.4 g  
Sodium bicarbonate        1.74 g  
Penicillin-streptomycin (10,000U-100mg/ml) (Gibco, USA) 10 ml  
Powdered DMEM medium, L-glutamine and sodium bicarbonate were 
dissolved in deionised water and the pH was adjusted to 7.2 with 5 M NaOH. 
The medium was sterile-filtered with a 0.22 μm filter. 
 
2.1.1.5  Complete DMEM (1 L)  
Basal DMEM         900 ml  
Fetal bovine serum (FBS, Gibo, USA)    100 ml  
FBS (if required) and penicillin-streptomycin were added aseptically and the 
medium was stored at 4 °C. Before use, the medium was warmed in a 37 °C 
water bath. 
 
2.1.1.6  Freezing medium for SH-SY5Y cells (100ml)  
Basal DMEM         25 ml  
Fetal bovine serum (FBS)      70 ml  
Dimethyl sulfoxide (DMSO)      5 ml  
Cells were stocked as 1ml aliquots with freezing medium and kept in -80 °C. 
 
2.1.1.7  Poly-d-lysine 
Freshly prepared poly-d-lysine (Sigma, USA) was used to coat plates a day 




water at a concentration of 0.1 mg/ml. The solution was sterile-filtered with a 
0.22 μm filter before coating.  
 
2.1.1.8  All-trans retinoic acid 
All-trans retinoic acid was prepared at a concentration of 3 mg/ml in DMSO to 
obtain a 10 mM stock solution. The solution was filter-sterilized with a        
0.22 µm filter and stored as 50 µl aliquots at -80 °C. It was used at a final 
concentration of 10 µM to induce differentiation of SH-SY5Y cells.  
 
2.1.1.9  SH-SY5Y differentiation medium 
Basal DMEM        99 ml 
FBS         1 ml 
10 mM all-trans retinoic acid (section 2.1.1.8)   100 µl 
The differentiation medium was freshly prepared each time with minimal 
exposure to light throughout preparation and treatment of cells as all-trans 
retinoic acid degrades upon exposure to light. 
 
2.1.1.10  Tetracycline 
Tetracycline (Sigma, USA) was dissolved in absolute ethanol at a 
concentration of 10 mg/ml, sterile-filtered with a 0.22 µm filter and stored at   
-20 °C. It was used at a final concentration of 1 µg/ml to induce gene 












 transfection reagent (Ambion, USA), lipofectamine
®
 
2000 (Invitrogen, USA), lipofectamine
®
 RNAiMAX (Invitrogen, USA) and 
Opti-MEM
®
 medium (Gibco, USA) were used for transfection.  
 
2.1.3  Primary cell culture reagents  
Mouse cortical neurons were isolated from E15 Swiss albino mice to culture 
primary neuronal cultures. Animals were obtained from the Laboratory 
Animal Centre (National University of Singapore, Singapore) and InVivos 
(Singapore). The experimental mice were handled according to National 
University of Singapore (IACUC/NUS) guidelines for laboratory animals. The 
protocol was approved by the Committee on the Ethics of Animal 
Experiments of the National University of Singapore (Protocol Number: 
025/11). All steps of primary culture were carried out using clear polyethylene 
terephthalate (PET) conical bottom centrifuge tubes (Corning, USA). 
 
2.1.3.1  1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 
HEPES (Sigma, USA)      6.51 g  
Deionised water        25 ml 
HEPES was dissolved in water and the pH adjusted to 7.4. The solution was 








2.1.3.2  Hank’s balanced salt solution (HBSS)  
HBSS (Invitrogen, USA)      97 ml  
100 mM sodium pyruvate       1 ml 
1 M HEPES (section 2.1.3.1)      1 ml 
Penicillin-streptomycin (10,000 U - 100 mg/ml)   1 ml  
HBSS buffer was stored at 4 °C and used for dissection and washing of 
cortical tissues.   
 








 (Invitrogen, USA)    97 ml  
100 mM sodium pyruvate (Sigma, USA)    1 ml 
1 M HEPES (section 2.1.3.1)      1 ml 
Penicillin-streptomycin (10,000 U-100 mg/ml)   1 ml  




 was prepared aseptically and stored at 4 °C. It 
was used to dissolve trypsin for dissociation of mouse cortices in primary 
neuronal culture studies. 
 
 
2.1.3.4  Trypsin 
10 X trypsin (PAA, The Cell Culture Company, Austria) was freshly-prepared 




 for gentle dissociation of 
mouse cortices in primary neuronal cultures studies. 
 
 
2.1.3.5  Trypsin inhibitor (1 mg/ml) 
Trypsin inhibitor from soybean (BDH Chemicals, England)  5 mg  




Freshly-prepared trypsin inhibitor solution (5 ml) was used for each mouse. 
The final solution was sterile-filtered with a 0.22 μm filter and warmed at     
37 °C before use. The trypsin inhibitor was used to neutralize the trypsin used 
to dissociate the mouse cortices. 
 
2.1.3.6  L-Glutamine 
200 mM L-Glutamine (Gibco, USA) was prepared by dissolving L-glutamine 
at a concentration of 29.2 mg/ml in deionised water. The solution was filter-
sterilised and stored as 1 ml aliquots at -20 °C. 
 
2.1.3.7  Neurobasal medium 
Neurobasal medium (Gibco, USA)     49 ml 
B27 serum-free supplement (Gibco, USA)    1 ml 
200 mM L-Glutamine (section 2.1.3.6)    125 µl 
Penicillin-streptomycin (10,000 U - 100 mg/ml)   0.5 ml  
The medium was prepared in a T-75 cell culture flask and equilibrated in the 
cell culture incubator at 37 °C for at least 3 hours before use. 
 
2.1.3.8  Trypan blue 
0.4 % Trypan blue (Sigma, USA) was prepared by dissolving trypan blue in 
PBS (section 2.1.1.1) at a concentration of 4 mg/ml. Trypan blue was used as 
cell stain to determine cell viability and determine the number of viable cells 






2.1.3.9  Oxygen and glucose deprivation (OGD) medium  
Earle’s balanced salt solution (EBSS) was used as the oxygen-glucose 
deprivation (OGD) medium for treatment of primary neuronal cultures to 
oxygen and glucose deprivation experiments. 
KCl         0.4 g 
NaCl         6.8 g 
NaHCO3        2.2 g 
NaH2PO4·H2O       0.14 g 
Penicillin-streptomycin (10,000 U-100 mg/ml)   10 ml 
All salts were dissolved in 990 ml of deionised water and sterile-filtered with a 
0.22 μm filter. Penicillin-streptomycin was added aseptically and the buffer 
stored at 4 °C.  
 
2.1.3.10  Glucose stock  
Powdered D(+)-glucose (4.5 g) was dissolved in 50 ml of deionised water to 
make a 500 mM glucose stock. The stock was sterile-filtered with a 0.22 μm 
filter and diluted to achieve the desired final concentrations.  
 
2.1.3.11  OGD control medium  
500 mM glucose (section 2.1.3.10) diluted in EBSS (section 2.1.3.9) to a final 
concentration of 25 mM was used as control medium for oxygen glucose 







2.1.3.12  MTT cell viability assay 
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma, 
USA) was prepared fresh in PBS (section 2.1.1.1) at a concentration of 10 
mg/ml and kept away from light. 
 
2.1.3.13  Kit for apoptotic, necrotic and healthy cells assay 
The 3-dye (FITC-Annexin V, ethidium homodimer III and Hoechst 33342) kit 
for quantitation of apoptotic, necrotic and healthy cells was purchased from 
Biotium, Inc (USA) and performed according to the manufacturer’s protocol. 
 
2.1.4  Reagents for Immunocytochemistry (ICC) 
2.1.4.1  Formaldehyde (4 %) 
Formaldehyde (37 %, v/v) (Merck, USA) was freshly diluting in PBS (section 




 X-100 (0.1 %) 
Triton
TM
 X-100 (Sigma, USA) was freshly diluted in PBS (section 2.1.1.1) to 
achieve a concentration of 0.1 %. 
 
2.1.4.3  PBS buffer with FBS  








2.1.4.4  Antibodies  
Mouse anti-MAP2 (1:500; Abcam, Cambridge, UK), mouse anti-NeuN 
(1:1000; Abcam, Cambridge, UK), rabbit anti-Sox2 (1:250; Abcam, 
Cambridge, UK), rabbit anti-CD11b (1:500; Abcam, Cambridge, UK), rabbit 
anti-GFAP (1:500; Abcam, Cambridge, UK) and mouse IgM anti-O4 (1:100; 
Sigma, USA) primary antibodies were used by dissolving in 5 % FBS in PBS 
(section 2.1.4.3). FITC-, Texas Red- and Cy5-coupled secondary antibodies 
(1:200; Abcam, Cambridge, UK) were also diluted in 5 % FBS in PBS 
(section 2.1.4.3) for immunocytochemistry studies.   
 
2.1.4.5  Mounting medium  
Aqueous faramount mounting medium (Dako, USA) was used to mount the 
cover slips fixed with cells onto microscope slides. 
 
2.1.5  Reagents for DNA extraction  
2.1.5.1  DNA extraction  
DNAzol® reagent (Invitrogen, USA) was used to extract DNA from cells.  
 
2.1.5.2  NaOH  









2.1.6  Reagents for DNA agarose gel electrophoresis 
2.1.6.1  10 X Tris-borate-EDTA (TBE) buffer  
Tris base         108 g  
Boric acid         55 g  
0.5 M EDTA (pH 8.0)       40 ml  
Tris base and boric acid was dissolved in 960 ml of sterile deionised water 
before adding 40 ml of EDTA, pH 8.0. Ten times TBE buffer was stored at 
room temperature. The stock solution was diluted to 1 X with sterile deionised 
water and used as a running buffer for DNA gel electrophoresis.  
 
2.1.6.2  Ethidium bromide  
Ethidium bromide (Sigma, USA) was dissolved in sterile deionised water at a 
concentration of 10 mg/ml, stored at room temperature and protected from 
light. The final working concentration was 0.1 μg/ml.  
 
2.1.6.3  DNA gel (1%)  
Electrophoresis grade agarose      0.5 g  
1 X TBE buffer (section 2.1.6.1)     50 ml  
Ethidium bromide (10 mg/ml) (section 2.1.6.2)   1 μl  
Powdered agarose in 1 X TBE buffer was heated to 100 °C to dissolve 








2.1.7  Reagents for RNA extraction from cells  
2.1.7.1  Ethanol  
Ethanol (75 %, v/v) was diluted in sterile deionised water.  
 
2.1.8  Reagents for RNA agarose gel electrophoresis  
2.1.8.1  10 X Morpholinopropanesulphonic acid (MOPS) running 
buffer  
MOPS         83.7 g  
Sodium acetate        8.2 g  
EDTA (pH 8.0)        3.7 g  
All regents were dissolved in 800 ml of sterile deionised water and the pH was 
adjusted to 7 with 5 M NaOH before making up to 1000 ml. The 10 X MOPS 
buffer was autoclaved and stored at room temperature. The stock solution was 
diluted to 1 X with sterile deionised water and used as a running buffer for 
RNA agarose gel electrophoresis.  
 
2.1.8.2  Deionised formamide  
500 ml formamide (Sigma, USA) was stirred with 500 mg Dowex XG8 resin 
for 1 hour and filtered through Whatman No.1 paper. Deionised formamide 
was stored at room temperature in the dark.  
 
2.1.8.3  RNA loading buffer  
Glycerol         50 % (v/v)  
Bromophenol blue                  0.4 % (w/v)  





2.1.8.4  RNA sample buffer (per sample)  
Deionised formamide (section 2.1.8.2)    10 μl  
37 % formaldehyde        3.5 μl  
10 X MOPS (section 2.1.8.1)      2 μl  
RNA Loading Buffer (section 2.1.8.3)     2 μl  
 
2.1.8.5  RNA agarose gel (1 %)  
Electrophoresis grade agarose      0.5 g  
Deionised water        43.5 ml  
37 % formaldehyde        1.5 ml  
10 X MOPS (section 2.1.8.1)      5 ml  
Ethidium bromide (10 mg/ml) (section 2.1.6.2)   1 μl  
Powdered agarose in water was heated to 100 °C to dissolve completely. It 
was then cooled to about 60 °C before the addition of 37 % formaldehyde,    
10 X MOPS and ethidium bromide.  
 
2.1.9  Reagents for RNA polyacrylamide gel electrophoresis  
2.1.9.1  Denaturing polyacrylamide gel (15 %) 
Urea          7.2 g  
40 % Acrylamide/Bis Solution, 19:1 (Bio-rad, USA)  5.63 ml  
10 X TBE Buffer (section 2.1.6.1)     1.5 ml  
Deionised water        1.9 ml  
TEMED (Bio-rad, USA)      15 μl  




Urea, Acrylamide/Bis solution and 10 X TBE buffer were incubated in a       
60 °C water bath. Once the urea dissolved, deionised water, TEMED and APS 
were added to the mixture and the gel was cast immediately.  
 
2.1.9.2 RNA sample buffer (per sample)  
10 X TBE Buffer (section 2.1.6.1)     2 μl  
Deionised formamide (section 2.1.8.2)     10 μl  
RNA Loading Buffer (section 2.1.8.3)     3 μl  
 
2.1.10  Reagents for Cloning  
2.1.10.1  Reverse transcription (RT)  
100 µM Random hexamer primer     1 μl  
5 X Reaction Buffer        4 μl  
RiboLock™ RNase Inhibitor (20 U/μl)     1 μl  
10 nM dNTP Mixture        2 μl  
RevertAid H Minus M-MuLV Reverse Transcriptase (200 U/μl)  1 μl  
Nuclease-free water            Top up to 20 μl  
The individual components for the RT mixture were obtained from 










2.1.10.2  Polymerase chain reaction (PCR)  
10 X Taq buffer with MgCl2       2.5 μl  
dNTP mixture        2.5 μl  
Forward primer (5 OD stock)      0.5 μl  
Reverse primer (5 OD stock)       0.5 μl  
Taq DNA Polymerase (2 units/μl)      1 μl  
Nuclease-free water        15.5 μl  
 
2.1.10.3  Ligation  
2.1.10.3.1  Ligation of TA cloning vector  
Salt solution         1 μl  
TOPO® vector        1 μl  
Nuclease-free water              Top up to 6 μl  
The individual components for TA ligation were obtained from TOPO® TA 
Cloning Kit for Sequencing (Invitrogen, USA).  
 
2.1.10.3.2  Ligation of luciferase and expression vectors  
2 X DNA Ligation buffer       5 μl  
T4 DNA Ligase (5 U/μl)       1 μl  
Nuclease-free water            Top up to 10 μl  
The individual components for ligation were obtained from Rapid DNA 







2.1.10.4  Plasmids for luciferase studies  
Reporter gene assays are used to validate miRNA:mRNA interaction. To 
determine miRNA:mRNA interaction between the 3’UTR of the target gene 
and a specific miRNA, the 3’UTR of the gene of interest is inserted 
downstream of a reporter gene, in this case, luciferase. The luciferase vectors 
used in this study were pMIR-REPORT™ Luciferase miRNA Expression 
Reporter Vector (Ambion, USA) and pRL-CMV vector (Promega, Madison, 
USA). 
 
2.1.10.5  Plasmids for expression studies 
pcDNA™4/TO/myc-HisA and pcDNA™6/TR plasmids (Invitrogen, USA) 
were used for tetracycline-regulated expression of the gene of interest in a 
mammalian host cell. The pcDNA™4/TO/myc-HisA expression vector 
contains 2 tetracycline operator 2 (TetO2) sites inserted into the human CMV 
promoter to allow tetracycline-regulated expression of the downstream gene 
[238]. Four Tet repressor molecules (consisting of 2 Tet repressor 
homodimers) bind to the TetO2 sequences such that the downstream gene is 
responsive to tetracycline. The Tet repressor is expressed from the 
pcDNA™6/TR plasmid which is co-transfected with pcDNA™4/TO/myc-
HisA. In the absence of tetracycline, Tet repressor binding to the TetO2 
sequences represses the expression of the gene downstream of 
pcDNA™4/TO/myc-HisA. With the introduction of 1 μg/ml tetracycline, the 
CMV/TetO2 promoter of pcDNA™4/TO/myc-HisA is derepressed and the 




pcDNA™4/TO/myc-HisA on its own was used for constitutive overexpression 
of lncRNAs in mammalian cells. 
  
2.1.10.6  Competent cells  
Competent TOP10 E. coli cells (50 μl) were used for each transformation 
procedure (Invitrogen, USA).  
 
2.1.10.7  Ampicillin  
Powdered ampicillin (Sigma, USA) was dissolved in sterile water to make 
concentrated stocks of 100 mg/ml. The stocks were aliquoted into small 
volumes and stored at -20 °C. The working concentration for ampicillin was 
100 μg/μl.  
 
2.1.10.8  Luria Bertani medium (LB)  
Tryptone         1 % (w/v)  
NaCl          1 % (w/v)  
Yeast Extract                   0.5 % (w/v)  
The LB broth was autoclaved and stored at 4 °C.  
 
2.1.10.9  LB agar plates  
Powdered agar (Gibco, USA) was mixed with LB broth to a final 
concentration of 1.3 % (w/v) and autoclaved. The mixture was cooled to 
approximately 60°C prior to the addition of ampicillin to a final concentration 
of 100 μg/μl (section 2.1.10.7). Twenty ml of the molten agar was poured into 




The LB agar plates were sealed using parafilm, inverted and stored at 4 °C. 
All plates were pre-warmed at 37 °C for 1 hour before use. 
 
2.1.10.10  Sterile glycerol  
Glycerol (Sigma, USA) was autoclaved and used to stock cells.  
 
2.1.10.11 Stocking medium 
40 % glycerol dissolved in LB broth was used to stock bacterial culture stocks 
at -80 °C. 
 
2.1.10.12  Plasmid isolation reagents  
The QIAprep® Spin Miniprep Kit was used for plasmid isolation. Upon 
arrival of the kit, RNase A was added to Buffer P1 and stored at 4 °C.  
 
2.1.10.13  Reagents for restriction enzyme digestion  
10 X Restriction Enzyme Buffer      2 μl  
H2O         Top up to 20 μl  
Restriction Enzyme        1 U  
The restriction enzymes used in this study were obtained from Promega 
(USA). The respective compatible buffers with 100 % activity were used for 








2.1.10.14  Reagents for sequencing  
2.1.10.14.1  Cycle sequencing reaction  
Terminator Ready Reaction Mixture      4 μl  
BigDye Sequencing Buffer       4 μl  
Primer (5 OD)        1 μl  
Nuclease-free water       Top up to 20 μl  
The individual components for TA ligation were obtained from BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA).  
 
2.1.10.14.2  Purification of extension products  
3 M Sodium acetate (pH 4.6)       3 μl  
95 % Ethanol         62.5 μl  
Nuclease-free water        14.5 μl  
 
2.1.11  Reagents for quantitative polymerase chain reaction (qPCR) 
2.1.11.1  Reverse transcription (RT) mixture for mRNA  
10 X RT buffer        1 μl  
25 mM MgCl2        2.2 μl  
10 mM dNTPs mixture       2 μl  
50 μM Random hexamers       0.5 μl  
20 U/μl RNase inhibitor       0.2 μl  
50 U/μl MultiScribe™ Reverse transcriptase     0.25 μl  
Nuclease-free water        1.85 μl  
The individual components were available in the Taqman RT Reagents kit 




2.1.11.2  Stem-loop RT mixture for miRNA  
10 X RT buffer        1.5 μl  
100 mM dNTPs mixture       0.15 μl  
20 U/μl RNase inhibitor       0.19 μl  
50 U/μl MultiScribe™ Reverse transcriptase    1 μl  
miRNA stem-loop primer      3 μl 
Nuclease-free water        7.16 μl  
The individual components for the miRNA RT mixture were obtained from 
the Taqman miRNA RT kit (Applied Biosystems, Carlsbad, CA, USA).  
 
2.1.11.3  SYBR green assay for mRNA  
2 X SYBR Green PCR Master Mixture     10 μl  
Forward primer (10 µM)       0.6 μl  
Reverse primer (10 µM)       0.6 μl  
Nuclease-free water        3.8 μl  
The real-time PCR master mixture reagents and primer-probes were obtained 
from Applied Biosystems (USA). Gene specific forward and reverse primers 
for SYBR Green assays were purchased from 1st Base (Singapore).  
 
2.1.11.4  Taqman assay for microRNA  
2 X Taqman Universal PCR Master Mixture    10 μl 
      (without AmpErase® UNG) 
20 X Taqman miRNA probe       1 μl  
Nuclease-free water        7.67 μl  
The TaqMan Universal PCR Master Mixture reagent, custom primers and 




2.1.12  Reagents for miRNA array  
2.1.12.1  miRNA dephosphorylation (per sample)  
Spike-in miRNA        2.0 μl  
Calf intestinal alkaline phosphatise (CIP) Buffer   0.5 μl  
CIP Enzyme         0.5 μl  
 
2.1.12.2  miRNA labelling (per sample)  
Labelling buffer        3.0 μl  
Hy3 Fluorescent label       1.5 μl  
DMSO         2.0 μl  
Labelling Enzyme        2.0 μl  
 
2.1.12.3  Wash buffers  
2.1.12.3.1 Wash buffer A  
20 X Salt buffer        60 ml  
10 % Detergent solution       12 ml  
Sterile water         528 ml  
Wash buffer A and two washing dishes was pre-warmed overnight to 56 °C 
prior to use.  
 
2.1.12.3.2 Wash buffer B  
20 X Salt buffer        20 ml  






2.1.12.3.3 Wash buffer C  
20 X Salt buffer        2 ml  
Sterile water         198 ml  
 
2.1.13  Reagents for mRNA array  
2.1.13.1  Reverse transcription master mixture  
Spike-Mix        5 µl 
T7 Promotor Primer        1.2 µl 
5 X First Strand Reaction buffer     4 µl 
0.1 M Dithiothreitol (DTT)      2 µl 
10 mM dNTP mix       1 µl 
MMLV-Reverse Transcriptase     1 µl 
RNaseOUT        0.5 µl 
Nuclease-free water          Top up to 20 µl 
 
2.1.13.2  Transcription master mix 
Nuclease-free water        15.3 µl  
4 X Transcription Buffer       20 µl 
0.1 M DTT         6 µl 
NTP mix         8 µl 
50 % PEG         6.4 µl 
RNase OUT         0.5 µl  
Inorganic pyrophosphatase       0.6 µl  
T7 RNA Polymerase        0.8 µl  




2.1.13.3 Fragmentation mix 
Cyanine 3-labeled, linearly amplified cRNA    1 μg 
10 X Blocking Agent        5 μl 
Nuclease-free water          Top up to 24 μL 
25 X Fragmentation Buffer       1 μl 
 
2.1.13.4   Hybridization mix 
cRNA from Fragmentation Mix      25 μL 
2 X GEx Hybridization Buffer HI-RPM     25 µl  
 
2.2  Methods  
2.2.1  Secondary Cell Culture  
2.2.1.1  Culturing SH-SY5Y cells  
SH-SY5Y cell lines were cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM). The medium was supplemented with 10 % fetal bovine serum, 100 
U of penicillin and 100 μg/ml of streptomycin (section 2.1.1.5). All cells were 
cultured in T-75 flasks and maintained in a 37 °C incubator with 5 % CO2.  
 
2.2.1.2  Culture of HeLa cells 
HeLa cells were cultured in DMEM complete medium (section 2.1.1.5). Upon 
reaching 80% confluency, the cells were harvested and seeded on 24-well 
plates at 60,000 cells per well in complete DMEM (section 2.1.1.5). The cells 






2.2.1.3 Poly-d-lysine coated 24-well plates 
24-well plates were coated with poly-d-lysine a day before cell seeding. Three 
hundred µl of 0.1 mg/ml poly-d-lysine (section 2.1.1.7) was added to each 
well of a 24-well plate and incubated at 37°C overnight. The next day, the 
poly-d-lysine solution was removed and each well washed twice with 1 ml of 
sterile autoclaved water. All the water was aspirated and the plates were 
allowed to dry in the cell culture hood for at least one hour prior to seeding on 
the same day. For immunocytochemistry, autoclaved 12 mm round glass cover 
slips (Marienfeld, Germany) were inserted into each well prior to coating and 
treated as described above. 
 
2.2.1.4  Differentiation of SH-SY5Y cells 
SH-SY5Y cells were cultured in DMEM complete medium (section 2.1.1.5). 
Upon reaching 80 % confluency, the cells were harvested and seeded in 24-
well poly-d-lysine coated plates at 60,000 cells per well in complete DMEM. 
The next day, the medium was changed to SH-SY5Y differentiation medium 
(Section 2.1.1.9). After three days, half of the medium was replenished with 
fresh differentiation medium and neuron-like cells were obtained on Day 5. 
 
2.2.2  Primary Cell Culture  
2.2.2.1  Culture of primary mouse cortical neurons  
Primary cultures of cortical neurons were established from E15 Swiss albino 
mouse brains [239]. Surgical tools were autoclaved before the procedure. The 
pregnant Swiss albino mouse was euthanized using carbon dioxide. The 




incision was made in the abdomen and the uterus containing the embryos was 
removed. The uterus was cut and embryonic sacs were released from which 
the embyos were removed. The embryos were collected in HBSS (section 
2.1.3.2). The embryos were decapitated and whole brain removed. The cortex 
was dissected out and meninges removed under a dissecting microscope. Each 
cortex was cut into 3-4 smaller pieces and collected in a 50 ml tube containing 
HBSS. The cortices were washed once with HBSS, centrifuged at 120 x g for 
1 minute and re-suspended in 0.05 % (w/v) trypsin (section 2.1.3.4) dissolved 




 (section 2.1.3.3) for 30 minutes at 37 °C [239]. 
The trypsin solution was removed and neutralized using freshly-prepared, 
sterile-filtered and pre-warmed 1 mg/ml trypsin inhibitor (Section 2.1.3.5) 
[240]. The cortices were obtained by centrifugation at 120 x g for 1 minute 
and 5 ml Neurobasal medium supplemented with B27, L-glutamine and 
penicillin-streptomycin (section 2.1.3.7) was added. Single cells were obtained 
by gentle trituration in Neurobasal medium using first a regular 10 ml pipette 
followed by an autoclaved 5¾ inch Pasteur pipette [241]. The dissociated cells 
were allowed to settle for 1 minute after which the supernatant was transferred 
into another tube. The single cell suspension was centrifuged for 5 mins at 120 
x g and the cells were resuspended again in Neurobasal medium. The cells 
were counted by trypan blue (section 2.1.3.8) exclusion using a 1:1 ratio and 
seeded on to poly-d-lysine coated 24 well plates (section 2.2.1.3) at a density 
of 120,000 cells/cm
2
. The cells were maintained in neurobasal medium at 37 
°C with 5 % CO2 in a tissue culture incubator. The medium was replenished 





2.2.2.2  Oxygen-glucose deprivation 
Oxygen and glucose deprivation (OGD) is an in vitro model of ischemic-
reperfusion injury. This is achieved by placing the cells in medium without 
glucose, serum and in an incubation chamber (maintained at 37 °C) in which 
oxygen is displaced with nitrogen. Primary neuronal cultures from day 6 were 
subjected to oxygen-glucose deprivation (OGD) conditions as previously 
described [242]. OGD medium (Section 2.1.3.9) was saturated with a mixture 
of 5 % CO2, 95 % N2, in a ProOx in vitro chamber (BioSpherix, USA) at      
37 ºC overnight, with O2 maintained at 0.1 %. Day 6 neuronal cultures were 
washed twice with this medium and incubated for 2 and 4 hours in the 
chamber. OGD was terminated by replacing the glucose-free EBSS with 
reperfusion medium (Neurobasal medium with L-glutamine and Penicillin-
streptomycin, without B27 supplement). Control cultures were treated 
identically but with OGD control medium (Section 2.1.3.11) and without 
exposure to no oxygen conditions. During reperfusion, the cells were 
maintained in a regular 5 % CO2 incubator for 24 hours before further studies. 
 
2.2.3  Transfection  
2.2.3.1  siRNA/miRNA transfection  
siPORT NeoFX transfection reagent (Ambion, USA) and Opti-MEM (Gibco, 
USA) were mixed in a ratio of 1:49 μl. The mixture was incubated at room 
temperature for 10 minutes. The siRNA/miRNA (Ambion, USA) was diluted 
to the desired concentration in 50 μl Opti-MEM. The diluted transfection 
reagent and the siRNA/miRNA were then mixed in a ratio of 1:1 and 




siRNA/miRNA-transfection reagent mixture was added drop-wise into wells 
containing 400 µl of respective medium for the specific cell type. Following 
24 hours of incubation, 500 μl of complete medium was added into the wells. 
Transfection was terminated at 48 hours. For transfection of neurons subjected 
to OGD, cells were transfected immediately after reperfusion and harvested 24 
hours after transfection. Wells treated with negative control siRNA/miRNA 
(Ambion, USA) were used to calculate the percentage of gene knockdown in 
the siRNA/miRNA treated wells.  
 
2.2.3.2  LNA GapmeR transfection in primary neurons  
Knockdown of long non-coding RNAs (lncRNAs) in this study was performed 
using Locked-Nucleic-Acid (LNA)™ longRNA GapmeRs. LNA™ longRNA 
GapmeRs are antisense oligonucleotides that consist of DNA monomers with 
LNA™ modified nucleotides on either side. The LNA™ modified nucleotides 
increase affinity for their target whereas nuclease resistance of the oligo and 
the DNA gap activates RNase H cleavage of the target lncRNA upon binding. 
LncRNAs can be localized in both the cytoplasm and nucleus [97]. Since 
RNase H is present in both cellular components, LNA™ Gapmers mediate 
significantly better knockdown of nuclear targets than siRNA mediated 
silencing. Therefore, LNA™ GapmeRs serve as the best tool for lncRNA 




 RNAiMAX (Invitrogen, USA) and Opti-MEM (Gibco, USA) 
were mixed at a ratio of 1.5:48.5 μl. The mixture was incubated at room 




desired concentration in 50 μl Opti-MEM. The diluted transfection reagent 
and the LNA™ longRNA GapmeR were then mixed at a ratio of 1:1 and 
incubated at room temperature for another 20 minutes. One hundred μl of 
LNA™ longRNA GapmeRs-transfection reagent mixture was added drop-
wise to Day 6 primary neuronal cultures containing 300 µl of Neurobasal 
medium. Scrambled LNA™ GapmeRs were transfected as control. Four hours 
after transfection, the medium was topped up with 500 µl Neurobasal medium. 
Transfection was terminated at 48 hours. Wells treated with scrambled LNA™ 
GapmeRs were used to calculate the percentage of gene knockdown in the 
LNA™ longRNA GapmeR treated wells.  
 
2.2.3.3  Expression plasmid transfection in primary neurons  
Lipofectamine
®
 2000 (Invitrogen, USA) and Opti-MEM (Gibco, USA) were 
mixed at a ratio of 12:38 μl. The mixture was incubated at room temperature 
for 10 minutes. Three µg of expression plasmid was diluted in 50 μl Opti-
MEM. The diluted transfection reagent and the expression plasmid were then 
mixed at a ratio of 1:1 and incubated at room temperature for another 20 
minutes. One hundred μl of expression plasmid-transfection reagent mixture 
was added drop-wise to Day 6 primary neuronal cultures containing 300 µl of 
Neurobasal medium. Expression plasmid without insert was transfected as 
control. Four hours after transfection, the medium was topped up with 500 µl 
Neurobasal medium. Transfection was terminated at 48 hours. Wells treated 
with expression plasmid without insert were used to calculate the percentage 
of gene expression in the wells treated with expression plasmid containing the 




2.2.3.4  Expression of plasmid in differentiated SH-SY5Y cells using 
tet on/off system   
To carry out the minigene splicing assay in SH-SY5Y cells, the tet on/off 
system was used. The ratio of 1:6 for TO:TR respectively was used for all 
transfection experiments. Prior to transfection, the cells were seeded in 
complete DMEM. On the day of transfection, Lipofectamine
®
 2000 
transfection reagent and Opti-MEM were complexed at a ratio of 3:150 μl and 
incubated at room temperature for 10 minutes. One hundred ng of 
pcDNA™4/TO/myc-HisA plasmid with insert and 600 ng of pcDNA™6/TR 
vector was added to 150 μl Opti-MEM per well. SH-SY5Y cells seeded earlier 
in 24-well plates were washed with 300 μl of Opti-MEM before adding 300 μl 
of the miRNA-transfection reagent mixture. The cells were maintained in the 
37 °C CO2 incubator for 5 hours. Towards the end of the 5 hour incubation, 
the medium was replaced with SH-SY5Y differentiation medium (Section 
2.1.1.9). The medium was replenished after 3 days. Four days after 
transfection, the miRNA inhibitor or mimics were transfected followed by 
tetracycline to express the gene of interest. siPORT NeoFX transfection 
reagent (Ambion, USA) and Opti-MEM (Gibco, USA) were mixed at a ratio 
of 1:49 μl. The mixture was incubated at room temperature for 10 minutes. 
The miRNA (Ambion, USA) was diluted in 50 μl Opti-MEM to achieve       
30 nM final concentration. Previously, optimization of miRNA inhibitor or 
mimics concentrations showed that a concentration of 30 nM resulted in 
optimal modulation of miRNA levels and hence this concentration was used 
for miRNA modulation studies in this thesis unless stated otherwise. The 
diluted transfection reagent and the miRNA were then mixed at a ratio of 1:1 




siRNA/miRNA-transfection reagent mixture was added drop-wise into wells 
containing 200 µl of SH-SY5Y differentiation medium. The cells were 
maintained in the 37 °C CO2 incubator for 3 hours. At the end of the 3 hour 
incubation, the medium was topped up with SH-SY5Y differentiation medium 
containing tetracycline to achieve a final concentration of 1 μg/ml tetracycline. 
The cells were harvested 24 hours later. Gene expression was normalized to 
cells treated with negative control miRNA (Ambion, USA). 
 
2.2.3.5  miRNA and reporter plasmid transfection  
For miRNA target interaction studies, miRNA inhibitor or mimic was co-
transfected with luciferase reporter plasmids harbouring the target recognition 
sites. miRNA transfection was first carried out. Lipofectamine
®
 2000 
transfection reagent (Invitrogen, USA) and Opti-MEM (Gibco, USA) were 
mixed at a ratio of 1.5:150 μl and incubated at room temperature for 10 
minutes. The miRNAs inhibitor or mimic (Ambion, USA) was diluted to a 
concentration of 30 nM in 150 μl Opti-MEM. The diluted transfection reagent 
and the miRNA complex were subsequently mixed at a ratio of 1:1 and 
incubated at room temperature for another 20 minutes. HeLa cells seeded 24 
hours earlier in 24-well plates were washed with 300 μl of Opti-MEM before 
adding 300 μl of the miRNA-transfection reagent mixture. The cells were 
maintained in the 37 °C CO2 incubator for 3 hours. Towards the end of the     
3 hour incubation, plasmid transfection preparation was carried out. 
Lipofectamine
®
 2000 transfection reagent and Opti-MEM were complexed at 
a ratio of 3:150 μl and incubated at room temperature for 10 minutes. Two 




Expression Reporter Vector (Ambion, USA) and 5 ng of pRL-CMV 
(Promega, Madison, USA) vector (section 2.1.10.4) were added to 150 μl 
Opti-MEM per well. pRL-CMV (Promega, Madison, USA) vector was used to 
determine transfection efficiency. The diluted transfection reagent and the 
plasmids were then mixed at a ratio of 1:1 and incubated at room temperature 
for another 20 minutes. At the end of the 3 hour incubation, the medium was 
removed and the cells were washed again with Opti-MEM. Three hundred μl 
of the plasmid transfection reagent mixture was added into the wells. The cells 
were maintained in the 37 °C CO2 incubator for another 3 hours. After the      
3 hours, the medium was replaced with complete medium (DMEM) and the 
cells were left to grow for another 48 hours, following which luciferase assay 
was performed.  
 
2.2.4  Luciferase assay  
The Dual-Luciferase® Reporter (DLR) assay system was employed (Promega, 
Madison, USA) to study miRNA:mRNA interaction. This assay system allows 
the simultaneous expression as well as measurement of two individual reporter 
enzymes within a single system. The firefly luciferase expression indicates the 
interaction between the miRNA and its target mRNA, whereas the activity of 
the co-transfected Renilla luciferase served as an internal control. Forty eight 
hours after transfection, the medium was removed and the cells were washed 
with PBS. One hundred μl of 1 X passive lysis buffer was added to each well 
and the cells were agitated for 10 minutes on a shaker. The cells were then 
collected and centrifuged at maximum speed for 2 minutes and the cell lysate 




white optical plate in a luminometer and firefly luciferase activity was 
measured after addition of 50 μl Dual-GloTM Luciferase substrate. The firefly 
luciferase activity was quenched by adding 50 μl of Stop & GloTM reagent and 
the luminescence for Renilla luciferase activity was measured. Firefly 
luciferase activity was normalized to the renilla luciferase activity. This ratio 
for every treatment was then normalized to the scrambled negative control to 
determine the miRNA:mRNA interaction. 
  
2.2.5  MTT cell viability assay 
The MTT cell viability assay is a colorimetric assay that measures the 
reduction of MTT into an insoluble formazan product by the activity of 
mitochondrial enzymes in viable cells. This assay was used to determine cell 
viability under different experimental conditions. After each treatment, 
concentrated MTT (10 mg/ml, section 2.1.3.12) was added to each well to a 
final concentration of 0.5 mg/ml. After 1 hour incubation at 37 °C in the dark, 
the MTT-containing medium was removed and the formazan crystals were 
dissolved in 200 μl dimethyl sulfoxide (DMSO) (MP Biomedical, USA) with 
gentle shaking for 10 minutes to ensure complete dissolution of the crystals. 
One hundred μl of the dissolved crystal solution was transferred to a 96-well 
plate with 100 μl DMSO used as a blank. The absorbance was measured at a 
wavelength of 570 nm using a multi-plate scanning spectrophotometer (Bio-
Rad, Model 680 Microplate Reader). Viability of the treated cells was 






2.2.6  Annexin V/Ethidium homodimer III/Hoechst nuclear staining 
The apoptotic, necrotic and healthy cells quantification kit from Biotium, 
USA, was used to quantitate each cell type. The two major processes of cell 
death are apoptosis and necrosis. The morphological assessment of cell death 
was carried out using Ethidium homodimer III/Annexin V/Hoechst 33342 
dyes based on cell membrane permeability and chromatin condensation. 
Apoptotic cells have intact membranes but condensed, fragmented chromatin 
whereas necrotic cells have disrupted cell membranes and enlarged nuclei. 
During apoptosis, phosphotidylserine which is normally found in the integral 
part of the plasma membrane becomes translocated to the extracellular face. 
The human anticoagulant, annexin V, is a 35 kDa Ca
2+
-dependent 
phospholipid protein with high affinity for phosphotidylserine. Annexin V 
labeled with fluorescein (FITC) hence stains cells green by binding to 
phosphotidylserine exposed on the outer leaflet. Necrosis resulting from a 
severe cellular insult, causes loss of internal organelle and plasma membrane 
integrity. This results in spillage of cytosolic and organellar contents into the 
surrounding environment. Ethidium homodimer III is a highly positively 
charged nucleic acid probe that is impermeable to live cells or apoptotic cells, 
but stains necrotic cells with red fluorescence. Hoechst 33342 is a cell 
membrane-permeable, minor groove-binding DNA stain that releases bright 
blue fluorescence upon binding to DNA and used to stain the nuclei of living 
cells. Condensation of DNA in apoptotic cells can also be detected using 
Hoechst 33342. This assay was used to quantify the different types of cell 
death under different experimental conditions. After each treatment, cells in 




solution for 15 minutes at room temperature. The dye solution was made up of 
5 μl of FITC Annexin V, 1 μl of Ethidium Homodimer III and 2 μl of Hoechst 
33342 per 100 μl of 1 X binding buffer. Stained cells were protected from 
light until visualized by fluorescence microscopy (Leica DMIRB, Germany). 
Images were captured at 40 × objectives and cell morphology was determined. 
A minimum of 3 fields of at least 100 cells per field were counted to 
determine the percentage of apoptotic cells from the total number of cells. 
Experiments were carried out in triplicates and repeated at least three different 
times (n ≥ 3).  
 
2.2.7  Immunocytochemistry (ICC)  
For immunofluorescence studies, the cells were grown on sterile coverslips in 
24-well plates. On specified days or after OGD treatment or transfection, the 
cells were fixed in 1 ml of 4 % formaldehyde dissolved in PBS (Section 
2.1.1.1) for 20 minutes, permeabilized with 1 ml of 0.1 % Triton X-100 
(Section 2.1.4.2) for 30 minutes and then blocked with 1 ml of 5% FBS in 
PBS (Section 2.1.4.3) for 30 minutes at room temperature. The coverslips 
were removed from the wells and placed on a clean surface. The fixed cells 
were incubated with 50 µl of mouse anti-MAP2 (1:500; Abcam, Cambridge, 
UK), mouse anti-NeuN (1:1000; Abcam, Cambridge, UK), rabbit anti-Sox2 
(1:250; Abcam, Cambridge, UK), rabbit anti-CD11b (1:500; Abcam, 
Cambridge, UK), rabbit anti-GFAP (1:500; Abcam, Cambridge, UK), mouse 
IgM anti-O4 (1:100; Sigma, USA) or rabbit anti-NEGR1 (1:500; Abcam, 
Cambridge, UK) primary antibody for 1 hour at room temperature. The 




50 µl of FITC-, Texas Red- or Cy5-coupled secondary antibodies (1:200; 
Abcam, Cambridge, UK) for 1 hour at room temperature. The coverslips were 
once again washed three times with PBS and 50 µl of Hoechst 33342 nuclear 
stain (Section 2.1.3.13) was overlaid on the coverslips for 1 minute. The 
coverslips were washed again three times before being mounted face down 
onto microscope slides. Images were viewed and analyzed using LSM710 
confocal imaging software (Carl Zeiss MicroImaging Inc, Germany). 
 
2.2.8   Evaluation of in vitro neurite outgrowth  
Images of Hoechst 33342 and MAP2 immunostained neurons (section 2.2.7) 
were imported into ImageJ and processed using the NeuriteTracer
® 
plugin 
according to Pool et al (2008). NeuriteTracer
® 
outputs of neurite length and 
number of nuclei for each field were retrieved. The average neurite length for 
each treatment was determined and analyzed by the student’s t-test. 
 
2.2.9  Extraction of DNA from cells  
DNA from SH-SY5Y cells was used to clone the NTRK2 gene fragments for 
generation of the NTRK2 splicing minigene. One ml of DNAzol
®
 Reagent 
(Invitrogen, USA) was added to one T-25 flask and the cells were lysed by 
agitating the flask. The lysate was collected into an eppendorf tube and 
pipetted with wide-bore pipette tips. Addition of 0.5ml of absolute ethanol 
precipitated the DNA. The samples were mixed by inversion and stored at 
room temperature for 1 minute. The DNA was visible as a cloudy precipitate 
and was transferred to a clean tube by spooling with a pipette tip. The sample 




times. After each wash, the tube was left to stand for 1 minute to allow the 
DNA to settle at the bottom and the ethanol was removed by pipetting. The 
tubes were then air dried for 15 seconds and the DNA pellet was dissolved in 
8 mM NaOH. The concentration and purity of genomic DNA was determined 
using ND-2000c Spectrophotometer (Nanodrop™, Thermo Fisher Scientific, 
USA). The DNA was stored at -20 °C and 1 μl of a 10 X diluted DNA was 
used to perform PCR in a 25 μl volume (Section 2.1.10.2).  
 
2.2.10  DNA gel electrophoresis  
DNA gel electrophoresis is used to separate different sizes of DNA molecules 
for separation, identification and purification. The size of DNA fragments in 
the sample to be run determines the percentage of agarose in the gel; high 
percentage agarose gels are used for separation of low molecular weight DNA 
molecules and vice versa. In this study, DNA fragments were resolved by 
electrophoresis in 1 % agarose gels. One percent DNA agarose gel (section 
2.1.6.3) was heated till molten and poured into a horizontal gel-casting tray 
with comb. After solidification, the comb was removed and the gel was 
submerged into an electrophoresis tank containing 1 X TBE running buffer 
(section 2.1.6.1). DNA samples were mixed with the 6 X loading buffer 
(Promega, USA) prior to loading into the gel. One hundred bp or 1 kb plus 
markers (Promega, USA) were used accordingly. Electrophoresis was carried 
out at 80 V for about 1 hour and the migration of the bands was viewed using 
a UV illuminator (Cell Biosciences, USA). The DNA fragment-of-interest was 





2.2.11  Isolation of total RNA from cells 
Upon completion of a treatment, medium from 24-well plates was aspirated 
and the wells were washed with PBS. One ml of TRizol® reagent was 
aliquoted into three wells of a 24-well plate and pipetted up and down to mix 
and lyse the cells. The TRIzol reagent was collected in a 1.5ml eppendorf 
tube. Total RNA was isolated according to the manufacturer’s instructions. In 
brief, 200 μl of saturated chloroform was added to the tube and mixed 
vigorously. The tube was incubated at room temperature for 3 minutes before 
centrifugation at 12,000 x g for 15 minutes at 4 °C. The aqueous phase was 
transferred to a new tube. Three units of DNase I was added to 500 µl of the 
aqueous phase and incubated in a 37 °C water bath for 20 minutes before the 
addition of 500 μl of isopropanol. The tube was shaken vigorously and left 
overnight at -80 °C. Total RNA was precipitated by centrifugation at           
12,000 x g for 10 minutes at 4 °C. The pellet was washed by centrifuging it 
with 1 ml of ice-cold 75 % ethanol (Section 2.1.7.1) at 12,000 x g for 5 
minutes at 4 °C. The supernatant was discarded and the resultant pellet was 
air-dried before it was dissolved in 20 μl of autoclaved water. RNA 
concentration was determined by ND-2000c Spectrophotometer (Nanodrop™, 
Thermo Fisher Scientific, USA) at 260 nm.  
 
2.2.12  Checking RNA integrity  
2.2.12.1  RNA agarose gel electrophoresis  
After RNA isolation, it is necessary to determine the RNA integrity to ensure 
it is not degraded for accurate subsequent analysis. Hence, the isolated RNA 




RNA gel was prepared as described in section 2.1.8.5 and the molten agarose 
was poured into a horizontal gel-casting tray with a comb to create wells for 
sample loading. Upon solidification, the comb was removed and the gel was 
submerged in an electrophoresis tank containing 1 X MOPS running buffer 
(section 2.1.8.1). The isolated RNA samples were mixed with the sample 
buffer as described in section 2.1.8.4. The mixture was incubated for 10 
minutes in a 65 °C water bath for 10 minutes and loaded into the gel wells. 
Electrophoresis was carried out at 100 V for approximately 20 minutes and the 
migration of the bands was viewed using a UV illuminator (Cell Biosciences, 
USA).  
 
2.2.12.2  Denaturing polyacrylamide gel electrophoresis  
The integrity of the small RNAs was analysed using denaturing 
polyacrylamide gel electrophoresis. The polyacrylamide gel was prepared as 
described in section 2.1.9.1 and cast in a vertical gel-casting tray. A comb was 
used to create wells for sample loading. After solidification, the comb was 
removed and the gel submerged into an electrophoresis tank containing 1 X 
TBE running buffer (section 2.1.6.1). The gel was pre-run for 30 minutes at 
100 V while the RNA samples were mixed with the sample buffer (section 
2.1.9.2) and heated at 95 °C for 5 minutes. The samples were chilled 
immediately in ice and spun down before loading into the gel wells. 
Electrophoresis was carried out at 100 V for about 2 hours and the gel was 
stained in water containing 1 µl of 10 mg/ml ethidium bromide (section 
2.1.6.2). The migration of the bands was viewed using a UV illuminator (Cell 




2.2.13  Cloning 
2.2.13.1  First strand cDNA synthesis for cloning  
Total RNA from mouse primary neuronal cultures and SH-SY5Y cells were 
reverse transcribed using the RevertAid™ H Minus First Strand cDNA 
Synthesis Kit (Thermo Scientific, USA) (Section 2.1.10.1). One μg of total 
RNA and 1 μl of random hexamers were aliquoted into a sterile PCR tube 
containing RNase free water. The volume was adjusted to 12 μl. The contents 
in the tube were mixed, centrifuged and incubated at 65 °C for 5 minutes. The 
tube was chilled on ice and the remaining components of the Fermentas 
RevertAid™ H Minus First Strand cDNA Synthesis Kit were added (Section 
2.1.10.1). The contents were mixed and centrifuged briefly. The PCR tube was 
incubated at 25 °C for 10 minutes, 60 minutes at 42 °C and 70 °C for 5 
minutes. One μl of the cDNA was directly used to perform PCR in a 25 μl 
volume (Section 2.1.10.2).  
 
2.2.13.2  Polymerase chain reaction (PCR)  
Complementary DNA or genomic DNA was used as template for PCR for 
cloning of messenger RNA or gene respectively. The reaction was prepared on 
ice in thin-walled PCR tubes as described in section 2.1.10.2. One μl of the 
template was added and the contents were spun down. The PCR cycling 
conditions were determined by the melting temperatures (Tm) of the primers 
used and the size of the product amplified. The annealing temperature was set 
5 °C below the primer Tm for 45 seconds while 72 °C was used as the 
extension temperature. After 30 cycles of amplification, 10 μl of the product 




desired fragment size, the gel fragment was excised out with a clean, sharp 
scalpel for extraction of the DNA from the gel.  
 
2.2.13.3  DNA gel extraction  
The QIAquick Gel Extraction kit (Qiagen) was used to extract and purify 
DNA from agarose gel. The excised gel was weighed and dissolved in 3 times 
the volume of QG buffer at 50 °C for 10 minutes. Once the gel had completely 
dissolved, one volume of isopropanol was added and the sample was loaded 
onto a QIAquick spin column (attached to a collection tube) and centrifuged at 
12,000 x g for 1 minute. The flow-through in the collection tube was discarded 
and the column was washed with 0.7 ml of buffer PE (Qiagen). Following 
centrifugation at 12,000 x g for 1 minute, the flow-through was discarded and 
the wash repeated. The column was spun one more time to remove any 
residual wash buffer. The spin column was placed in a clean 1.5ml microfuge 
and the bound DNA was eluted with 20 µl of nuclease-free water by 
centrifuging for 2 minute at 12,000 x g. The integrity of the DNA was verified 
by running 2 µl of the eluant on a 1 % agarose gel. The remaining DNA was 
used for cloning or stored at stored at –20 °C.  
 
2.2.13.4  Ligation and transformation  
Ligation of PCR products and vector were performed in a vector:insert ratio of 
1:3 for maximum ligation efficiency. Approximately 50 ng of plasmid was 
used for each ligation reaction (sections 2.1.10.3.1 and 2.1.10.3.2) and the 
ligation mixture was incubated at room temperature for 30 minutes. 




on ice. At the end of the 30 minutes, the ligation mixture was added to 50 μl of 
the competent cells (section 2.1.10.6) and mixed gently. The tube was kept in 
ice for another 30 minutes. The cells were then heat-shocked for 1 minute at 
42 °C and returned to ice for 5 minutes. Two hundred and fifty µl of SOC 
medium (Invitrogen, USA) was added to the cells and the mixture transferred 
to a 10 ml falcon tube. The cells were incubated for 1 hour at 37 °C with 
shaking at approximately 150 rpm before plating on LB-agar plates (section 
2.1.10.9) containing ampicillin (section 2.1.10.7). The plates were incubated at 
37 °C for approximately 18 hours to allow colonies to grow. Single colonies 
were picked and re-grown for another 18 hours in 1.5 ml LB broth (section 
2.1.10.8) containing ampicillin.  
 
2.2.13.5  Plasmid extraction  
Extraction of plasmid from bacterial cells was carried out using the QIAprep® 
Spin Miniprep Kit (section 2.1.10.12) for further verification of the cloned 
fragments. One point five ml of the individually grown colonies were 
transferred into an eppendorf tube and pelleted by centrifuging at 12,000 x g 
for 2 minutes. The supernatant was discarded and the pellet resuspended in 
250 μl of Buffer S1. The tube was vortexed vigorously to ensure complete 
resuspension. Two hundred and fifty μl of Buffer S2 was added and mixed 
thoroughly by inverting the tube 4-6 times. After no more than 5 minutes,   
350 μl of Buffer S3 was added and mixed immediately by inverting the tube 4-
6 times. Subsequently, the tube was centrifuged at 12,000 x g for 10 minutes 
to obtain a compact white pellet. The supernatant was filtered through the 




750 μl of Buffer W2. Residual wash buffer was removed by an additional 
centrifugation. The spin column was placed in a clean 1.5 ml microfuge and 
the plasmid DNA was eluted with 20 μl of nuclease-free water by 
centrifugation for 2 minutes.  
 
2.2.13.6  Restriction enzyme digestion  
Restriction enzyme digestion was carried out to confirm for presence of the 
cloned fragment in the vector. Approximately 1 μg of the extracted and 
purified plasmid (section 2.2.13.5) was added to the restriction enzyme 
mixture (section 2.1.10.13) and the volume adjusted to 20 μl. The tubes were 
incubated at 37 °C overnight. For double digests, buffers compatible with both 
enzymes were used and analysed on a 1 % DNA agarose gel (section 2.1.6.3). 
If the digested fragment was required for further cloning, the fragment was 
excised with a clean, sharp scalpel and the DNA purified from the gel (section 
2.2.13.3).  
 
2.2.13.7  Sanger dideoxy DNA sequencing 
Sequencing of the cloned DNA fragments was carried out using the cycle-
sequencing technique and the sequencing was performed in an automated 
DNA sequencer (ABI PRISM
®
 3100 Genetic Analyzer, Applied Biosystems, 
USA) using M13 forward and reverse primers. This method employs a 
combination of traditional Sanger-Dideoxy sequencing chemistry (Sanger et 






2.2.13.7.1 Sequencing reaction 
The sequencing reaction is a polymerase chain reaction (PCR) which utilises 
the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 
USA) with specific primers and a DNA template. The sequencing mixture 
comprises fluorescence-tagged dideoxynucleotides that each emit specific 
fluorescence, Taq DNA polymerase. The reaction was set up as described in 
Section 2.1.10.14.1 and amplified for 25 cycles at 96 °C for 30 seconds, 50 °C 
for 15 seconds and 60 °C for 4 minutes.  
 
2.2.13.7.2  Purification of sequencing products 
The cycle-sequencing products were cleaned before proceeding to sequencing. 
The 20 µl sequencing reaction was topped up to 100 μl as described in section 
2.1.10.14.2. The mixture was vortexed briefly and allowed to precipitate on 
ice for 15 minutes. The products were pelleted by centrifugation at 12,000 x g 
for 20 minutes and the supernatant removed. Five hundred µl 75 % ethanol 
was added and the mixture vortexed followed by centrifugation for 15 
minutes. The ethanol was removed and the pellet dried for 10 minutes in a 
speed vacuum (Hetovac VR-1, Heto Lab Equipment, Denmark). The DNA 
pellet was resuspended in 10 µl Hi-Di
TM
 formamide (Applied Biosystems, 
USA) by vortexing for 1-2 minutes. The sample was loaded on 96-well plates 
and heated for 2 minutes at 95 °C before loading in the ABI PRISM
®
 3100 







2.2.14  Quantitative polymerase chain reaction (qPCR) 
Quantitative PCR or real-time PCR technology relies on real-time monitoring 
of the PCR amplification process using fluorescence to quantify the initial 
amount of template with high accuracy over a wide range of concentrations 
[243]. Changes in gene expression with a particular treatment were therefore 
determined by quantitative PCR. Quantitative PCR systems require highly 
specific primers and/or probes that fluoresce upon binding to double-stranded 
DNA or sequence-specific fluorescent oligonucleotide probes. This ensures 
that the correct PCR product is generated. Two detection systems widely used 
are the SYBR green and Taqman assay systems. The SYBR green assay 
utilizes gene-specific forward and reverse primers and a DNA intercalating 
dye. The Taqman assay also makes use of gene-specific forward and reverse 
primer with an additional gene-specific fluorescent probe. The PrimerExpress 
2.0 software was used to design gene specific primers such that the amplicons 
were no larger than 200 bp. Two-step reverse-transcription PCR was used. 
Reverse transcription of total RNA was first performed to generate cDNA 
followed by a separate real-time PCR step.  
 
2.2.14.1  Reverse transcription (RT)  
2.2.14.1.1  RT of mRNA  
Total RNA (200 ng in 2 μl) was reverse transcribed using 8 μl of reverse 
transcription mixture (section 2.1.11.1) to generate 10 μl of first strand 
complementary DNA (cDNA). cDNA synthesis was performed in a PCR 
machine (Perkin-Elmer, Germany) at 25 °C for 10 minutes, 37 °C for 60 




2.2.14.1.2  Stem-loop RT of miRNA  
Total RNA (10 ng in 2 μl) was reverse transcribed using 13 μl of miRNA RT 
mixture (section 2.1.11.2) to generate 15 μl of RT product. The 
complementary DNA was synthesized using a PCR machine (Perkin-Elmer, 
Germany) at 16 °C for 30 minutes, 42 °C for 30 minutes and 85 °C for 5 
minutes. miRNA specific primers were purchased as MicroRNA Assay kits 
(Applied Biosystems, USA).  
 
2.2.14.2  Real-time PCR  
2.2.14.2.1  Real-time PCR for mRNA  
Fifteen μl of the SYBR green assay mix (section 2.1.11.3) was mixed with 5 
μl of RT product (section 2.1.11.1) and loaded onto 96 well optical plates. The 
plates were sealed with an optical adhesive cover (Applied Biosystems, USA) 
and the reactions were carried out on Applied Biosystems 7500 sequence 
detection system. Thermal cycling conditions were 50 °C for 2 minutes, 95 °C 
for 10 minutes followed by 40 cycles at 94 °C for 15 seconds and 60 °C for 1 
minute per cycle. GAPDH was used as an internal calibrator. Results were 
generated from 3 technical replicates and 3 biological replicates for each 
dataset. Gene expression was quantified using the delta-delta Ct method and 
significance tested using the Student’s t-test. 
 
2.2.14.2.2  Real-time PCR for miRNA  
One point three three µl of miRNA RT product (Section 2.1.11.2) was added 
to the Taqman miRNA mix (section 2.1.11.4) and loaded onto 96 well optical 




Biosystems, USA) and the reactions carried out on Applied Biosystems 7500 
sequence detection system. Thermal cycling conditions were 50 °C for 2 
minutes, 95 °C for 10 minutes followed by 40 cycles at 94 °C for 15 seconds 
and 60 °C for 1 minute per cycle. The miRNA specific probes were purchased 
as MicroRNA Assay kits (Applied Biosystems, USA). GAPDH was used as 
an internal calibrator. Results were generated from 3 technical replicates and 3 
biological replicates for each dataset. Gene expression was quantified using 
the delta-delta Ct method and significance tested using the Student’s t-test. 
 
2.2.15  miRNA array  
2.2.15.1.1  Sample labelling  
The components of the miRCURY LNA
TM
 microRNA power labelling kit 
(Exiqon, Denmark) were thawed on ice. Total RNA from different treatments 
was extracted and diluted to a final concentration of 1 μg in 2 μl. 
Dephosphorylation of the miRNA was first performed to remove 5’-
phosphates from terminal of the miRNAs. Two μl of the CIP mixture (section 
2.1.12.1) was mixed with the RNA sample in a PCR tube and incubated in a 
PCR machine at 37 °C for 30 minutes followed by 95 °C for 5 minutes. The 
reaction was snap cooled in ice to terminate the reaction. The sample was spun 
down and 8.5 μl of the labelling mixture (section 2.1.12.2) was added. The 
miRNAs were labelled with Hy3 fluorophores in a PCR cycler with heated lid 
at 16 °C for 1 hour followed by 65 °C for 15 minutes. The samples were 
protected from light and kept at 4 °C for hybridization which was performed 





2.2.15.1.2  Sample preparation for hybridization  
The labelled product was diluted in 12.5 µl of nuclease-free water and the 
contents transferred into a new PCR tube. Twenty five µl of 2 X hybridization 
buffer (Exiqon, USA) was added to the sample and the contents vortex and 
spun down. The sample was denatured at 95 °C for 2 minutes and cooled on 
ice. Before loading the sample, pipette tips were pre-wet in 50 µl of                 
1 X hybridization buffer in nuclease-free water pre-warmed at 56 °C.  
 
2.2.15.1.3  Setting up of hybridization chamber  
The MAUI hybridization chamber was switched on and pre-heated to 56 °C. 
The miRCURY LNA™ microRNA Array chip (miRBase version 16.0) was 
warmed on the pre-heated block for 5 minutes and loaded onto a chip holder. 
A cover was aligned onto the exposed surface of the array chip to seal the 
exposed chip surface (Exiqon, Denmark). The enclosed chip assembly was 
placed back into the MAUI hybridization chamber for sample loading.  
 
2.2.15.1.4  Loading of sample for miRNA array  
Before sample loading onto the array slide, the pipette tips were pre-wet with 
1 X hybridization buffer. Forty five µl of the sample was slowly injected into 
the chip via the inlet port in the chip cover to ensure no bubbles were 
introduced. Sample introduction was stopped when the fluid reached the outlet 
port of the cover. The excess fluid was wiped away and the ports sealed with 
an adhesive tape. The enclosed chip assembly was loaded onto the pre-heated 
MAUI
®
 hybridization chamber, enclosed with a pre-wet humidity casing and 




2.2.15.1.5  Washing of miRNA array slides  
After hybridization, the chips were removed from the MAUI hybridization 
chamber and returned to a chip holder. The holder was soaked in 400 ml of 
pre-warmed Buffer A (section 2.1.12.3.1) and the cover of the chip was peeled 
away while the holder was fully submerged. The exposed chip was transferred 
to a rack immersed in a dish containing 200 ml of pre-warmed Buffer A. The 
chip was rinsed by gently plunging the rack for 2 minutes, ensuring the chip 
completely submerged throughout the washing procedure. The rack was then 
transferred to 200 ml of wash buffer B (section 2.1.12.3.2) at room 
temperature and the chip was stored here while the remaining chips were 
disassembled and rinsed in a similar manner. After collected all the chips in 
Buffer B, they were rinsed by gently plunging the rack for 2 minutes. 
Thereafter, the rack was moved to another dish containing fresh Buffer B 
solution and the chips washed by plunging for another 2 minutes. A third wash 
was carried out in wash buffer C (Section 2.1.12.3.3) and the final wash in  
200 ml of 99 % ethanol for 1 minute. The chips were dried by centrifugation at 
1,000 x g for 5 minutes at 23 °C and scanned immediately at 532 nm. 
  
2.2.15.1.6  Scanning of miRNA array chips  
The miRNA array chips were scanned on the InnoScan 700 Microarray 
scanner (Innopsys, France) and the signal intensity quantified using the Mapix 







2.2.15.2  LncRNA and mRNA arrays 
2.2.15.2.1  Sample labeling 
Expression profiling of lncRNAs and mRNAs was carried out side-by-side on 
the Arraystar Mouse LncRNA Microarray v2.0. Sample labeling and array 
hybridization were performed according to the Agilent One-Color Microarray-
Based Gene Expression Analysis protocol (Agilent Technologies, USA) with 
minor modifications. mRNA was purified from total RNA after removal of 
rRNA (mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre, USA). 
Then, 1 µg of total RNA, spike-in mix and T7 promoter primer (section 
2.1.13.1) were mixed and made-up to a volume of 11.5 µl using nuclease-free 
water. The primer and template were denatured at 65 °C for 10 minutes and 
then incubated on ice for 5 minutes. The remaining components of the reverse 
transcription master mix (section 2.1.13.2) were added to achieve a final 
volume of 20 µl. The samples were incubated at 40 °C for 2 hours, 65 °C for 
15 minutes and then kept on ice for 5 minutes. Sixty µl of transcription master 
mix (section 2.1.13.2) was added to each sample and incubated at 40 °C for 2 
hours. This procedure allowed amplification and transcription of the total 
RNA into fluorescent cRNA along the entire length of the transcripts without 
3’ bias utilizing a random priming method. The labeled cRNAs were purified 
by RNeasy Mini Kit (Qiagen, USA). The concentration and specific activity of 








2.2.15.2.2  Hybridization, washing and scanning of array chips  
One μg of each labeled cRNA was fragmented by adding 5 μl 10 × Blocking 
Agent and 1 μl of 25 × Fragmentation Buffer (section 2.1.13.3), and then 
heating the mixture at 60 °C for 30 minutes. Twenty five μl 2 × GE 
Hybridization buffer (section 2.1.13.4) was added to dilute the labeled cRNA. 
Fifty μl of hybridization solution was dispensed into the gasket slide and 
assembled to the Mouse LncRNA Array v2.0 (8×60 K, Arraystar Inc., 
Rockville, USA) microarray slide. The slides were incubated for 17 hours at 
65 °C in an Agilent Hybridization Oven. The hybridized arrays were washed, 
fixed and scanned on the Agilent DNA Microarray Scanner (part number 
G2505C). Thirty one thousand four hundred and twenty three lncRNAs and 
25,376 coding (mRNA) transcripts which were collected from the 
authoritative data sources including RefSeq, UCSC Known genes, Ensembl 
and many related literatures could be detected. Agilent Feature Extraction 
software (version 11.0.1.1) was used to analyze acquired array images.  
 
2.2.15.3  Pathway and gene ontology and target prediction analyses 
Gene ontology (GO) analysis for differentially expressed mRNA (Signal Log 
Ratio (SLR) > 1 or SLR < 1 relative to Day 2) was performed in the standard 
enrichment computation method using the Agilent GeneSpring GX software 
(version 11.5.1). For associated genes of lncRNAs (SLR > 1 or SLR < 1 
relative to Day 2), overrepresented GO biological processes were assigned 
using FuncAssociate [244] with p < 0.05. Overrepresented GO biological 
processes for differentially expressed miRNAs (SLR > 0.6 or SLR < 0.6 




that had differentially expressed mRNA as well as lncRNA associated with 
them were selected for pathway enrichment analysis using the web-accessible 
program, Database for Annotation, Visualization and Integrated Discovery 
(DAVID) version 6.7 [246,247].  
 
Both TargetScan (http://www.targetscan.org/) and microRNA.org 
(http://www.microrna.org/microrna/home.do) were utilised to predict the 
targets of the selected microRNAs. RNAhybrid (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/) was used for microRNA target prediction for lncRNA.  
This tool determined the minimum free energy hybridisation for a long and 
short RNA, to predict the targets for ncRNAs [248]. 
 
2.2.15.4  Statistical analyses 
For mRNA and lncRNA data analyses, quantile normalization and subsequent 
data processing were performed using the GeneSpring GX v11.5.1 software 
package (Agilent Technologies, USA). For miRNA data analysis, background-
subtracted mean intensity of 300 was selected as a threshold value before 
normalization against all endogenous controls. For comparison of mRNA, 
lncRNA and miRNA profiles, data for maturing neurons was normalized to 
day 2 and data for neurons subjected to OGD was normalized to 0 hour 
control. Hierarchical clustering plots were generated using TIGR multiple 
experimental viewer software [249]. All the microarray data described in this 
study have been deposited in the NCBI Gene Expression Omnibus under 
accession number GSE44834. Signal values lower than 300 were omitted from 




using all mouse internal controls in the chips and. For comparison purposes, 
the data was expressed as relative fold change with respect to controls. 
Statistical comparisons between controls and test samples are performed using 
Student’s t-test and ANOVA. A p-value < 0.05 was considered to be 
statistically significant. Hierarchical clustering plot was generated using TIGR 




3 ESTABLISHMENT OF PURE MATURING PRIMARY 
CORTICAL NEURONAL CULTURES IN VITRO 
3.1  Introduction 
The neocortex is the outer covering of the cerebral hemispheres unique to 
mammals and responsible for higher cognitive function such as voluntary 
movement, speech and spatial reasoning [7,8]. It has a simple six-layered 
structure, with each layer possessing a distinguished cell density and neuronal 
morphology [9,10]. Neurons in each layer must form appropriate connections 
with other neurons within the layer as well as with cells in other layers and 
distal parts of the brain [11]. Proper neocortex function is therefore dependent 
on timely production and positioning of neurons during development [12].  
 
The neocortex is comprised of two major groups of neurons-glutamatergic 
excitatory neurons and γ-aminobutyric acid (GABA)-ergic inhibitory 
interneurons that give rise to excitation and inhibition respectively. Excitatory 
neurons make up approximately 70-80% of neocortical neurons and generate 
the output which is in turn modulated by the inhibitory interneurons [9,12].  
 
In mouse development, fertilization of the egg gives rise to the zygote on 
embryonic day 0.5 (E0.5) which undergoes cell division, cell proliferation, and 
an increase in tissue volume until E7.5. Organogenesis, including 
neurogenesis, begins at E8.0. The structures of the central nervous system are 
derived from the neural plate which folds into the neural tube at E8 [250,251]. 
At E9, the anterior part of the neural tube differentiates into the 
prosencephalon (forebrain) at the rostral end, followed by the mesencephalon 




further segregates into the telencephalon (future cerebral cortex and basal 
ganglia) and diencephalon (future thalamus, hypothalamus and epithalamus) at 
E9.5 [251]. Each hemisphere of the telencephalon contains a lateral ventricle 
(Figure 3.1). The dorsal telencephalon gives rise to the cerebral cortex 
consisting of two cerebral hemispheres whereas the ventral telencephalon 
gives rise to the basal ganglia [9]. Excitatory neurons generated from 
progenitors located within the dorsal telencephalon migrate radially to form 
the cerebral cortex (Figure 3.1). The inhibitory interneurons, on the other 
hand, are derived from precursors located in the ventral telencephalon (MGE, 
AEP) and migrate tangentially to invade the emerging cortex [9,12].  
 
 
Figure 3.1: Distinct origins of excitatory neurons and inhibitory 
interneurons in the developing mouse neocortex. The proliferative zone of 
the dorsal telencephalon gives rise to excitatory neurons which migrate 
radially to the cortical plate (red arrows). Inhibitory interneurons, on the other 
hand, are produced in the proliferative zone of the ventral telencephalon and 
migrate tangentially to reach the neocortex via two major routes (blue dashed 
arrows). Colored regions indicate proliferative zones across the embryonic 
brain expressing different transcription factors that are essential for proper 
neurogenesis of distinct neuronal populations. AEP, anterior entopeduncular 
area; LGE, lateral ganglionic eminence; LP, lateral pallium; MGE, medial 





The developing telencephalon is composed of a pseudostratified layer of 
neuroepithelial cells (also known as neural progenitors, NPs) that line the 
lateral ventricle, known as the ventricular zone (VZ; Figure 3.2) [9]. These 
neural progenitors proliferate during telencephalic development to expand the 
progenitor pool till E10 when corticogenesis begins. The neural progenitors 
then take on radial glial morphology and each progenitor divides 
asymmetrically to generate a new radial glial cell as well as a post-mitotic 
neuron. Neurons undergo radial migration from the germinal zones guided by 
radial glia cells (RGC) to reach the mantle layers (Figure 3.2). At E10.5, the 
earliest born cortical neurons form the preplate (PP), a band of differentiated 
neurons superficial to proliferative cells of the ventricular zone. From E11.5, 
subsequent generations of post-mitotic neurons migrate into the preplate and 
intercalate between the inner and outer cell populations, to form the nascent 
cortical plate (CP) [252]. Therefore, the cortical plate splits the preplate into 
upper marginal zone (MZ) and lower subplate (SP) [252]. The marginal zone 
located above the cortical plate, forms L1 of the postnatal cortex whereas the 
subplate is located below the 6 cortical layers. The nascent cortical plate 
subsequently become layers (L) 2 to 6 of the neocortex [14]. The cortical plate 












Figure 3.2: Schematic of projection neuron generation and migration in 
the mouse neocortex. Before neurogenesis, neural progenitors (NPs) in the 
ventricular zone (VZ; blue) of the developing neocortex divide to expand the 
progenitor pool. At ∼E11.5, NPs assume radial glial morphology and divide 
asymmetrically to generate neurons, which migrate from the germinal zones 
guided by radial glia cells (RGC) to reach the outer layers. The first earliest 
born neurons form the preplate (PP). Subsequent generations of post-mitotic 
neurons migrate into the PP and intercalate between the inner and outer cell 
populations to form the nascent cortical plate (CP), which will subsequently 
become layers (L) 2 to 6 of the neocortex. Additional incoming CP neurons 
then split the PP into the marginal zone (MZ) and the subplate (SP). The MZ 
forms L1 of the postnatal cortex whereas the SP is located below the 6 cortical 
layers. Therefore, neurons destined for the SP are generated first, followed by 
those destined for the deep layers (L6 and L5; red), and finally, those destined 
for the upper layers (L4, L3 and L2; green). Therefore, the cortical layers are 
sequentially generated in an ‘inside-out’ fashion. Some daughter cells of NPs 
become intermediate progenitor cells (IPCs), migrating away from the VZ and 
undergoing symmetric neurogenic divisions in the SVZ. This mode of 
neurogenesis contributes significantly to upper layer neurons. At ∼E17.5, the 
radial scaffold is dismantled and NPs become gliogeneic, generating cortical 
and subependymal zone (SEZ) astrocytes (Ast) and giving rise to a layer of 
ependymal cells (EL). BV, blood vessel; CR: Cajal-Retzius neuron; DL Pyr, 
deep-layer pyramidal neuron; IZ, intermediate zone; UL Pyr, upper-layer 






With the progression of neurogenesis, various subtypes of projection neurons 
are generated sequentially through consecutive asymmetric divisions of neural 
progenitors [14]. Neurons destined for the marginal zone, a cell sparse layer 
identified as L1 of the postnatal cortex comprising Cajal-Retzius neurons [9], 
and subplate are generated first at E11.5 (Figure 3.2). This is followed by 
generation of neurons destined for the deep layers, L6 and L5, which are 
produced from approximately E11.5 to E13.5. Neurons that will form the 
upper layers, L4, L3 and L2 are generated around E13.5 to E16 [14]. The 
migration of newborn neurons into the cortical plate occurs in an inside-first, 
outside-last manner; early-born neurons form the deep layers, whereas later-
born neurons migrate past older neurons to form more superficial layers 
(Figure 3.2). Therefore, the cortical layers are sequentially generated in an 
‘inside-out’ fashion [9,14]. Some daughter cells of neuronal progenitors 
become intermediate progenitor cells (IPCs), migrating away from the 
ventricular zone and undergoing symmetric neurogenic divisions in the 
subventricular zone (SVZ). This mode of neurogenesis contributes 
significantly to upper layer neurons [14]. Neurogenesis thus takes place from 
approximately E11 to E16. Throughout the migration process to establish the 
6-layered structure, neurons mature to give rise to their characteristic neuronal 
phenotype (Figure 3.3) [15]. The immature post-mitotic neurons first show 
intense lamellipodial and filopodial protrusive activity. This leads to the 
appearance of several immature neurites. This neuronal symmetry eventually 
breaks to result in a single neurite growing rapidly to become the axon and the 
remaining neurites take on a dendritic identity. This is followed by rapid axon 




pyramidal neurons with dendritic spines (Figure 3.3) [15]. An excess of 
connections is formed initially and later the synapses and neuritis are pruned 
to form a network with proper connectivity structure [1,253]. At E17.5, the 
radial scaffold dismantles and neural progenitors generate astrocytes (Figure 
3.2) [14]. Oligodendrocytes are first detected around birth, but the vast 
majority of both astrocytes and oligodendrocytes are produced during the first 




Figure 3.3: Polarization of cortical pyramidal neurons in vitro. During 
neuronal polarization in vitro, immature post-mitotic neurons display intense 
lamellipodial and filopodial protrusive activity that lead to the appearance of 
multiple immature neurites. This neuronal eventually breaks and a single 
neurite grows rapidly to become the axon and the remaining neurites take on a 
dendritic identity. This is followed by rapid axon and dendritic outgrowth 
which then mature to terminally differentiated pyramidal neurons with 
dendritic spines. Figure is adapted from Polleux et al [15] with slight 
modifications. 
 
Since neurons form the basic functional unit of the nervous system [2], 
studying these cells can pave the way to understanding the mechanisms 
involved in central nervous system development and disease. It is hence 
necessary to study these cells in isolation from the other support cells present 
in the brain, such as astrocytes, oligodendrocytes and microglia. Cell lines 
derived from central nervous system precursors have several limitations as 




neurons, including the ability to form well-defined axons, dendrites and 
synapses [255,256]. Hence, primary neuronal cultures are used as these 
neurons in culture undergo distinct stages of differentiation, with extension of 
lamellopodia, followed by axonal and dendritic outgrowth, and finally synapse 
formation and maturation [256-259]. Furthermore, in vitro neuronal cultures 
allow the environment to be defined precisely and neurons can be studied in 
isolation from other cell types that can possibly modify neuronal responses 
directly or indirectly [260].  
 
Since neurogenesis takes place from E11 to E16 with glial cells appearing 
from E17 onwards (Figure 3.2), primary neuronal cultures are harvested 
mostly from E15 mouse embryos [240,261-263] and in some reports from E16 
mouse embryos [239,260]. These cultures were reported to be almost purely 
neuronal (>99%). However, to study neurons during development and injury 
in vitro that can be followed up for further expression profiling studies, it is 
necessary to obtain neuronal cultures with the highest purity with no 
contamination from glial cells. To ensure this, primary cultures of cortical 
neurons were established from E15 embryos as well as an earlier (E14) and a 
later (E16) embryonic day to determine the optimal embryonic day to achieve 
pure neuronal cultures to study neuronal maturation. In vitro maturation of 
these cultures from Day 2 to Day 8 was studied and purity as well as 
functionality of the cultures characterized by immunostaining with cell-type 
specific markers. Cultures with the highest neuronal purity would hence serve 





3.2 Establishment of primary cortical neuronal culture 
Primary cultures of cortical neurons were established from E14, E15 and E16 
Swiss albino mouse brains [240,241,261,263] as described in Section 2.2.2.1. 
Neuronal cell viability during harvesting was found to be 93.6 ± 1.7 % as 
determined by trypan blue staining. Yield of the primary cultures was              
4 180 000 ± 290 000 viable cells per embryo. Cortical neurons from E14, E15 
and E16 fetuses attached to the poly-D-lysine coated plates by 4 hours (Figure 
3.4). At 16 hours after plating, neurite outgrowth was prominent with cells 
displaying long axons (yellow arrows) and minor dendritic protrusions (red 
arrows; Figure 3.4). Axons and dendrites became longer at 24 hours after 
plating and were just beginning to make connections with neighbouring 
neurons at 48 hours (Figure 3.4). Formation of connections between neurons 
provide proper growth signals to the axon which then mediate downstream 
survival and maturation signals to the neuronal cell body [72,73]. Therefore, to 
determine the inter-neuronal signals that mediate neuronal survival, cultures 
that had just begun to establish connections with neighbouring neurons were 
selected as the starting point to study maturation and survival of the neurons. 
Since connections between neighbouring neurons were starting to be 








Figure 3.4: Images depicting in vitro maturation of E15 derived primary cortical neuron cultures during first 48 hours. Images are 
representative of maturation of cultures derived from E14 to E16 mouse embryos. Cortices were dissociated to obtain single cells and maintained 
in Neurobasal medium supplemented with B27, L-glutamine and Penicillin-Streptomycin. Neuronal cells attached to the poly-D-lysine coated 
plates by 4 hours after plating. Neurite outgrowth was prominent with cells displaying long axons (yellow arrows) and minor dendritic 
protrusions (red arrows) at 16 hours and 24 hours after plating. Connections had formed between most neighbouring cells at 48 hours. Cultures 









3.3 Characterization of murine E14 derived primary cortical 
neuronal cultures  
With establishment of the in vitro neuronal cultures, it was necessary to 
characterize the purity of the maturing neurons derived from each embryonic 
day which could not be determined from the phase bright pictures shown 
above (Figure 3.4). Immunostaining with the neuronal markers, microtubule-
associated protein 2 (MAP2) and neuronal nuclei (NeuN) [264], a neuronal 
progenitor marker, (SRY (sex determining region Y)-box 2 (SOX2) [265], 
microglial marker (CD11b) [266], oligodendrocyte marker (O4) [267] and 
astrocyte marker (glial fibrillary acidic protein, GFAP) [268] was carried out. 
Since neuronal connections were beginning to form on Day 2 (Figure 3.4), 
cultures were followed starting from Day 2. These E14 derived cultures 
yielded neurons which matured from Day 2 to Day 8 (Figure 3.5). This was 
evident from the increased MAP2 staining, a dendritic marker [269,270], that 
showed the presence of neurite outgrowth (Figure 3.5). Early neurite 
outgrowth was observed on Day 2 which became more extensive with 
maturation on Day 4 (Figure 3.5). Intense staining with MAP2, also a positive 
marker for neuronal maturation [264], on days 6 and 8 indicated establishment 
of a mature neuronal network.  
 
To further characterize the presence of post-mitotic neurons, cultures were 
stained with NeuN, a marker for post-mitotic neurons and Sox2, a marker for 
neuronal progenitors. NeuN staining was negligible on Day 2 but stained 
neurons on Day 4 (Figure 3.6). NeuN staining increased from Day 4 to Day 8 
indicating presence of post-mitotic neurons particularly on the latter days, 




which decreased on Day 4 (Figure 3.6), indicating presence of neuronal 
progenitors.  
 
Finally, to determine neuronal purity, cultures were stained for the microglial 
marker, CD11b, oligodendrocyte marker, O4 and astrocyte marker, GFAP. 
Cultures did not show any staining for these 3 markers, indicating absence of 
glial cells (Figure 3.7).  Hence, E14 derived primary cortical neuronal cultures 
gave rise to pure maturing neurons but showed presence of neuronal 






Figure 3.5: Maturation of murine E14 derived primary cortical neuronal cultures. Cultures were immunostained for the neuronal marker 
MAP2 and nuclear marker, Hoescht 33342. Short neurites at the early stages of development (Day 2) gave rise to an extensive network of 













Figure 3.6: Characterization of post-mitotic neurons and neuronal progenitors in murine E14 derived primary cortical neuronal 
cultures. Cultures were immunostained for NeuN, a marker for post-mitotic neurons and Sox2, a marker for neuronal progenitors. NeuN 
staining was negligible on Day 2 but stained neurons on Day 4 and increased till Day 8, indicating presence of post-mitotic neurons. Cultures 











Figure 3.7: Evaluation of neuronal purity of murine E14 derived primary cortical neuronal cultures. Cultures were immunostained for 
microglial marker (CD11b), oligodendrocyte marker (O4) and astrocyte marker (GFAP). Cultures stained negatively for all 3 markers indicating 
absence of microglia, oligodendrocytes and astrocytes. E18 astrocyte enriched cultures were used as positive control for CD11b, O4 and GFAP 









3.4 Characterization of murine E15 derived primary cortical 
neuronal cultures  
E15 derived cultures, similar to the E14 cultures, yielded neurons which 
matured with increasing neurite outgrowth from Day 2 to Day 8 (Figure 3.8). 
This was depicted by the increased MAP2 staining and establishment of an 
extensive neuronal network from Day 2 to Day 8 (Figure 3.8). Increasing 
NeuN staining from Day 2 to Day 8 also supported the presence of post-
mitotic neurons particularly on the latter days, Days 6 and 8 (Figure 3.9). Sox2 
staining was absent in these cultures on all 4 days, indicating absence of 
neuronal progenitors in these cultures (Figure 3.9). 
 
Determination of neuronal purity by staining for the glial cell markers, CD11b, 
O4 and GFAP displayed absence of any immunostaining, indicating no 
contamination from microglia, oligodendrocytes and astrocytes respectively 
(Figure 3.10). Hence, E15 derived neuronal cultures which displayed 
increased staining for MAP2 and NeuN from Day 2 to Day 8, reflective of 
neuronal maturation, but absence of Sox2, CD11b, O4 and GFAP staining, 
were found to be purely post-mitotic cultures. Further qualitative analysis of 
the immunostained images for the neuronal specific marker, MAP2, confirmed 
that more than 99 % of the cells in the E15 cultures were of the neuronal cell 





Figure 3.8: Maturation of murine E15 derived primary cortical neuronal cultures. Cultures were immunostained for the neuronal marker 
MAP2 and nuclear marker, Hoescht 33342. Short neurites at the early stages of development (Day 2) gave rise to an extensive network of 













Figure 3.9: Characterization of post-mitotic neurons and neuronal progenitors in murine E15 derived primary cortical neuronal 
cultures. Cultures were immunostained for NeuN, a marker for post-mitotic neurons and Sox2, a marker for neuronal progenitors. NeuN 
staining increased steadily from Day 2 to Day 8, indicating presence of post-mitotic neurons on all 4 days. Sox2 staining was absent in all 4 days 











Figure 3.10: Evaluation of neuronal purity of murine E15 derived primary cortical neuronal cultures. Cultures were immunostained for 
microglial marker (CD11b), oligodendrocyte marker (O4) and astrocyte marker (GFAP). Cultures stained negatively for all 3 markers indicating 
absence of microglia, oligodendrocytes and astrocytes. E18 astrocyte enriched cultures were used as positive control for CD11b, O4 and GFAP 









3.5 Characterization of murine E16 derived primary cortical 
neuronal cultures  
E16 derived cultures yielded neurons that matured with increasing neurite 
outgrowth from Day 2 to Day 8 (Figure 3.11) as depicted by the increased 
MAP2 staining and interconnected neurites. Increasing NeuN staining from 
Day 2 to Day 8 further supported the presence of post-mitotic neurons 
throughout maturation (Figure 3.12). Negligible Sox2 staining in these 
cultures also indicated absence of any neuronal progenitors (Figure 3.12). 
 
Determination of neuronal purity using CD11b, O4 and GFAP staining 
showed no staining for CD11b or O4, implying absence of microglia and 
oligodendrocytes (Figure 3.13). However, these cultures showed staining for 
GFAP on Days 6 and 8, indicating presence of astrocytes in the cultures 
(Figure 3.13). E16 derived neuronal cultures therefore, displayed neuronal 
maturation in vitro but showed contamination from astrocytes on the latter 







Figure 3.11: Maturation of murine E16 derived primary cortical neuronal cultures. Cultures were immunostained for the neuronal marker 
MAP2 and nuclear marker, Hoescht 33342. Short neurites at the early stages of development (Day 2) gave rise to an extensive network of 













Figure 3.12: Characterization of post-mitotic neurons and neuronal progenitors in murine E16 derived primary cortical neuronal 
cultures. Cultures were immunostained for NeuN, a marker for post-mitotic neurons and Sox2, a marker for neuronal progenitors. NeuN 
staining increased steadily from Day 2 to Day 8, indicating presence of post-mitotic neurons on all 4 days. Sox2 staining was absent in all 4 days 











Figure 3.13: Evaluation of neuronal purity of murine E16 derived primary cortical neuronal cultures. Cultures were immunostained for 
microglial marker (CD11b), oligodendrocyte marker (O4) and astrocyte marker (GFAP). Cultures stained negatively for CD11b and O4, 
implying absence of microglia and oligodendrocytes. However, cultures stained positive for GFAP on Days 6 and 8, indicating presence of 









3.6 Validation of neuronal culture purity 
Characterization of E14, E15 and E16 derived neuronal cultures by 
immunostaining revealed that E15 derived cultures comprised of purely post-
mitotic neurons (> 99 %) undergoing maturation as displayed by increased 
staining for MAP2 and NeuN from Day 2 to Day 8. This was accompanied by 
absence of Sox2, CD11b, O4 and GFAP staining indicating absence of 
neuronal progenitors, microglia, oligodendrocytes and astrocytes respectively. 
Further validation of purity of these cultures was determined by quantifying 
the abundance of cell-type specific miRNAs.  
 
Neuron-specific miR-124, astrocyte-enriched miR-143 and glia-enriched miR-
223 were quantified using stem-loop quantitative real-time PCR [271]. It was 
found that miR-124 was highly expressed in E14, E15 and E16 Day 8 cultures 
(E14 CT = 25.4 ± 0.1, E15 CT = 21.0 ± 0.0, E16 CT = 27.1 ± 0.2 compared to 
NTC (no template control) CT = 39.0 ± 0.3, p < 0.01; Table 3.1). Specificity of 
this neuron-specific miRNA was verified in E18 astrocyte enriched cultures 
(CT = 38.5 ± 0.6) which showed no significant difference as compared to NTC 
(CT = 39.0 ± 0.3). Expression of the astrocyte-enriched miR-143 was 
determined to be non-significant in E14, E15 and E16 Day 8 cultures (E14 CT 
= 34.1 ± 0.2, E15 CT = 33.0 ± 0.0, E16 CT = 36.5 ± 0.7) as compared to NTC 
(CT = 34.4 ± 0.9) and present in positive control E18 astrocyte enriched 
cultures (CT = 30.4 ± 0.0 compared to NTC CT = 34.4 ± 0.9, p < 0.01; Table 
3.1). However, miR-143 was significantly expressed in Day 2 E16 derived 
neuronal cultures (CT = 32.7 ± 0.1 compared to NTC CT = 34.4 ± 0.9, p<0.05; 




expression were determined to be non-significant in E14 and E15 Day 8 
cultures (E14 CT = 37.8 ± 0.8, E15 CT = 38.8 ± 0.4) as compared to NTC (CT 
= 38.4 ± 0.6) and present in positive control E18 astrocyte enriched cultures 
(CT = 33.0 ± 0.2 compared to NTC CT = 38.4 ± 0.6, p < 0.01; Table 3.1) 
[271]. However, miR-223 was significantly expressed in E16 Day 8 cultures 
with mean CT = 34.7 ± 0.5 compared to NTC CT = 38.4 ± 0.6, p < 0.05 (Table 
3.1). This indicated presence of glia in E16 derived neuronal cultures. These 
results further validated the immunostaining data that contamination from 
astrocytes and glial cells was negligible in the E14 and E15 derived neuronal 
cultures but present in the E16 derived neuronal cultures. Hence, murine E15 
derived primary cortical neuronal cultures served as the most pure (> 99 % 









Table 3.1: Expression level of miR-124, miR-143 and miR-223, in primary 
cultures. qPCR was carried out on 10 ng RNA from maturing neurons to 
determine the purity of the E14, E15 and E16 derived primary cortical 
neuronal cultures. qPCR amplification was carried out for a maximum of 40 
cycles. Expression is shown as mean CT ± SD. Two biological replicates were 
used as described in the methods section (Section 2.2.14.2.2). Statistical 
significance were evaluated using the Student’s t-test (*p<0.05, **p<0.01). 
 
miR-124 (Mean CT ± SD) 




39.0 ± 0.3 
25.2 ± 0.2** 21.1 ± 0.7** 27.9 ± 0.5** 
38.5 ± 0.6 
Day 4 25.2 ± 0.3** 21.0 ± 0.7** 28.6 ± 0.6** 
Day 6 24.7 ± 0.1** 21.1 ± 0.3** 25.5 ± 0.3** 
Day 8 25.4 ± 0.1** 21.0 ± 0.0** 27.1 ± 0.2** 
miR-143 (Mean CT ± SD) 




34.4 ± 0.9 
34.2 ± 0.2 32.3 ± 1.6 32.7 ± 0.1* 
30.4 ± 0.0** 
Day 4 34.4 ± 0.3 32.6 ± 0.7 35.6 ± 0.4 
Day 6 32.4 ± 0.6 33.9 ± 1.0 36.1 ± 0.5 
Day 8 34.1 ± 0.2 33.0 ± 0.0 36.5 ± 0.7 
miR-223 (Mean CT ± SD) 




38.4 ± 0.6 
38.0 ± 1.7 36.3 ± 0.2 32.8 ± 0.9** 
33.0 ± 0.2** 
Day 4 36.5 ± 1.2 38.4 ± 0.2 32.6 ± 0.3** 
Day 6 37.2 ± 0.3 39.0 ± 0.4 34.6 ± 0.4* 




3.7  Functional characterization of neurons in culture 
Having verified that primary cortical neuronal cultures derived from E15 
embryos yield the highest purity of post-mitotic neurons during maturation in 
vitro, it was necessary to determine if the neurons obtained were functional 
and possessed neuronal functions, more specifically, neurotransmission 
through synapses.  
 
Synapse formation is a key event in the development of functional neuronal 
networks where neurons communicate and influence nearby neurons through 
synapses. Communication across chemical synapses is mediated by the release 
of neurotransmitters from presynaptic terminals that influence the excitability 
of postsynaptic neurons by triggering specific receptors [272]. This process is 
mediated by proteins such as synapsin I on the surface of synaptic vesicles in 
the presynaptic terminal. Synapsin I is a neuron-specific phosphoprotein 
localized to the cytoplasmic surface of presynaptic vesicles [273] which 
appears in the central nervous system during synaptogenesis [274,275]. MAP2 
is a cell body or dendritic marker associated with cytoskeletons [269,270]. 
Therefore, double-immunostaining for synapsin I and MAP2 can identify both 
pre- and postsynaptic terminals.  
 
Contacts between neurons were seen on Day 2 as determined by MAP2 
immunostaining. MAP2 immunoreactivity was evident in the cell body and 
thick dendrites, consistent with reports of presence of MAP2 in cell bodies and 
dendrites but not in axons (Figure 3.14) [274]. Immunostaining for synapsin I 




bodies and dendrites of neurons on Day 2 (Figure 3.14). These corresponded 
to synaptic vesicle clusters within presynaptic specializations [276]. The 
number of punta increased dramatically from Day 4 to Day 8, indicative of 
increased synapse formation with maturation (Figure 3.14). This was coupled 
with increased dendritic extension and branching as depicted by MAP2 
staining.  
 
Characterization of primary cortical neuronal cultures derived from E14, E15 
and E16 mouse embryos showed that E15 derived cultures yielded the highest 
purity (> 99 % neuronal) of cultures during maturation (Day 2 to Day 8) with 
no contamination from neuronal progenitors, microglia, oligodendrocytes or 
astrocytes. Further functional characterization of the E15 derived cultures was 
carried out using synapsin I and MAP2 immunostaining to identify 
presynaptic and postsynaptic specializations respectively. This identified 
increasing synaptic vesicles with neuronal maturation and hence synapse 
formation, an indicator of functional neurons. Henceforth, E15 derived 






Figure 3.14: Functional characterization of murine E15 derived primary cortical neuronal cultures. Cultures were immunostained for the 
nuclear marker, Hoescht 33342, neuronal marker, MAP2, and synaptic marker, Synapsin I. Neurite outgrowth from Day 2 to Day 8 was coupled 









4 EXPRESSION PROFILING OF RNA TRANSCRIPTS DURING 
NEURONAL MATURATION AND ISCHEMIC INJURY  
4.1 Introduction 
Neuronal development is a tightly regulated multi-step process. Neural stem 
cells proliferate, differentiate and mature to give rise to the neuronal 
morphology and fully functional neurons [13]. Timely maturation of neurons, 
characterized by axonal and dendritic outgrowth, synaptogenesis, synaptic and 
neuronal pruning, modulation of neurotransmitter sensitivity and myelination, 
determines neuronal connections with extraordinary precision [22,277,278]. 
These culminate into large, integrated networks of synapses with specific 
functions in the brain [20-22].  
 
In the fully developed nervous system, the long term survival of post-mitotic 
neurons is imperative for proper function throughout an organism’s life.  
Furthermore, given their limited regenerative potential, neurons cannot afford 
to be vulnerable to apoptosis. Therefore, the cell death pathway needs to be 
tightly regulated during the neuronal maturation process [42]. Neurons employ 
multiple mechanisms to restrict the apoptotic pathway as they mature, thereby 
reducing their apoptotic susceptibility (Figure 4.1). This is carried out by 
reducing the availability of pro-apoptotic proteins. Firstly, miR-29 
transcription is increased to repress the synthesis of BH3-only pro-apoptotic 
proteins [43]. Secondly, Bax protein remains cytosolic in mature neurons [44] 
and APAF-1 expression is also repressed [45]. Finally, caspase-3 levels are 
significantly reduced in mature neurons [46]. Hence, implementation of 
apoptotic brakes at several points along the apoptotic pathway results in 









Figure 4.1: Changes in apoptotic thresholds during neuronal development 
and neuronal injury or neurodegeneration. Developing neurons undergo 
programmed cell death, a necessary phenomenon for proper nervous system 
development. After the developmental period, maturation of the neurons takes 
place to restrict the apoptotic pathway thereby permitting long-term survival.  
During neuronal injury or neurodegeneration, restriction of these apoptotic 
mechanisms is lost, causing mature neurons to resemble their immature 




However, during neuronal injury or neurodegeneration, restriction of these 
apoptotic mechanisms is lost, causing mature neurons to resemble their 
immature phenotype (Figure 4.1) [42]. Likewise is observed in ischemic injury 
during which neuronal gene expression is dysregulated [34,47]. For instance, 
the expression of genes essential to axonal extension and neuronal survival, 
such as the cell adhesion molecule NB-3, is inversely regulated during 
ischemic injury, resulting in impaired neuronal survival and neurite outgrowth 
[279].  Hence the ability to salvage neurons during ischemic injury, or 
neuroprotection, can be achieved by identifying genes important for neuronal 
maturation, but dysregulated during ischemic injury and possibly inhibiting or 
reducing their dysregulation. 
 
Non coding RNAs (ncRNAs) are endogenously produced regulators of gene 
expression [280]. The distinct temporal and spatial expression of ncRNAs, 
namely microRNAs (miRNAs) and long ncRNAs (lncRNAs), intricately 
regulates gene expression throughout the neuronal maturation process 
[142,281]. miRNAs, the most well-characterized ncRNAs, are short 
endogenous molecules, approximately 22 nucleotides in length. In general, 
these small ncRNAs interact with their target mRNAs by complementary 
binding to bring about transcriptional and translational regulation [282,283]. 
Brain-specific and brain-enriched miRNAs, miR-124 and miR-134, are vital 
regulators of neuronal functions associated with neurogenesis and synaptic 
plasticity respectively [92,143]. LncRNAs, on the other hand, are transcripts 
longer than 200 nucleotides [118]. These RNA molecules coordinate gene 




transcription or translation and genomic imprinting [136]. LncRNAs have 
been shown to play a role in embryogenesis and development of the central 
nervous system [142].  
 
Alongside dysregulation of gene expression, several studies have also 
demonstrated that ncRNAs that direct neuronal gene expression are 
dysregulated in neurovascular diseases such as stroke [34,40,96]. Moreover, 
modulation of certain miRNAs has been shown to confer neuroprotection in 
cerebral ischemic models [145-147]. Nevertheless, the exact role of lncRNAs 
in ischemic disease warrants further investigation.  
 
This study was aimed at first determining the expression profile of coding 
(mRNA) and regulatory non-coding (lncRNAs and miRNAs) RNAs in 
maturing neurons and neurons subjected to ischemic insult. Bioinformatics 
analysis and comparison between the 2 models would elucidate genes and 
their associated regulatory ncRNAs crucial to neuronal survival but 
dysregulated during ischemic injury. This would allow the use of ncRNAs as 
therapeutic molecules to modulate expression of their target gene(s) for 










4.2 Maturation of cortical neuron 
For an in vitro model of neuronal maturation, pure cortical neuronal cultures 
were necessary. Primary neuronal cultures were established from embryos of 
E15 pregnant Swiss albino mice as these yielded > 99 % pure neuronal 
cultures as described in the previous results section (Chapter 3). Neuronal 
cultures were allowed to mature for 8 days (Figure 4.2). Neuronal cultures 
were immunostained for microtubule-associated protein 2 (MAP2), a dendritic 
marker [269,270] and marker for neuronal maturation [264]. Early neurite 
outgrowth was observed on Day 2 (Figure 4.2) which became more extensive 
with maturation on Day 4. Intense staining with MAP2 on days 6 and 8 
indicated establishment of a mature neuronal network (Figure 4.2). Hence, 
increased staining for MAP2 from Day 2 to Day 8 indicated maturation of 




Figure 4.2: Maturation of mouse primary neuronal cultures. Cultures 
contained > 99% neuronal cells. Short neurites at the early stages of 
development (Day 2) gave rise to an extensive network of neurites by Day 8. 
Green - Microtubule-associated protein 2 (MAP2); red - Glial fibrilliary acidic 








4.3 Transcriptome of maturing neurons 
Maturing neurons were used to study the changes in the transcriptome which 
would favour neuronal development and survival, hence serving as a pro-
survival model. Changes in the transcriptome over the 8 days were determined 
via RNA expression profiling. Expression patterns of mRNAs, lncRNAs and 
miRNAs during maturation were determined by normalizing gene expression 
to Day 2.  
 
Of the 14213 mRNA transcripts detected through profiling, 6965 (49.0 %) of 
them exhibited differential gene expression (SLR > 1 or SLR < -1; Figure 4.3). 
Among these, two clusters of highly down- and up-regulated genes were 
observed (Figure 4.3, Supplementary Figure 4.1). Profiling of lncRNAs 
detected 15715 transcripts and approximately 47.4 % (7455) of these showed 
differential expression (SLR > 1 or SLR < -1) on at least one of the days as 
compared to Day 2 (Figure 4.4). Highly down-regulated clusters (clusters 1 
and 4) and up-regulated clusters (clusters 2 and 3) were also observed (Figure 
4.4, Supplementary Figure 4.2, Supplementary Table 4.1). About 2.3 % of 
these differentially expressed lncRNAs were derived from ultraconserved 
segments (100 % identity with no insertions or deletions) between orthologous 
regions of the human, rat, and mouse genomes, while 60 % of them were 
intergenic. The remaining 2993 lncRNAs were associated with known genes 
in either an antisense (20 %) or sense overlap (13 %) or in a bidirectional       
(7 %; head to head to a coding transcript within 1000 bp) manner (Figure 4.5).  




NCBI Gene Expression Omnibus (GEO) and can be retrieved under accession 
number GSE44834.    
 
Of the 1040 miRNA probes, 395 (38.0 %) were detected on our miRNA 
profiling. Two distinct clusters of down- (Clusters 1 and 3; Supplementary 
Figure 4.3) and up-regulated miRNAs (Cluster 2; Supplementary Figure 4.3) 
were identified in the mature neurons (Figure 4.6).  
 
Independent hierarchical clustering (HCL) analysis of all three sets of data 
(Figure 4.3, 4.4, 4.6) showed that day 4 was clustered further from days 6 and 
8, possibly reflecting similar processes in play on the latter days to achieve a 
distinct neuronal network (Figure 4.3, 4.4, 4.6). The similar HCL between the 
3 separate entities also highlighted the existence of the tight regulatory 





Figure 4.3: Hierarchical clustering analyses of 6965 differentially 
expressed mRNAs in maturing cortical neurons. Two clusters of highly 
down- and up-regulated mRNAs were identified. Details of genes in each 
cluster are listed in Supplementary Figure 4.1. Total RNA from 4 separate 
experiments (n = 4) carried out in triplicates were pooled for each time points. 
The microarray analyses were carried out for each time point on the pooled 
RNA. Hierarchical clusters were constructed using average linkage and 
Euclidean distance as the similarity measure. The microarray data has been 
deposited in the NCBI Gene Expression Omnibus (GEO) and can be retrieved 






Figure 4.4: Hierarchical clustering analyses of 7455 differentially 
expressed lncRNAs in maturing neurons. Four clusters of highly down- and 
up-regulated lncRNAs with their orientation to the genome or proximal gene 
loci were identified. Details of lncRNAs in each cluster and their associated 
genes are listed in Supplementary Figure 4.2 and Supplementary Table 4.1. 
Total RNA from 4 separate experiments (n = 4) carried out in triplicates were 
pooled for each time points. The microarray analyses were carried out for each 
time point on the pooled RNA. Hierarchical clusters were constructed using 
average linkage and Euclidean distance as the similarity measure. The 
microarray data has been deposited in the NCBI Gene Expression Omnibus 
(GEO) and can be retrieved under accession number GSE44834. Green – 













Figure 4.5: Subgroup analyses of 7455 altered lncRNAs in relation to 
their nearby coding genes. Sense overlapping lncRNAs have an exon that 
overlaps a coding transcript exon on the same genomic strand. Intronic 
lncRNAs overlap the intron of a coding transcript on the same genomic strand. 
Antisense lncRNAs are transcribed from the antisense strand and overlap in 
part with a coding transcript. Bidirectional lncRNAs are oriented head to head 
to a coding transcript within 1000 bp. Intergenic lncRNAs are lncRNAs that 






Figure 4.6: Hierarchical clustering analyses of 395 miRNAs detected in 
maturing cortical neurons. Clusters of highly down- and up-regulated 
miRNAs were identified. Details of miRNAs in each cluster are listed in 
Supplementary Figure 4.3. Total RNA from 4 separate experiments (n = 4) 
carried out in triplicates were pooled for each time points. The microarray 
analyses were carried out for each time point on the pooled RNA. Hierarchical 
clusters were constructed using average linkage and Euclidean distance as the 
similarity measure. The microarray data has been deposited in the NCBI Gene 
Expression Omnibus (GEO) and can be retrieved under accession number 




4.4 Identification of biological processes regulated by mRNAs, 
lncRNAs and miRNAs 
As the lncRNAs and miRNAs could be regulating distinct biological processes 
by modulation of mRNA expression, independent Gene Ontology (GO) 
analysis on the transcriptome data was carried out. Significant biological 
processes (p<0.05) were independently identified for the three data sets 
(mRNA, lncRNA, miRNA) over the three time points of days 4, 6 and 8 
(Figures 4.7, 4.8, 4.9).  Up-regulated mRNAs on day 4 were implicated in 
positive regulation of membrane potential, vesicle transport along 
microtubules as well as response to growth hormone stimulus (Figure 4.7). 
Regulation of synapse maturation, axonogenesis and dendritic spine 
morphogenesis was also observed for the later maturation days (Figure 4.7). 
The differentially expressed lncRNAs on day 4 were specifically responsible 
for mRNA splice site selection and microtubule-based processes (Figure 4.8) 
which concur with the altered mRNA processes (Figure 4.7). Regulation of 
transcription, neurogenesis and cell differentiation was also observed for the 
later maturation days (Figure 4.8). The differentially expressed miRNAs 
primarily regulated axonogenesis, neuron projection development, synaptic 
plasticity and synaptic transmission, processes that are crucial for development 
and maintenance of neurons (Figure 4.9).  Processes other than those directly 
associated with neuronal differentiation were also observed to be regulated by 
the 3 separate entities (Figures 4.7, 4.8, 4.9). This could possibly be due to 








Figure 4.7: Significant biological processes associated with differentially expressed mRNAs. Significant biological processes were 











Figure 4.8: Significant biological processes associated with differentially expressed lncRNAs associated with genes in 
sense/antisense/bidirectional orientation. Significant biological processes were shortlisted based on p<0.05. Green – processes associated with 











Figure 4.9: Significant biological processes associated with differentially expressed miRNAs. Significant biological processes were 









Integration of this analysis was carried out by comparing the significant 
biological processes associated with differentially expressed mRNAs, 
differentially expressed lncRNAs associated with genes in 
sense/antisense/bidirectional orientation and differentially expressed miRNAs. 
It was observed that overlapping processes were regulated by ncRNAs during 
maturation. Processes regulated by differentially expressed mRNAs as well as 
both lncRNAs and miRNAs were attributed to dendritic morphogenesis and 




Figure 4.10: Significant biological processes which are common to the 
differentially expressed mRNAs, lncRNAs, and miRNAs. Significant 
biological processes associated with differentially expressed mRNAs, 
differentially expressed lncRNAs associated with genes in 
sense/antisense/bidirectional orientation and differentially expressed miRNAs 




4.5 Identification of pathways and genes essential for neuron 
development and survival 
To elucidate genes that were regulated by both ncRNAs, a systematic 
approach was adopted to first shortlist genes with both differentially expressed 
mRNAs and lncRNAs associated with them. Subsequent pathway analysis on 
the shortlisted genes revealed proliferation and differentiation related 
pathways, cell adhesion molecules and neurotrophin signalling to be over-
represented (Table 4.1).  Of these, 23 genes (shown in bold) were predicted 
targets of the differentially expressed miRNAs (Table 4.1). The corresponding 
altered miRNAs predicted to target the mRNA of these genes are listed in 
Table 4.2. Following that, genes that are crucial in maintaining the mature 
neuronal phenotype were identified. Eleven out of the 23 genes were found to 
be differentially expressed on days 6 and 8 (Figure 4.11).  
 
Table 4.1: Pathways implicated during neuronal maturation. 
Genes identified had differentially expressed mRNAs and lncRNAs associated 
with them. mRNA of genes in bold were predicted to be targets of the altered 









Abl1, Araf, Axin2, Brca2, Cdh1, 
Ctnna2, E2f2, Fgf12, Fgfr1, Gli2, 
Igf1r, Ikbkb, Ikbkg, Itgb1, Kit, 
Pax8, Plcg1, Prkcb, Ptch1, Ptgs2, 




Cd40, Cd8b1, Cdh1, Cdh4, Cntn1, 
F11r, H2-d1, Itgb1, Madcam1, 





Abl1, Calm1, Camk2d, Ikbkb, 
Ntrk2, Pik3cd, Plcg1, Rapgef1, 
Sh2b1, Sh2b3, Sort1, Trp73 
Prostate cancer 0.01 1.14 
Araf, Creb3l2, E2f2, Fgfr1, Igf1r, 
Ikbkb, Ikbkg, Pdgfc, Pik3cd, Tcf7l1 
Glioma 0.013 0.91 
Araf , Calm1, Camk2d, E2f2, Igf1r, 




Table 4.2: List of 23 differentially expressed mRNAs in the top 3 pathways and the differentially expressed miRNAs that were predicted 
to target them. 
 





miR-101a, -101b, -128, -132, -15a, -15b,  -16, -195, -203, -212, -30a, -30b, -30d, -30e, -
378,  -7a, -7b 
Axin2 miR-107, -15b, -15a, -16, -195, -221, -222, -290-5p, -374, -495 
E2f2 miR-106a, -106b, -17, -20a, -20b, -21, -221, -222, -301b, -302a, -335-5p, -721, -495, -93 
Fgfr1 miR-15b, -15a, -16, -195, -214, -22, -328, -342-3p, -376b, -339-5p, -495 
Igf1r let-7a, let-7b, let-7d, let-7f, let-7g, let-7i, miR-30a, -30b, -30d, -30e, -376b, -488, -98 
Ikbkb 
miR-130b, -15b, -15a, -16, -17, -190, -195, -20a, -20b, -214, -218, -29a, -29b, -29c, -301b, 
-33, -721, -93 
Itgb1 miR-214, -29a, -29b, -29c 
Kit 
miR-107, -128, -137, -15a, -15b, -16, -185, -19a, -19b, -195, -218, -221, -222, -301b, -361, 
-410, -431, -542-3p, -721, -882 
Prkcb miR-129-5p, -203, -326, -433, -495, -873 
Ptgs2 
miR-101b, -101a, -107, -129-5p, -132, -15a, -15b, -16, -195, -212, -33, -342-3p, -338-3p, -
374, -381, -410, -411, -433, -7a, -7b, -873 
















Pathway Gene Differentially expressed miRNAs predicted to target gene 
Cell adhesion 
molecules 
Cdh4 miR-124, -129-5p, -132, -148b, -149, -212,  -33 
Cntn1 
miR-106a, -106b, -124, -129-5p, -136, -146b-5p, -153, -17, -191, -20a, -20b, -203, -204, -
218, -25, -300, -326, -33, -361, -363-5p, -374, -376a, -376b, -377, -381, -410, -411, -488, -
495, -873, -93 
F11r miR-125b-5p, -214, -290-5p, -338-3p,  -342-3p,  -377, -410 
Ncam1 miR-128, -204, -290-5p, -377, -411, -431, -542-3p 
Negr1 
miR-101a, -101b, -124, -129-5p, -135b, -136, -203, -21, -329, -362-3p, -377, -382, -7a, -
7b, -9 
Nrxn1 
miR-128, -129-5p, -137, -142-3p, -190, -208b, -218, -290-5p, -329, -335-5p, -338-3p, -
339-5p, -342-3p, -374, -377, -495 




miR-106a, -106b, -129-5p, -130b, -135b, -136, -17, -185, -191, -20a, -20b, -203, -214, -
30a, -30b, -30d, -30e, -361, -377, -381, -382, -495, -873, -882, -93 
Ntrk2 miR-101b, -101a, -124, -138, -329, -33, -431, -873 
Rapgef1 miR-124, -138, -149, -203, -411, -488, -495, -542-3p, -873 
Sh2b3 let-7b, let-7d, let-7f, let-7g, let-7i, -218, -30a, -30b, -30d, -30e, -326, -542-3p, -98 
Sort1 miR-135b, -142-3p, -146b, -149, -15b, -190, -195, -324-5p, -361, -542-3p, -9 








Genes identified in the proliferation and differentiation related pathways 
(Table 4.1) regulate cell cycle arrest that is required for neuronal 
differentiation, axonal outgrowth as well as cell survival. Of these, Axin2, 
Igf1r, Ikbkb, Prkcb and Ralgds had differentially expressed mRNAs and 
lncRNAs associated with them in mature neurons (Days 6 and 8) and were 
also predicted targets of the differentially expressed miRNAs (Figure 4.11). A 
decreased expression of Axin2 and Ralgds and up-regulation of Igf1r, Ikbkb, 
and Prkcb mRNAs were observed in the mature neuronal phenotype (Days 6 
and 8; Figure 4.11). LncRNAs associated with Axin2 
(ENSMUST00000143435), Igf1r (AK040698) and Ikbkb (uc009ldv.1) showed 
a reciprocal expression profile with their mRNA. mRNA-lncRNA pairs of 
Prkcb (ENSMUST00000118119) and Ralgds (uc008iyq.1), however, showed 
a similar expression profile.  
 
Amongst the cell adhesion molecules Cntn1, Ncam1, Negr1 and Nrxn1 had 
differentially expressed mRNAs and lncRNAs associated with them and were 
also predicted to be targeted by the altered miRNAs (Figure 4.11). Expression 
of Ncam1, Negr1 and Nrxn1 was up-regulated and expression of Cntn1 was 
down-regulated upon maturation (Days 6 and 8). Cntn1, Ncam1, Negr1 and 
Nrxn1 mRNA-lncRNA pairs displayed an inverse relationship (Cntn1: 
AK004399 and AK140484; Ncam1: uc009pjm.1 and AK156022; Negr1: 
uc008rva.1; Nrxn1: uc008dwg.1). Negr1 had another lncRNA associated with 












Figure 4.11: Differentially expressed RNA transcriptome associated with 
cell adhesion molecules regulation, proliferation and differentiation 
pathways, neurotrophin signalling pathway as determined by microarray 
(pooled RNA from 4 separate experiments for each time point). mRNA 
expression of the gene is indicated followed by the expression of the 
associated lncRNA. Differentially expressed miRNAs that are predicted to 
target the gene (TargetScan and microRNA.org) are indicated. Validated 
miRNAs are underlined. Expression is indicated in SLR relative to Day 2. 
Green – down-regulation; red – up-regulation; (S) - sense overlap; (AS) - 









In the neurotrophin signalling pathway Ikbkb (common to the proliferation and 
differentiation pathway), Ntrk2 and Sh2b3 had differentially expressed 
mRNAs and lncRNAs associated with them and were predicted to be co-
regulated by the altered miRNAs. Elevated levels of Ntrk2 and Sh2b3 mRNA 
transcripts were observed in mature neuronal phenotype with a reciprocal 
expression profile to their respective lncRNAs (Days 6 and 8; Figure 4.11).  
  
Based on these observations, it was postulated that regulation of these 11 
genes (Axin2, Igf1r, Ikbkb, Prkcb, Ralgds, Cntn1, Ncam1, Negr1, Nrxn1, 
Ntrk2 and Sh2b3) by both lncRNAs and miRNAs could be implicated in 
neuronal maturation. The expression of the 11 mRNAs, 1 randomly selected 
lncRNA per gene and miRNAs was validated by qPCR in maturing neurons 
on Days 2, 4, 6, 8 as well as more mature neurons on Day 14 (Tables 4.3 and 
4.4). Expression validation showed that the expression profile (Pearson’s 
correlation coefficient, R) on the first 8 days (Rarray) was consistent up to Day 
14 (RqPCR) (Tables 4.3 and 4.4). This also confirmed that the expression of the 
selected mRNAs, lncRNAs and miRNAs correlated to the microarray data. In 
view of this, subsequent analysis was based on the first 8 days from the 
microarray data. To further characterize how lncRNAs regulate these genes 
upon ischemia, their expression was determined in neurons subjected to an in 








Table 4.3: Validation and quantification of mRNA and 1 randomly selected lncRNA in maturing neurons. Pearson’s correlation 
coefficient (Rarray) based on the microarray data, was computed between SLR and days 2, 4, 6, 8 after maturation. Pearson’s correlation 
coefficient (RqPCR) based on qPCR, was computed between fold change and days 2, 4, 6, 8, 14 after maturation. Expression is shown in fold 
change ± SD relative to Day 2. Expression of GAPDH was used as a control/housekeeping gene to normalize mRNA and lncRNA expression. 
Statistically significant differences were tested using the Student’s t-test (*p<0.05, **p<0.01). Mean CT value ± SD for the no template control 
(NTC) is indicated.  
 
Gene mRNA Microarray qPCR (Fold change ± SD) qPCR (CT ± SD) 
 
lncRNA Rarray D4 D6 D8 D14 RqPCR NTC 
Proliferation and differentiation related pathway 
Axin2 NM_015732 -0.83 -1.38 ± 0.01* -1.34 ± 0.01* -1.16 ± 0.01 -2.63 ± 0.17* -0.88 Undetermined 
 
ENSMUST00000143435 0.28 1.08 ± 0.06 1.70 ± 0.06* 3.28 ± 1.04* 3.04 ± 1.52* 0.86 39.3 ± 0.7 
Igf1r NM_010513 0.54 -1.75 ± 0.01** -2.08 ± 0.02** -1.68 ± 0.02** -1.24 ± 0.02** 0.00 Undetermined 
 
AK040698 -0.97 -1.65 ± 0.01** 1.08 ± 0.02* 1.27 ± 0.13* -4.77 ± 0.01** -0.71 Undetermined 
Ikbkb NM_010546 0.87 -1.27 ± 0.01* -1.44 ± 0.02* -1.32 ± 0.02* -2.34 ± 0.02** -0.95 Undetermined 
 
uc009ldv.1 -0.04 -1.35 ± 0.15 -1.68 ± 0.02** -1.96 ± 0.02** -1.90 ± 0.24** -0.81 35.6 ± 0.7 
Prkcb NM_008855 0.95 1.88 ± 0.07** 2.01 ± 0.01** 2.99 ± 0.02** 11.48 ± 0.20** 0.99 36.8 ± 0.1 
 
ENSMUST00000118119 0.94 1.12 ± 0.01* 1.00 ± 0.01 -1.01 ± 0.01 1.90 ± 0.74* 0.83 Undetermined 
Ralgds NM_009058 -0.64 -1.21 ± 0.05* -1.22 ± 0.01** -1.02 ± 0.02 -1.40 ± 0.01** -0.68 37.0 ± 0.1 
 















Gene mRNA Microarray qPCR (Fold change ± SD) qPCR (CT ± SD) 
 
lncRNA Rarray D4 D6 D8 D14 RqPCR NTC 
Cell adhesion molecules 
Cntn1 NM_001159648 -0.78 1.39 ± 0.06* 1.76 ± 0.05** 2.27 ± 0.03** 2.69 ± 0.05** 0.93 34.9 ± 0.1 
 
AK140484 0.47 -1.45 ± 0.01* 1.10 ± 0.01 1.07 ± 0.02 -1.40 ± 0.07* -0.34 Undetermined 
Ncam1 NM_010875 0.89 -1.05 ± 0.06 1.29 ± 0.01** 1.35 ± 0.02** 1.44 ± 0.04** 0.85 Undetermined 
 
AK156022 -0.41 1.03 ± 0.03 1.01 ± 0.02 -1.07 ± 0.03* -2.32 ± 0.01** -0.90 37.1 ± 0.1 
Negr1 NM_001039094 0.96 1.46 ± 0.03** 2.60 ± 0.01** 2.82 ± 0.02** 2.15 ± 0.05** 0.62 Undetermined 
 
uc008rva.1 -0.53 1.09 ± 0.02* 1.02 ± 0.02 -1.09 ± 0.01** -1.16 ± 0.04** -0.85 Undetermined 
Nrxn1 NM_020252 0.21 1.17 ± 0.01** 1.03 ± 0.02 1.07 ± 0.01** 1.69 ± 0.01** 0.86 Undetermined 
 
uc008dwg.1 -0.48 -1.63 ± 0.01** -1.34 ± 0.03* -1.55 ± 0.02** -1.44 ± 0.02* -0.44 Undetermined 
Neurotrophin signalling pathway 
Ntrk2 NM_008745 0.96 1.16 ± 0.08 2.06 ± 0.01** 3.82 ± 0.01** 4.90 ± 1.93** 0.93 Undetermined 
 
AK021278 -0.87 -1.50 ± 0.12* -1.40 ± 0.07* -1.46 ± 0.04* -1.70 ± 0.12* -0.78 37.1 ± 0.3 
Sh2b3 NM_008507 0.84 -1.35 ± 0.02** -1.14 ± 0.06 1.00 ± 0.06 1.44 ± 0.03** 0.79 37.0 ± 0.1 
 

















Table 4.4: Validation and quantification of miRNAs in maturing neurons. Pearson’s correlation coefficient (Rarray) based on the microarray 
data, was computed between SLR and days 2, 4, 6, 8 after maturation. Pearson’s correlation coefficient (RqPCR) based on qPCR, was computed 
between fold change and days 2, 4, 6, 8, 14 after maturation. Expression is shown in fold change ± SD relative to Day 2. Expression of GAPDH 
was used as a control/housekeeping gene to normalize miRNA expression. Statistically significant differences were tested using the Student’s t-
test (*p<0.05, **p<0.01). Mean CT value ± SD for the no template control (NTC) is indicated.  
 
 
Microarray qPCR (Fold change ± SD) qPCR (CT ± SD) 
 
Rarray D4 D6 D8 D14 RqPCR NTC 
miR-124 -0.44 1.25 ± 0.01* 1.16 ± 0.09* -1.12 ± 0.05 -1.70 ± 0.01** -0.99 Undetermined 
miR-129 -0.22 1.81 ± 0.04** 2.24 ± 0.03** 1.34 ± 0.02* -4.80 ± 0.01** -0.95 Undetermined 
miR-218 -0.35 1.30 ± 0.03** -1.07 ± 0.04* 1.31 ± 0.02** 1.23 ± 0.08** 0.15 Undetermined 
miR-290-5p 0.15 -1.04 ± 0.19 1.16 ± 0.01** 1.36 ± 0.47 2.25 ± 1.09* 1.00 Undetermined 
miR-326 0.44 1.43 ± 0.29 1.25 ± 0.02** 1.87 ± 0.01** -1.26 ± 0.03* -0.70 Undetermined 
miR-203 -0.99 -1.67 ± 0.02** -3.17 ± 0.03** -3.16 ± 0.02** -5.44 ± 0.01** -0.93 Undetermined 














4.6 Viability of neuronal cultures during OGD conditions 
Primary mouse cortical neurons, on the day 6 of culture were subjected to 
OGD (2, 4 hours) followed by 24 hour reperfusion. Exposure to 2 hours of 
OGD resulted in apoptosis (Figure 4.12). Increased apoptosis was observed in 
neurons subjected to 4 hours OGD as compared to those subjected to 2 hours 
OGD (Figure 4.12). The percentage of viable cells significantly decreased 
from 87.0 % with 2 hours of OGD to 67.3 % with 4 hours of OGD (Figure 
4.12). Exposure to 2 hours of OGD resulted in degenerated neurites as shown 
by shorter neurites stained with MAP2 (Figure 4.13). Neurites were more 
degenerated when exposure to OGD was increased to 4 hours (Figure 4.13).  
 
Figure 4.12: Cell viability of primary neurons subjected to oxygen and 
glucose deprivation (OGD). Primary neuronal cultures subjected to OGD 
were stained with the nuclear stain, Hoechst 33342 (blue), and necrotic cells 
marker, Ethidium homodimer III (red). Exposure to OGD showed an increase 
in apoptotic cells, indicated by condensed nuclei (green arrow heads) and 
necrotic cells (red open arrow heads). Healthy cells were expressed as a 
percentage (mean ± SD) of the total cells. All experiments were carried out n 
= 4 and in triplicates. Statistically significant differences were tested using the 










Figure 4.13: Immunostaining of primary neurons subjected to oxygen and 
glucose deprivation (OGD). Bright-field immunostained images illustrating 
cell death in healthy neuronal cultures subjected to OGD. Cells subjected to 
increasing ischemic injury displayed degenerated neurites. BF - Bright-field; 







4.7 mRNA-lncRNA expression patterns in ischemic injury 
Expression of mRNAs and lncRNAs associated with the genes identified 
earlier in Section 4.5 were verified in these samples to identify the roles of 
these transcripts in neuronal survival (maturation) and cell death (OGD). The 
validity of the ischemic model was confirmed by checking the expression of 
genes known to be dysregulated during ischemic injury. Ephx2, which encodes 
for soluble epoxide hydrolase (sEH), an important enzyme in the metabolic 
breakdown of arachidonic acid-derived eicosanoids [284] was found to be up-
regulated upon exposure to OGD (Table 4.5). Another gene, Hsp72, encoding 
for the 72-kD inducible heat shock protein that can attenuate cerebral ischemic 
injury upon overexpression [285], was found to be down-regulated (Table 
4.5). Hence, this confirmed that the ischemic injury model set-up and array 
were accurate and reliable.  
 
 
Table 4.5: Expression of mRNAs known to be dysregulated in cerebral 
ischemia in microarray data of neurons subjected to OGD. The gene name 
is indicated followed by the mRNA expression (SLR) in neurons subjected to 
2 hours and 4 hours OGD.  
 
mRNA  2hrs OGD  4hrs OGD  
Ephx2  1.54  1.10  






The relative changes in mRNA and lncRNA expression for the 11 genes 
during ischemic injury is shown in Table 4.6. Next, Pearson’s correlation was 
performed on the 11 genes based on their mRNA and lncRNA expression in 
the two models; maturation and OGD. A reversal in direction (+/– or –/+) of 
the Pearson’s correlation coefficient was observed from maturation to 
ischemic injury for the mRNA and lncRNA expression associated with most 
of the genes (indicated in bold in Table 4.6). For instance, Negr1 mRNA 
(NM_001039094) showed a Pearson’s correlation coefficient of 0.96 during 
maturation which was reversed to -0.99 during ischemic injury. This indicated 
an opposite expression profile upon ischemic injury as compared to during 
maturation (Table 4.6).  
 
Further interrogation of Pearson’s correlation coefficient of the mRNA-
lncRNA pairs for each gene in the maturation and ischemic models was used 
to determine the relationship between the two entities (Table 4.6). Same 
direction (+/+ or -/-) of Pearson’s correlation coefficient for the mRNA-
lncRNA in the 2 models was defined as a synergistic relationship between the 
mRNA and its associated lncRNA whereas an opposite direction (+/- or -/+) 
suggested an inverse relationship. For example, the Prkcb mRNA and lncRNA 
in the proliferation and differentiation related pathway had a correlation 
coefficient of 0.95 and 0.94 respectively, indicating increased expression of 
both transcripts during maturation. During ischemic injury, both transcripts 
decreased in expression with a correlation coefficient of -0.25 and -0.59 for 
the mRNA and lncRNA respectively. Hence, the Prkcb mRNA-lncRNA 




and ischemic injury. On the other hand, the Axin2 mRNA-lncRNA pair 
(antisense overlap orientation) in the same pathway was inversely related 
during both maturation and ischemic injury (Table 4.6). Furthermore, cell 
adhesion molecules such as Cntn1, Ncam1, Negr1 and Nrxn1 as well as Sh2b3 
in the neurotrophin signalling pathway displayed a mainly inverse relationship 
between mRNA and antisense lncRNA gene pairs.  These findings seem to 
indicate a predominant reciprocal relationship between antisense lncRNAs and 
their associated mRNA. Among the 11 genes, a distinct inverse or synergistic 
expression was observed between the mRNA and lncRNA of 7 genes namely, 
Axin2, Prkcb, Cntn1, Ncam1, Negr1, Nrxn1, Sh2b3 (Table 4.6). Hence, the 
next step was to determine the miRNAs that could be regulating these 7 genes 








Table 4.6: Expression of mRNA and lncRNAs associated with selected genes identified in the proliferation and differentiation associated 
pathway, cell adhesion molecules and neurotrophin signalling pathway during ischemic injury. Reqseq number for the mRNA of each 
gene and the sequence number of the associated lncRNA are indicated. Expression is shown in SLR ± SD relative to Day 2. Pearson’s 
correlation coefficient (R) was computed between SLR and days after maturation or hours of exposure to OGD ischemic injury. R-value in bold 
indicated opposite direction of the Pearson’s correlation coefficient (R) in maturation and ischemic injury. One sample t-test was used to 
calculate the p-value from 2 replicates for comparison of expression during maturation (Day 6 and Day 8) and OGD (2 hours and 4 hours OGD). 
Day 2 and 0 hour OGD were used as the µ values for maturation and OGD respectively (*p<0.10, **p<0.05). Student’s t-test was used to 




p<0.05). The inferred relationship between the mRNA-lncRNA 
expression from maturation and ischemic injury as well as genomic orientation of the associated lncRNA is also indicated. 
 
Gene mRNA 
Genomic orientation of 
lncRNA 









Proliferation and differentiation related pathway 
Axin2 NM_015732  0.03 ± 0.03 1.54 ± 0.33
##




-0.46 ± 0.06 -0.26 ± 0.03
#
 0.28 -0.55* Inverse 
Igf1r NM_010513  0.07 ± 0.01 0.25 ± 0.03
##
 0.54* 0.97  
 AK040698 antisense overlap, intron 1.34 ± 0.31 1.31 ± 0.26 -0.97* 0.86** Inconclusive 
Ikbkb NM_010546  -0.49 ± 0.09 0.10 ± 0.01
##
 0.87** 0.16  
 uc009ldv.1 sense overlap, promoter -2.05 ± 2.06 -1.22 ± 0.38 -0.04 -0.59* Inconclusive 
Prkcb NM_008855  -0.89 ± 0.13 -0.23 ± 0.03
##
 0.95** -0.25  
 ENSMUST00000118119 sense overlap, intron -0.82 ± 0.09 -0.49 ± 0.05
##
















Genomic orientation of 
lncRNA 









Proliferation and differentiation related pathway 
Ralgds NM_009058  0.12 ± 0.02 -0.25 ± 0.05
##
 -0.64** -0.65  
 uc008iyq.1 
sense overlap,        
intron-exon 
1.23 ± 0.15 0.41 ± 0.06
##
 -0.73** 0.32 Inconclusive 
Cell adhesion molecules 
Cntn1 NM_001159648  0.34 ± 0.06 0.39 ± 0.06 -0.78* 0.91**  
 AK004399 sense overlap, 3'UTR -0.33 ± 0.03 -0.59 ± 0.06
##
 0.99* -1.00* Inverse 
 AK140484 antisense overlap, intron 0.09 ± 0.01 -0.33 ± 0.04
##
 0.47* -0.75 Inverse 
Ncam1 NM_010875  -1.38 ± 0.21 -0.35 ± 0.04
##
 0.89* -0.25  
 uc009pjm.1 sense overlap, promoter -0.23 ± 0.02 0.00 ± 0.10
##
 -0.92* -0.01 Inconclusive 
 AK156022 antisense overlap, intron 1.34 ± 0.13 0.69 ± 0.07
##
 -0.41 0.52* Inverse 
Negr1 NM_001039094  -0.39 ± 0.04 -0.60 ± 0.06
#
 0.96** -0.99*  
 uc008ruz.1 (AK083124) Bidirectional -0.98 ± 0.13 -0.70 ± 0.08 0.50* -0.70* Synergistic 
 uc008rva.1 (BC048612) Bidirectional 0.98 ± 0.24 1.15 ± 0.24 -0.53* 0.93** inverse 
Nrxn1 NM_020252  -0.93 ± 0.18 -0.14 ± 0.02
##
 0.21** -0.14  
 uc008dwg.1 sense overlap, intron 0.08 ± 0.02 0.35 ± 0.06
##


















Genomic orientation of 
lncRNA 










Neurotrophin signalling pathway 
Ntrk2 NM_008745  -0.36 ± 0.04 -0.25 ± 0.02
#
 0.96** -0.68*  
 AK021278 antisense overlap, intron 0.16 ± 0.02 -0.49 ± 0.05
##
 -0.87** -0.72 Inconclusive 
Sh2b3 NM_008507  -1.50 ± 0.34 -1.77 ± 0.42 0.84** -0.93**  
 AK007127 
antisense overlap,  first 
intron 
-0.06 ± 0.02 0.37 ± 0.07
##














4.8 Regulation of axonogenesis and dendritogenesis by lncRNAs and 
miRNAs 
Seven genes (Axin2, Prkcb, Cntn1, Ncam1, Negr1, Nrxn1, Sh2b3) were found 
to be associated with lncRNAs that could regulate them. This was followed up 
with elucidation of miRNAs that could be co-regulating these 7 genes along 
with their respective lncRNAs. Using the list of miRNAs altered during 
neuronal maturation (Figure 4.11), 10 miRNAs (miR-124, miR-128, -129-5p, -
203, -218, -290-5p, -326, -329, -377 and -495) were predicted or validated to 
target 2 or more of the 7 genes.  An overview of the intricate regulatory 
network of lncRNAs and miRNAs over the 7 genes is shown in Figure 4.14. 
Each gene was regulated by at least one lncRNA and one miRNA. 
Furthermore, since each miRNA could regulate 2 or more of these 7 genes, 
these miRNAs could be important modulators of neuronal development. 
Interestingly, miR-124, -128, -129-5p, -218, -326, -329, -377 and -495 have 
been reported to exhibit brain specific or brain-enriched expression pattern 
[166,271,286-289]. miR-329, -377 and -495 belong to the miR-379-410 
cluster that modulates activity-dependent dendritogenesis [290]. It was also 
observed that the cell adhesion molecules Cntn1, Ncam1, Negr1 and Nrxn1, 
which are responsible for neurite outgrowth and synaptogenesis, could 
possibly be regulated by both lncRNAs and miRNAs (Figure 4.14, genes in 
bold). 
 
Hence, co-regulation of mRNA expression by lncRNAs and miRNAs could be 
the key to modulating neuronal homeostasis for precise neuronal development. 
Dysregulation of this delicate lncRNA-mRNA-miRNA network during 






Figure 4.14: Overview of integrated network of genes regulated by both lncRNAs and miRNAs, that are crucial for precise neuronal 
development. LncRNAs associated with the gene are underlined. Ten differentially expressed miRNAs targeting the respective genes are 
indicated. miRNAs shaded in grey (miR-329, -377, -495) belong to the miR-379-410 cluster. Red font – up-regulated 

















Supplementary Figure 4.1: Differentially expressed genes in each cluster 
as identified in hierarchical clustering analysis of 6965 differentially 
expressed mRNAs (SLR > 1) in maturing neurons (Figure 4.3). Genes 
showing -6 < SLR < -1.5 (cluster 1), 3.5 < SLR < 7.5 (cluster 2) on Day 6 or 







Supplementary Figure 4.2: Differentially expressed lncRNAs in each 
cluster as identified in hierarchical clustering analysis of 7455 
differentially expressed lncRNAs (SLR>1) in maturing neurons (Figure 
4.4). LncRNAs showing SLR = -8 (cluster 1), 2.4 < SLR < 3.4 (cluster 2), 1.3 
< SLR < 2 (cluster 3), -4.5 < SLR < -3 (Cluster 4) on day 6 or day 8 are shown 
to represent the cluster. Genes associated with the lncRNAs in each cluster are 














Supplementary Figure 4.3: Differentially expressed miRNAs in each 
cluster as identified in hierarchical clustering analysis of 395 miRNAs 
after background subtraction of signal intensity less than 300 in maturing 
cortical neurons (Figure 4.6). miRNAs showing -3 < SLR < -0.3 (cluster 1), 
1.2 < SLR < 2.2 (cluster 2), -0.1 < SLR < -0.6 (Cluster 3) on day 6 or day 8 
are shown to represent the cluster. Green – down-regulation; red – up-




Supplementary Table 4.1: Associated gene names of lncRNAs for each 
cluster indicated in Supplementary Figure 4.2. N.A.: not applicable as 
lncRNA is intergenic. 
 
Cluster LncRNA sequence name Associated gene name 
1 
ENSMUST00000136988 N. A. 
ENSMUST00000160545 radial spoke head protein 3 homolog A 
AK016186 promethin 
AK140199 N. A. 
ENSMUST00000120038 filensin 
ENSMUST00000150111 N. A. 
AK157753 N. A. 
AK131936 N. A. 
MM9LINCRNAEXON11613+ N. A. 
ENSMUST00000120964 N. A. 
uc009mdo.1 
mitochondrial tRNA modification 




protein phosphatase 1 regulatory subunit 
12B 
ENSMUST00000145638 hypothetical protein LOC233812 
AK131893 
condensin-2 complex subunit H2 
isoform b 
uc.64+ EH domain-binding protein 1 
ENSMUST00000133752 palladin 
ENSMUST00000143962 
fibroblast growth factor receptor 
substrate 3 
ENSMUST00000133231 N. A. 
MM9LINCRNAEXON10527+ N. A. 
AK011807 
tetratricopeptide repeat protein 23 
isoform 1 
NR_003517 protein SFI1 homolog 
ENSMUST00000109666 N. A. 
3 
ENSMUST00000154992 
peroxisomal multifunctional enzyme 
type 2 
AK050092 N. A. 
AK139812 N. A. 
ENSMUST00000119652 N. A. 
AK156415 N. A. 
ENSMUST00000117585 N. A. 
ENSMUST00000117760 N. A. 
uc008pwq.1 N. A. 
uc009rwl.1 N. A. 




















Cluster LncRNA sequence name Associated gene name 
4 
MM9LINCRNAEXON10225- N. A. 
ENSMUST00000129364 zinc finger protein 335 
MM9LINCRNAEXON10254- N. A. 
uc007boy.1 striated muscle-specific 
AK002799 cip1-interacting zinc finger protein 
MM9LINCRNAEXON10523+ N. A. 
uc007jey.1 folliculin 
ENSMUST00000128848 
inactive ubiquitin carboxyl-terminal 
hydrolase 
ENSMUST00000155388 homeobox protein Hox-B3 








5 REGULATION OF NEGR1 EXPRESSION BY MICRORNA-
203 AND BIDIRECTIONAL LONG NON-CODING RNAS 
5.1 Introduction 
Expression profiling of RNA transcripts during neuronal maturation and 
ischemic injury has highlighted two pathways crucial to neuronal survival, the 
cell adhesion molecules and the neurotrophin signalling pathway (Table 4.1). 
To determine the most promising neuroprotectant, ncRNAs regulating a gene 
from each pathway (Figure 4.14, genes in bold) were characterized and their 
effects on neurite outgrowth and neuronal survival were evaluated.  
 
Four cell adhesion molecules, Cntn1, Ncam1, Negr1 and Nrxn1, were 
identified as important regulators of neuronal survival (Chapter 4) and had 
lncRNAs and miRNAs predicted to regulate their expression  [291]. Of these 4 
molecules, the expression of Negr1 mRNA was most significantly up-
regulated during neuronal maturation and most significantly down-regulation 
during ischemia (Table 4.6). This observation suggested that dysregulation of 
expression of this molecule could be a critical determinant of neuronal cell 
death. Hence, being able to modulate its expression would serve as a 
therapeutic approach for ischemic injury.  
 
NEGR1 (Neuronal growth regulator 1) is an IgLON protein belonging to the 
immunoglobulin superfamily of cell adhesion molecules [292]. It is expressed 
at high levels in the cerebral cortex, hippocampus, and cerebellum with 
increasing expression during postnatal development which stabilizes in 
adulthood [69,76]. Negr1 is implicated in neurite outgrowth [77,78] and is a 




development. Interestingly, three independent human genome-wide 
association studies have identified Negr1 as an obesity-associated locus [80-
82]. Furthermore, ablation of Negr1 function resulted in a reduction in body 
mass [83]. Schäfer et al. (2005) also reported that after entorhinal cortex 
lesion, expression of NEGR1 protein is induced on reactive astrocytes, which 
in turn promotes neurite outgrowth of hippocampal neurons [69]. This 
suggests a function for Negr1 as a trans-neural growth-promoting factor for 
outgrowing axons following hippocampal denervation [69]. Studies to 
determine regulators of Negr1 expression would provide insights into the 
mechanism of regulation for appropriate neuronal function as well as how 
dysregulation upsets this balance in an injury or disease state. These regulators 
could hence serve as neuroprotectants in injury or disease.  
 
Non-coding RNAs (ncRNAs), namely lncRNA and miRNAs, are 
endogenously produced regulators of gene expression [280]. miRNAs are 
short endogenous molecules, approximately 22 nucleotides in length. These 
small RNAs interact with their target mRNAs by complementary binding to 
bring about transcriptional and translational regulation [282,283]. LncRNAs, 
on the other hand, are transcripts more than 200 nucleotides long that 
coordinate gene expression through genomic imprinting, epigenetic 
modification, mRNA splicing and control of transcription or translation [136].  
 
Earlier in the study, putative miRNA and lncRNA based modulators of Negr1 
expression were identified (Chapter 4). Therefore this section of the study 




expression in an in vitro neuronal system. Furthermore, functional studies 
were performed to determine the effect of Negr1 modulation on neuronal 
structure and function as well as the therapeutic potential of identified 
regulatory RNAs in ischemic conditions. 
 
5.2 Regulation of Negr1 mRNA expression by miR-203 
5.2.1 Bioinformatics predictions of miRNAs targeting Negr1 mRNA  
In the previous chapter, it was found that expression of Negr1 mRNA was 
most significantly up-regulated during neuronal maturation with a Pearson’s 
correlated coefficient of 0.96, p<0.05 (Table 4.6). Also, it was the most 
significantly down-regulated mRNA during ischemic injury with a Pearson’s 
correlation coefficient of -0.99, p<0.05 (Table 4.6). Five miRNAs, miR-124, -
129-5p, -203, -329, and -377, were predicted to regulate the murine Negr1 
mRNA 3’UTR (Figure 4.14). These 5 miRNAs were mapped onto the 3’UTR 
(Figure 5.1). miR-129-5p, -329 and -377 had one binding site, miR-124 had 2 
binding sites and miR-203 had 3 binding sites (Figure 5.1).  
 
Conserved miRNA binding sites imply these regions are under selective 
pressure and therefore biologically functional [283]. Therefore, further 
bioinformatics analysis was carried out to determine miRNAs that had 
conserved binding sites on both the mouse and human Negr1 3’UTR. The 
mouse and human Negr1 3’UTR were aligned and the miRNAs were mapped 
onto it. Amongst the 5 miRNAs, only binding sites for miR-124, -203 and -
377 were conserved in mouse and human (Figure 5.2). These 3 miRNAs were 











Figure 5.1: Schematic representation of miRNAs predicted to target the Mus musculus Negr1 3’UTR. The solid black line represents the 
3’UTR region of mouse Negr1 (not drawn to scale). The first nucleotide of the 3’UTR region has been re-numbered as 1. The 5 miRNAs 














                     miR-124  3’  CCGUAAGUGGCGCACGGAAU  5’ 
                                              ǀǀǀǀǀǀǀ  
Mmu  TATGCTTCTCCTT-----------CTAATCTCAGCATGGGTGTGCCTTCATAAAATAATC 618 
Hsa  TGTGCAGCTCTGCTTCTCTTTCCTGTAAGTTCAGCATGGGTGTGCCTTCATACAATAATA 628    
     * ***  ***               ***  ********************** ******  
  
                     miR-377  3’  UGUUUUCAACGGAA-—ACACACUA  5’ 
                                         ǀǀǀǀ     ǀǀǀǀǀǀǀ  
Mmu  TATGAGTTCAGTATTGTTCAAATAAGGCTACAGTATTTGCTTTTTTGTGTGAATGTATTG 2404  
Hsa  TATGAGTTCAATATTG-TCAAATAAGGCTACAGTATTTGCTTTTTTGTGTGAATGTATTG 2514 
     ********** ***** ******************************************* 
  
                           miR-203  3’  GAUCACCAGGAUUUGUAAAGUG  5’ 
                                                      ǀǀǀǀǀǀǀ  
Mmu  CTTATGAAGTTAATTTATCTTTTGATTTACAACAATTTCTTTAGCTATTCATTTCAGCGT 2594   
Hsa  TTTATAAATTGATTTATCTTTTAATCTATAACAATTTGTGTTAGCTGTTCATTTCAGGAT 2704 
      **** ** * * **    ***    *   *  * **   ****** **********  * 
  
   3’  GAUCACCAGGAUUUGUAAAGUG  5’  miR-203 
                      ǀǀǀǀǀǀ  
Mmu  -TGAGATTGAGAGAGAGCATTTCAAACATAAAGTCACTTTGGGG---TTCACAGCTTCAC 3015   
Hsa  AAAGATTTGAGAGGGAGAATTTCAAACTTAAAGCCACTTTTGGGGGGTTTATAACTTAAC 3184 
           ******* *** ********* ***** ****** ***   ** * * *** ** 
  
                         miR-203  3’  GAUCACCAGGAUUUGUAAAGUG  5’ 
                                                     ǀǀǀǀǀǀ  
Mmu  AAAGAGGTCAGGTTTCTAACTATTTATTGAAGTGTGTGGGTGTACAGTATTTCAATAGAT 3367   
Hsa  AAAGAGGTCAGGTTTTTAACTATTTATTGAAGTATGTGGATGTACAGTATTTCAATAGAT 3541 
     *************** ***************** ***** ******************** 
   
miR-124  3’  CCGUAAGUGGCGCACGGAAU  5’ 
                          ǀǀǀǀǀǀ  
Mmu  ATGAATATGGATAAGTGGTATTGCCTTAAGATCCTCTGAA-ATGTACTTACTTTAAAGAC 3426 
Hsa  ATGAATATGAATAAATGGTA-TGCCTTAAGATTCTTTGAATATGTATTTACTTTAAAGAC 3600 
     ********* **** ***** *********** ** **** ***** *************  
 
Figure 5.2: Alignment of 3’UTR sequence of murine (Mmu) and human 
(Hsa) Negr1 gene. The sequences were obtained from NCBI (Mouse: 
NM_001039094.3; Human: NM_173808.2). The predicted conserved binding 
sites of selected miR-124, -203 and -377 on the 3’UTR of mouse and human 







5.2.2  Expression of Negr1 associated mRNA and miRNAs in primary 
cortical neuronal cultures 
Having shortlisted 3 miRNAs that could possibly target and regulate 
expression of Negr1, it was necessary to determine the expression profile of 
these regulatory RNAs and Negr1 during neuronal maturation. The expression 
of NEGR1 protein during neuronal development was first validated using 
immunocytochemistry in maturing primary neurons. Day 2 and Day 8 primary 
neuronal cultures were immunostained for both microtubule-associated protein 
2 (MAP2), a marker of neuronal maturation, as well as NEGR1 protein 
(Figure 5.3). MAP2 staining showed short neurites just beginning to extend on 
Day 2 (Figure 5.3). This overlapped with light staining for NEGR1 protein. 
On Day 8, extensive neurite outgrowth was observed which overlapped with 
intense staining for NEGR1 protein (Figure 5.3). This indicated that Negr1 
expression and protein level increased dramatically during maturation and 
neurite outgrowth from Day 2 to Day 8, consistent with reports of its 














Figure 5.3: NEGR1 protein expression during cortical neuron maturation in vitro. Primary mouse cortical neuronal cultures on Day 2 and 8 
were fixed, immunostained and visualized using confocal microscopy. Green - Microtubule-associated protein 2 (MAP2); pink – Neuronal 









Measurement of NEGR1 protein level was followed up with measurement of 
Negr1 mRNA, miR-124, -203 and -377 expression levels during neuronal 
development using quantitative real-time PCR. The expression of Negr1 
mRNA increased significantly by 2.82 ± 0.04 (p=0.001) fold from Day 2 to 
Day 8 (Figure 5.4). This was consistent with the drastic increase in NEGR1 
protein levels (Figure 5.3). Up-regulation of expression was also observed for 
miR-124 (relative expression = 1.22 ± 0.02, p=0.021) and -377 (relative 
expression = 5.13 ± 1.01, p=0.033) during neuronal development. However, 
miR-203 showed significantly reduced expression of 0.26 ± 0.01, p=0.001 
(Figure 5.4). Since miRNAs mediate translational repression of mRNA 
expression by binding to the 3’UTR of the target mRNA [282,283], the 
increased expression of Negr1 mRNA could be mediated by the reduced 
expression of miRNAs targeting it. From the quantitative real-time PCR data, 
only miR-203 showed an opposite expression to the increased Negr1 mRNA 
expression (Figure 5.4). This was further verified by measuring the expression 
of the Negr1 mRNA and putative miRNAs in neurons subjected to OGD 
(Figure 5.5). Neurons subjected to OGD showed a significant reduction in 
Negr1 mRNA and miR-124 expression but significantly increased miR-203 
and miR-377 expression (Figure 5.5). In both models, miR-203 showed an 
opposite expression profile to the Negr1 mRNA expression, indicating it is a 










Figure 5.4: Quantification of Negr1 mRNA and miRNA expression during 
murine cortical neuron maturation by qPCR. Expression of Negr1 mRNA 
and miRNAs predicted to target both the mouse and human Negr1 3’UTR was 
measured in Day 8 neurons and normalized to Day 2 neurons. Expression of 
GAPDH was used as a control/housekeeping gene to normalize mRNA and 
miRNA expression. Data are presented as mean ± SD, n=3. Statistical 
significance was tested using the Student’s t-test and p-value is indicated next 
to the relative expression. 
 
 
Figure 5.5: Quantification of Negr1 mRNA and miRNA expression in 
primary neurons subjected to 4 hours OGD by qPCR. Expression of Negr1 
mRNA and miRNAs predicted to target both the mouse and human Negr1 
3’UTR was measured in neuronal cultures subjected to 4 hours OGD and 24 
hours reperfusion. The changes in expression were compared against control 
cultures not subjected to OGD. Expression of GAPDH was used as a 
control/housekeeping gene to normalize mRNA and miRNA expression. Data 
are presented as mean ± SD, n=3. Statistical significance was tested using the 




5.2.3  miRNA interaction studies on Negr1 3’UTR 
Reporter gene assays are used widely to validate miRNA:mRNA interaction. 
To determine miRNA:mRNA interaction between the 3’UTR of the target 
gene and a specific miRNA, the 3’UTR of the gene of interest is inserted 
downstream of a reporter gene, for example, luciferase. Hence, to evaluate the 
regulatory activity of miR-203 on Negr1, the 3’UTR of both the mouse and 
human Negr1 genes was cloned. 
 
The 3’UTR of mouse and human Negr1 harbours 3 binding sites for miR-203 
(Figure 5.2). A common set of primers were used to amplify the mouse and 
human Negr1 3’UTR fragments containing all 3 binding sites (Table 5.1, 
Figure 5.6). These primers amplified a 1125bp fragment of the mouse Negr1 
3’UTR and a 1190bp fragment of the human Negr1 mRNA (Figure 5.7).  
 
Table 5.1: Primer design to amplify fragments of human and mouse 
Negr1 3’UTR with miR-203 binding sites. RE sites are underlined. 
 
Primer RE site Sequence (5’ → 3’) 
Forward - AATAAGGCTACAGTATTTGCTTT 
Reverse - CACCTATTGGAAACAGTACAACA 
Forward with RE site Spe I ATCAACTAGTAATAAGGCTACAG 









2355 CATGAGTATTTATGAGTTCAGTATTGTTCAAATAAGGCTACAGTATTTGCTTTTTTGTGT Mmu 
2466 CATGAGTATTTATGAGTTCAATATTG-TCAAATAAGGCTACAGTATTTGCTTTTTTGTGT Hsa 
     ******************** ***** ********************************* 
 
2415 GAATGTATTGCATATAATGTTCAAGTAGGTGATTTTACATTGACGGGCATCTGAAATGTC Mmu 
2525 GAATGTATTGCATATAATGTTCAAGTAGATGATTTTACATTTATGGACATATAAAATGTC Hsa 
     **************************** ************ * ** *** * ******* 
 
2475 TGATTACTCCATTTTATCAGTCCTGACTGTACAAGATTGTTGCAATTTCAGAATAGCAGT Mmu 
2585 TGATTACCCCATTTTATCAGTCCTGACTGTACAAGATTGTTGCAATTTCAGAATAGCAGT Hsa 
     ******* **************************************************** 
                           miR-203  3’  GAUCACCAGGAUUUGUAAAGUG  5’ 
                                                      ǀǀǀǀǀǀǀ 
2535 CTTATGAAGTTAATTTATCTTTTGATTTACAACAATTTCTTTAGCTATTCATTTCAGCGT Mmu 
2645 TTTATAAATTGATTTATCTTTTAATCTATAACAATTTGTGTTAGCTGTTCATTTCAGGAT Hsa  
      **** ** * * **    ***    *   *  * **   ****** **********  * 
 
2495 TATGTTTTCCACAATATCCATTTGTGGGATTCCTTTTGTTGCCCCTAAATTTTTAAAGAA Mmu 
2705 TATATTTTCTACAAGTTCCACTTGTGGGACTCCTTTTGTTGCCCCTATTTTTTTTTAAAG Hsa 
     *** ***** ****  **** ******** *****************  *****  * *  
 
2655 AGAAGGAAAAAATGATGATAGAGAAAGGAGAATGTGAAAATGGAGAAAAGGAAAAAAGAG Mmu 
2765 AAGGAAGAAAGAAAAATAAGTAGCAGTTTAAAAATGAGAATGGAGAGAAAAGAAAAAGAA Hsa 
     *      *** *  *  *   ** *     **  *** ******** **   *******  
 
2715 TATGG-----------------GGGATAAACAGAAATGACTGAAGGAAG----------- Mmu 
2825 TGAAAAGGAAAGGCAGTAAAGAGGGAAAAAAAGGAAGGATGGAAGGAATGAAGGAAGGAA Hsa 
     *                     **** *** ** ** **  *******             
 
2747 -CGAA--------GA-GGTTGGGAGGGAGA-----------GTGGGGGAGAGCTGGAATC Mmu 
2885 GGGAGGAAGGGGAGAAGGTAGGAAGAAAGAAAGGATGAGAGGGAAGGAAGAATCAGAGTA Hsa 
       **         ** *** ** **  ***           *   ** ***    ** *  
 
2786 TTCTGCTGATGAGCCTATTGGACTGCATTCTTGGTTTAACTGCAAATGGCCGAATTT--T Mmu 
2945 TTAGGGTAGTTAACTTACACATTTGCATTCTTAGTTTAACTGCAAGTGGTGTAACTACGT Hsa 
     **  * *  * * * **      ********* ************ ***   ** *   * 
 
2844 TTCCCAATGATCTTATTCTACACCTAAGTCCTGCTATACCCTGTGGTCCTG-CTGGGCAG Mmu 
3005 TTTTCAATGATCGCATTTGAAACATAAGTCCTATTATACCATTAAGTTCCTATTATGCAG Hsa 
     **  ********  ***  * ** ********  ****** *   ** *    *  **** 
 
2903 AATTTAT-TGAATGATTCCACTGCCCAGGCCACAGTACTGAGTGCTTTTTGCAGACAC-- Mmu 
3065 CAATTATATAATAAAAAGTACTGCCCAAGTTATAGTAATGTGGGTGTTTTTGAGACACTA Hsa 
     * **** * *   *    ******** *  * **** ** * *  ****  ******   
    3’  GAUCACCAGGAUUUGUAAAGUG  5’  miR-203 
                       ǀǀǀǀǀǀ 
2960 -TGAGATTGAGAGAGAGCATTTCAAACATAAAGTCACTTTGGGG---TTCACAGCTTCAC Mmu 
3125 AAAGATTTGAGAGGGAGAATTTCAAACTTAAAGCCACTTTTGGGGGGTTTATAACTTAAC Hsa 
           ******* *** ********* ***** ****** ***   ** * * *** ** 
 
3016 TGAAAAA---TTATCTTCTCATAACATTTATGATATGTCTAGAAAGTAGACTGGAAAGCT Mmu 
3185 TGAAAAATTAATGCTTCATCATAACATTTAAGCTATATCTAGAAAGTAGACTGGAGAACT Hsa 
     *******    *   *  ************ * *** ****************** * ** 
 
3073 AAGAATCAC--CCGGATAATTCAGGACAAAA-CTGCACACATATA-GAGAAGTACCCCCA Mmu 
3245 GAGAAAATTACCCAGGTAATTCAGGGAAAAAAAAAAATATATATATATATAAATACCCCT Hsa 
      ****      ** * *********  ****     * * *****     *    ****  
 
3129 ATCTGTGAAGTATGAACACTCTGAGCAACTGAACTATCAAAGTCAACCAATGGTATTGAT Mmu 
3305 ACATTTGAAGTCAGAAAACTCTGAAAAACTGAATTATCAAAGTCAATCATCTATAATGAT Hsa 
     *  * ******  *** *******  ******* ************ **    ** **** 
 
 
3189 –CAAATTACTGAATAATTGTTAATTTACCCATTGTGCTTAGCTTTGTAACACAGCTGAAA Mmu 
3365 CAAATTTACTGAACAATTGTTAATTTATCCATTGTGCTTAGCTTTGTGACACAGCCAAAA Hsa 





3248 GTTACCTATTTAATCTTTTCAATAAAAATTGTTTTTTTTGAAATCCAGAAATGATTTTAA Mmu 
3425 GTTACCTATTTAATCTTTTCAATAAAAATTGTTTTTTGAAA---TCCAGAAATGATTTAA Hsa 
     *************************************   *    *   **    ***** 
                         miR-203  3’  GAUCACCAGGAUUUGUAAAGUG  5’ 
                                                     ǀǀǀǀǀǀ 
3308 AAAGAGGTCAGGTTTCTAACTATTTATTGAAGTGTGTGGGTGTACAGTATTTCAATAGAT Mmu 
3482 AAAGAGGTCAGGTTTTTAACTATTTATTGAAGTATGTGGATGTACAGTATTTCAATAGAT Hsa 
     *************** ***************** ***** ******************** 
 
3368 ATGAATATGGATAAGTGGTATTGCCTTAAGATCCTCTGAAATGTACTTACTTTAAAGACT Mmu 
3542 ATGAATATGAATAAATGGTATGCCTTAAGATTCTTTGAATATGTATTTACTTTAAAGACT Hsa 
     ********* **** ******  * * *   ** *   * ***** ************** 
 
3428 GGAAAACACCCTTCCTGTCT-TTAGTAAAACATCCATATTTCATAATCTGATGTAAAATA Mmu 
3602 GGAAAAAGCTCTTCCTGTCTTTTAGTAAAACATCCATATTTCATAACCTGATGTAAAATA Hsa 
     ******  * ********** ************************* ************* 
 
3487 TGTTGTACTGTTTCCAATAGGTGAATATAAAGTCAGTTTATCAATTAAAGTATGTATTTG Mmu 
3662 TGTTGTACTGTTTCCAATAGGTGAATATAAACTCAGTTTATCAATTAAAATATGTATTTG Hsa 
     ******************************* ***************** ********** 
 
Figure 5.6: Alignment of mouse (Mmu) Negr1 3’UTR (NM_001039094.3) 
and human (Hsa) Negr1 3’UTR (NM_173808.2) harbouring 3 miR-203 
binding sites. The predicted miR-203 binding sites are mapped in blue and the 
miRNA seed regions are underlined. Forward and reverse primers used for 


















Figure 5.7: Schematic representation of fragments of the mouse (green) and human (blue) Negr1 3’UTR that were cloned. The solid 
green and blue lines represent the 3’UTR region of mouse and human Negr1 respectively (not drawn to scale). The first nucleotide of the 3’UTR 
region has been re-numbered as 1. PCR amplification using the primers indicated in Figure 5.6 gave rise to a 1125 bp fragment (light green) for 













 vector (Figure 5.8) 
and verified by sequencing. Positive clones with the mouse or human Negr1 
3’UTR were used to re-amplify the 3’UTR with appropriate restriction sites at 
each end. A Spe I site was added to the forward primer and a Hind III site was 
added to the reverse primer (Table 5.1). The fragment containing the 




 vector and the 
sequence confirmed by DNA sequencing. Thereafter, the 3’UTR was excised 
with Spe I and Hind III enzymes for sub-cloning into the pMIR-REPORT 












 vector was 
employed for cloning and sequencing of the amplified mouse or human Negr1 
















Figure 5.9: Map of the Ambion® pMIR-REPORT™ miRNA Expression 
Reporter Vector. The pMIR-Report™ Luciferase vector was used for 
reporter gene studies to test putative miR-203 binding sites on the mouse or 
human Negr1 3’UTR. The vector contains firefly luciferase under the control 
of a mammalian promoter/terminator system, with a miRNA target cloning 
region downstream of the luciferase translation sequence.  
The amplified 3’UTR initially cloned into pCR®4-TOPO® vector was excised 
using the appropriate restriction enzymes. The same enzymes were also 
employed to linearize the pMIR-Report™ Luciferase vector. The purified 









To determine if there is any interaction between miR-203 and the Negr1 
3’UTR, the Negr1 3’UTR containing the 3 miR-203 binding sites was cloned 
into the reporter vector, pMIR-REPORT™ (Figure 5.9). This was carried out 
for both the mouse and human Negr1 3’UTR. The desired plasmid was co-
transfected with miR-203 inhibitor or mimic into HeLa cells. HeLa cells are 
commonly used for transfection in reporter gene assay studies as they have 
high transfection efficiency.  
 
Cells co-transfected with miR-203 inhibitor and the luciferase reporter 
construct with mouse Negr1 3’UTR showed significantly increased luciferase 
activity of 1.18 ± 0.08 (p=0.02) (Figure 5.10). Likewise, co-transfection with 
miR-203 mimic resulted in significantly reduced luciferase activity of 0.76 ± 
0.10 (p=0.02) (Figure 5.10). Having observed a small but significant increase 
in relative luminescence when miR-203 inhibitor was co-transfected with the 
mouse Negr1 3’UTR, it was necessary to confirm if miR-203 indeed interacts 
with this 3’UTR. Hence, the putative miR-203 binding sites on the human 
Negr1 3’UTR were also tested using the luciferase reporter assay. Similar to 
the murine construct, transfection of miR-203 inhibitor with the pMIR-
REPORT-human Negr1 3’UTR construct significantly increased luciferase 
activity to 1.14 ± 0.02 (p=0.01) (Figure 5.11). Conversely, co-transfection of 
the human Negr1 3’UTR construct with miR-203 mimic significantly reduced 
luciferase activity to 0.77 ± 0.04 (p=0.02) (Figure 5.11). These results show 








Figure 5.10: Direct inhibitory effect of miR-203 on mouse Negr1 3’UTR. 
Luciferase reporter construct containing the mouse Negr1 3’UTR fragment 
with 3 miR-203 binding sites was co-transfected with 30 nM miR-203 
inhibitor or mimic into HeLa cells. Luminescence for luciferase gene activity 
was obtained 48 hours post-transfection. The relative luciferase activity was 
normalized to respective negative controls. Data are presented as mean ± SD, 
n=3. Statistical significance was tested using the Student’s t-test and p-value is 




Figure 5.11: Direct inhibitory effect of miR-203 on human Negr1 3’UTR. 
Luciferase reporter construct containing the human Negr1 3’UTR fragment 
with 3 miR-203 binding sites was co-transfected with 30 nM miR-203 
inhibitor or mimic into HeLa cells. Luminescence for luciferase gene activity 
was obtained 48 hours post-transfection. The relative luciferase activity was 
normalized to respective negative controls. Data are presented as mean ± SD, 
n=3. Statistical significance was tested using the Student’s t-test and p-value is 




5.2.4 Regulation of Negr1 mRNA expression and neurite outgrowth by 
miR-203  
Luciferase reporter assay showed a direct interaction between miR-203 and 
the human and mouse Negr1 3’UTR. As a preliminary study, the human 
neuroblastoma cell line SH-SY5Y was selected to assess the regulatory 
function of miR-203 on Negr1 expression. Proliferating SH-SY5Y 
neuroblastoma cells are differentiated to a neuronal-like phenotype by 
treatment with 10 µM retinoic acid (RA) for 5 days [293]. These RA-
differentiated SH-SY5Y cells withdraw from the cell cycle, express neuron-
specific markers such as MAP2 and display neuritic processes [293]. These 
characteristics make RA-treated SH-SY5Y cells very similar to actual 
neurons, and hence, serve as an appropriate in vitro neuronal culture.  
 
Before proceeding with functional studies, the expression of Negr1 mRNA 
and miR-203 upon retinoic-acid induced differentiation of SH-SY5Y cells was 
measured (Figure 5.12). Retinoic acid induced differentiation resulted in a 
3.56 ± 0.57 (p=0.001) and 1.33 ± 0.01 (p=0.023) fold increase in Negr1 








Figure 5.12: Quantitation of Negr1 mRNA and miR-203 expression 
during RA-induced differentiation of SH-SY5Y cells over 5 days. 
Expression was normalized to SH-SY5Y cells treated with DMSO vehicle. 
Expression of GAPDH was used as a control/housekeeping gene to normalize 
mRNA and miRNA expression. Data are presented as mean ± SD, n=3. 
Statistical significance was tested using the Student’s t-test and p-value is 
indicated next to the relative expression.  
 
 
Since miR-203 binds to the human Negr1 3’UTR, changes in miR-203 
expression should be reflected in Negr1 mRNA levels accordingly. To 
modulate miR-203 levels, 5 day RA-treated SH-SY5Y cells were transfected 
with miR-203 inhibitor and mimic independently. This was followed by 
measurement of changes in the miRNA and mRNA levels (Figure 5.13). 
Transfection of miR-203 inhibitor decreased the miR-203 level to 0.600 ± 
0.071 (Table 5.2) which resulted in a significant increase in Negr1 mRNA 
expression to 1.39 ± 0.11 (p=0.020) (Figure 5.13). Introduction of miR-203 
mimic increased the miR-203 level to 4861 ± 3 (Table 5.2). This resulted in 
significant down-regulation of Negr1 mRNA expression to 0.77 ± 0.02 




mimics resulted in corresponding regulation of Negr1 mRNA expression in 
human RA-differentiated SH-SY5Y cells (Figure 5.13).  
 
 
Table 5.2: Relative expression of miR-203 in 5 day RA-differentiated SH-
SY5Y cells transfected with either miR-203 inhibitor or mimic at a 
concentration of 30 nM and harvested 48 hours after transfection. 
 
Treatment Relative expression of miR-203 
miR-203 inhibitor 0.600 ± 0.071 






Figure 5.13: Relative Negr1 mRNA expression in 5 day RA-differentiated 
SH-SY5Y cells transfected with either miR-203 inhibitor or mimic at a 
concentration of 30 nM. Cells were harvested 48 hours after transfection and 
expression was normalized to respective negative controls. Data are presented 
as mean ± SD, n=3. Statistical significance was tested using the Student’s t-







Having observed that modulation of miR-203 levels can control Negr1 mRNA 
expression in human RA-differentiated SH-SY5Y cells, the study was 
progressed into primary neuronal cultures to determine if these results can be 
replicated in postmitotic neurons. Furthermore, studying primary neurons 
would also allow the investigation of the role of miR-203 in maintenance of 
neuronal structure and function.  
 
First and foremost, it was necessary to determine the effect of Negr1 mRNA 
knockdown on neuronal structure. For this, siRNA against the mouse Negr1 
mRNA was transfected into Day 6 neurons at different doses of 5 nM, 10 nM, 
30 nM and 50 nM. Increasing concentration of siRNA resulted in a dose-





Figure 5.14: Relative Negr1 mRNA expression in murine primary cortical 
neuronal cultures transfected with different doses of siRNA against Negr1 
mRNA. Cells were harvested 48 hours after transfection and expression was 
normalized to respective negative controls. Data are presented as mean ± SD, 
n=3. Statistical significance was tested using the Student’s t-test and p-value is 





It has been reported that Negr1 regulates neurite outgrowth [70,294]. Hence, 
treated cells were immunostained with MAP2, a marker of neuronal 
differentiation which stains neurites, to determine alterations in neurite 
outgrowth. Knockdown of Negr1 mRNA resulted in a dose-dependent 
reduction in neurite outgrowth (Figure 5.15). Therefore, modulation of Negr1 





Figure 5.15: Regulation of neurite outgrowth in a dose-dependent manner 
by knockdown of Negr1 mRNA in murine primary cortical neuronal 
cultures. Mouse primary cortical neuronal cultures on Day 6 were transfected 
with different doses of siRNA against Negr1 mRNA. Cells were fixed 48 
hours later and immunostained with MAP2 antibody. Average neurite 
outgrowth per neuron was determined using NeuriteTracer
® 
plugin. Average 
neurite outgrowth was normalized to control cultures. Representative MAP2 
stained images for each treatment are shown. Data are presented as mean ± 
SD, n=3. Statistical significance was tested using the Student’s t-test and p-







Knockdown of the Negr1 mRNA and the reduction in neurite outgrowth 
established the importance of Negr1 in maintenance of neuronal structure. 
This was followed up with modulation of miR-203 expression in primary 
cortical neuronal cultures to determine how this miRNA regulates neurite 
outgrowth. Primary neuronal cultures were transfected with either miR-203 
inhibitor or mimic on Day 6 cultures and the cells harvested after 48 hours to 
quantify the Negr1 mRNA and miR-203 expression as well as neurite 
outgrowth. Transfection of miR-203 inhibitor on Day 6 significantly reduced 
miR-203 expression to 0.235 ± 0.024 (Table 5.3). This resulted in significantly 
increased expression of Negr1 mRNA (Figure 5.16) which increased neurite 
outgrowth to 134 ± 16 % (p=0.020) as compared to control (Figure 5.17). 
Conversely, transfection of miR-203 mimic on Day 6 increased miR-203 by 
8582 ± 28 fold (Table 5.3). Increasing miR-203 expression on Day 6 resulted 
in a significant reduction in Negr1 mRNA expression to 0.865 ± 0.028 of 
control cultures (Figure 5.16) and decreased neurite outgrowth to 56.0 ± 10.0 
% (p=0.002) (Figure 5.17). These observations indicate that miR-203 
knockdown could mediate neurite outgrowth by up-regulating expression of 
the neurite outgrowth promoting molecule, Negr1. 
 
Table 5.3: Relative expression of miR-203 in murine primary cortical 
neuronal cultures transfected with either miR-203 inhibitor or mimic at a 
concentration of 30 nM on Day 6 and harvested 48 hours after 
transfection. 
 
Treatment Relative expression of miR-203 
miR-203 inhibitor 0.235 ± 0.042 


















Figure 5.16: Relative Negr1 mRNA expression in murine primary cortical 
neuronal cultures transfected with either miR-203 inhibitor or mimic at a 
concentration of 30 nM on Day 6. Cells were harvested 48 hours after 
transfection and expression was normalized to respective negative controls. 
Data are presented as mean ± SD, n=3. Statistical significance was tested 












Figure 5.17: miR-203 regulates neurite outgrowth in murine primary 
cortical neuronal cultures. Primary neuronal cultures on Day 6 were 
transfected with either miR-203 inhibitor or mimic at a concentration of        
30 nM. Cells were fixed 48 hours later and immunostained with NEGR1 and 
MAP2 antibody. Average neurite outgrowth per neuron was determined using 
NeuriteTracer
® 
plugin. Average neurite outgrowth was normalized to 
respective negative controls. Representative MAP2 stained images for each 
treatment are shown. Data are presented as mean ± SD, n=3. Statistical 
significance was tested using the Student’s t-test and p-value is indicated next 




5.2.5 Modulation of Negr1 mRNA in OGD conditions 
Having shown in vitro modulation of Negr1 by miR-203 under normal 
conditions and its effects on neurite outgrowth, it was necessary to investigate 
if modulation of miR-203 during ischemic conditions could control Negr1 
expression levels and neuronal viability. Thus in vitro ischemic conditions 
were mimicked by exposure to oxygen and glucose deprivation (OGD) for 4 
hours which showed greater down-regulation of Negr1 mRNA expression as 
compared to 2 hours (Table 4.6).  
 
Validation of expression using real-time analysis showed that Negr1 
expression was down-regulated to 0.79 ± 0.09 after 4 hours OGD (Figure 
5.18). This was due to up-regulation of miR-203 levels (relative expression = 
1.38 ± 0.09) (Table 5.4). To test the functionality of miR-203 to modulate 
Negr1 expression during OGD, neurons subjected to OGD were transfected 
with miR-203 inhibitor or mimic, following which alterations in Negr1 
expression were quantified. Treatment with miR-203 inhibitor after OGD 
reduced miR-203 levels to 0.33 ± 0.07 and increased Negr1 mRNA expression 
to 1.18 ± 0.05 (Table 5.4, Figure 5.18). On the other hand, treatment with 
miR-203 mimic increased miR-203 expression by 39321 ± 748 fold which in 
turn reduced Negr1 mRNA expression to 0.28 ± 0.02 (Figure 5.18).  
 
Neuronal viability was measured using colorimetric MTT assay. Exposure to 4 
hours OGD showed 85.2 ± 2.0 % cell viability as compared to control cells 
(Figure 5.19). Treatment with miR-203 inhibitor significantly increased cell 




significant change in cell viability (Figure 5.19). Hence, reduced miR-203 
levels could increase Negr1 mRNA expression which could in turn increase 
cell viability in neurons subjected to OGD.  
 
 
Figure 5.18: Relative Negr1 expression in primary neurons transfected 
with miR-203 inhibitor or mimic and subjected to 4 hours OGD. Neuronal 
cultures subjected to 4 hours OGD were transfected with miR-203 inhibitor or 
mimic after exposure to OGD and allowed to undergo reperfusion for 24 
hours. Total cellular RNA was used to quantify Negr1 mRNA levels. The 
changes in expression were compared against control cultures not subjected to 
OGD. Data are presented as mean ± SD, n=3. Statistical significance was 
tested using the Student’s t-test and p-value is indicated next to the relative 
expression. 
 
Table 5.4: Relative miR-203 expression in primary neurons transfected 
with miR-203 inhibitor or mimic and subjected to 4 hours OGD. Neuronal 
cultures subjected to 4 hours OGD were transfected with miR-203 inhibitor or 
mimic after exposure to OGD and allowed to undergo reperfusion for 24 
hours. Total cellular RNA was used to quantify miR-203 levels. The changes 
in expression were compared against control cultures not subjected to OGD. 
Data are presented as mean ± SD, n=3.  
 
 
miR-203 expression level 
OGD + scrambled 1.38 ± 0.09 
OGD + miR-203 inhibitor 0.33 ± 0.07 






Figure 5.19: Percentage cell viability of primary neuronal cultures treated 
with miR-203 inhibitor or mimic after OGD. Cell viability was measured 
using Annexin V/Ethidium homodimer III/Hoechst nuclear staining and 
expressed as a percentage of control cultures not subjected to OGD. Data are 
presented as mean ± SD, n=3. Statistical significance was tested using the 




Thus far, it has been shown that miR-203 binds both the human and murine 
Negr1 3’UTR. Modulation of miR-203 expression could therefore inversely 
regulate Negr1 mRNA expression and neurite outgrowth in primary neuronal 
cultures. Further utilizing this miRNA:mRNA interaction in an in vitro 
ischemic condition, inhibition of miR-203 expression could successfully 




5.3 Regulation of Negr1 mRNA expression by its bidirectional 
lncRNA  
5.3.1 Bioinformatics analysis of Negr1 bidirectional promoter region  
In the previous chapter, in addition to Negr1 being regulated by 5 miRNAs, 
Negr1 was found to have 2 lncRNAs associated with it, AK083124 and 
BC048612. Expression of Negr1 mRNA was significantly up-regulated during 
neuronal maturation and down-regulated during ischemic injury (Table 5.5). 
Interestingly, both lncRNAs associated with the Negr1 gene were 
differentially expressed during neuronal maturation and dysregulated during 
ischemic injury as well. The orientation of the lncRNA transcripts with respect 
to the Negr1 gene was mapped to determine the possible regulatory effects of 
the lncRNAs on the gene. The lncRNA transcripts (L_AK083124, 
L_BC048612; L_ prefix denotes lncRNA) were transcribed within 1000 bp of 
the Negr1 mRNA transcription start site (m_NM_001039094; m_ prefix 
denotes mRNA) but from the opposite direction (Figure 5.20). L_AK083124 
comprised of 3 exons whereas L_BC048612 is comprised of 2 exons (Figure 
5.20). Both transcripts shared only the first exon. This implies that the Negr1 
promoter is a bidirectional promoter (orange bracket line), responsible for 
bidirectional transcription (Figure 5.20). It is noteworthy that unlike miRNAs, 
lncRNAs show low sequence conservation between species [295]. Similarly 
for the 2 bidirectional lncRNAs, no orthologues were identified in the human 
transcriptome. Hence, characterization of these lncRNAs was confined to mice 


















Table 5.5: Expression of Negr1 associated mRNA and lncRNAs during 
neuronal maturation and ischemic injury. Pearson’s correlation coefficient 
(R) was computed between SLR and days after maturation or hours of 
exposure to OGD ischemic injury as determined by microarray (Table 4.6). 
One sample t-test was used to calculate the p-value from 2 replicates for 
comparison of expression during maturation (Day 6 and Day 8) and OGD (2 
hours and 4 hours OGD) using Day 2 and 0 hour OGD as the µ values 
respectively (*p<0.10, **p<0.05).  
 
Negr1 Sequence No. Pearson’s correlation coefficient (R) 
  Maturation Ischemic injury 


















Figure 5.20: Long non-coding RNAs predicted to regulate Mus musculus Negr1 gene expression. UCSC genome browser showing Negr1 
lncRNAs transcribed in an opposite direction to the Negr1 gene. Refseq numbers for each transcript is indicated. L_ prefix denotes lncRNA; m_ 











Genes with tissue-specific promoter-associated ncRNAs show a positive 
correlation between the expression of their ncRNA and mRNA, suggesting 
that these ncRNAs transcribed from bidirectional promoters regulate tissue-
specific gene expression [296]. To determine if there was any correlation in 
mRNA and lncRNA expression, their expression profile was compared in 
different tissues. Expression was compared between tissues enriched in Negr1 
mRNA expression (adult 8 week cerebellum and cortex) and tissues poor in 
Negr1 mRNA expression (adult 8 week heart and liver), using RNA 
sequencing data available in the UCSC Genome Browser [297] (Figure 5.21). 
Signals were detected for the mRNA in the cortex and cerebellum but were 
absent in the heart and liver, indicating presence of the Negr1 mRNA in the 
former 2 tissues but absence in the latter two (Figure 5.21). Similarly, signals 
were detected for the lncRNAs in both cortex and cerebellum but not for the 
lncRNAs (Figure 5.21). The positive correlation of expression between the 
lncRNAs and mRNA in different tissues was suggestive of a possible 
regulatory relationship between the lncRNA and mRNA expression.  
 
Bidirectional promoters are reported to be associated with CpG islands [296]. 
Tomikawa et al., 2011 also showed that expression of antisense promoter 
associated non-coding RNAs resulted in DNA demethylation as well as 
replacement of the H3K9m3 repressive histone mark with H3K4 methylation, 
resulting in expression of the gene in the opposite direction [298]. To 
determine if the Negr1 promoter was associated with such features, the Negr1 




(http://genome.ucsc.edu/) on the Mouse July 2007 (NCBI37/mm9) assembly  
[299,300].  
 
The Negr1 promoter indeed had CpG islands associated with it with a CpG 
count of 70 and spanning more than 300 bases, as indicated by the dark green 
shading overlapping the lncRNAs and mRNA transcription start sites (Figure 
5.21). In addition, examination of the DNA hypomethylation status, an 
indicator of actively transcribed genes [301], between the 4 tissues examined 
earlier showed that hypomethylation spanned a wider region in the cortex and 
cerebellum as compared to the liver and heart (Figure 5.21) [302]. This 
suggests that the hypomethylation status of the promoter region in tissues 
expressing Negr1 mRNA and lncRNA differed from tissues that were absent 





Figure 5.21: UCSC Genome Browser showing RNA sequencing data, CpG islands and DNA hypomethylation status in 8 week old mouse 









It has been also been reported that bidirectional promoters exhibit increased 
levels of histone modifications such as mono-, di- or tri-methylation of lysine 
4 of histone 3 (H3K4m1/2/3), which are associated with active chromatin 
[303]. Of these, H3K4m3 is a hallmark of gene promoters [304]. To determine 
if the Negr1 associated ncRNAs could influence the histone modification 
status of the Negr1 bidirectional promoter, chromatin modification marks 
proximal to the Negr1 bidirectional promoter were determined in the 4 tissues 
(adult 8 week cerebellum, cortex, heart and liver) from histone modification 
ChIP-seq data available in the UCSC Genome Browser [297] (Figure 5.22). 
The active chromatin mark H3K4 tri-methylation (H3K4m3) and the 
repressive chromatin mark, H3K27 tri-methylation (H3K27m3), were 
analyzed (Figure 5.22).  
 
In both the cortex and cerebellum, co-expression of the Negr1 mRNA and 
lncRNA overlapped with H3K4m3 histone modifications near the Negr1 
promoter (Figure 5.22). The repressive H3K27m3 histone modification was 
absent in the cerebellum (Figure 5.22). Data for H3K27m3 modification was 
not available for the cortex (Figure 5.22). 
 
In contrast to the brain tissues, both heart and liver showed absence of 
expression of both Negr1 mRNA and lncRNA (Figure 5.22). Interestingly, in 
the heart, H3K4m3 modification was found proximal to the Negr1 promoter 
like the cerebellum and cortex (Figure 5.22). However, repressive H3K27m3 
histone modification was found to span a larger region of the promoter, 




inactivation of transcription at the promoter. In the liver, however, H3K4m3 
were absent at the promoter but H3K27m3 spanned the region proximal to the 
promoter (Figure 5.22). Presence of the repressive H3K27m3 histone 
modification could therefore be preventing Negr1 mRNA transcription in both 
these tissues.  
 
Hence, increased DNA hypomethylation and presence of activating H3K4m3 
histone modification with absence of the repressive chromatin mark 
H3K27m3 could be contributing to Negr1 mRNA expression in brain tissues. 
In contrast, in the heart and liver, a shorter region of DNA hypomethylation 
and presence of repressive H3K27m3 mark could be preventing Negr1 mRNA 
expression. Therefore, activation and repression of histone modifications 
could be mediated by Negr1 lncRNA expression and hence modulation of 











Figure 5.22: UCSC Genome Browser showing RNA sequencing data and histone modification ChIP-seq data (peaks and signals) in 8 









5.3.2 Expression of Negr1 associated mRNA and lncRNAs in primary 
cortical neuronal cultures 
In silico analysis suggested a possible regulatory role of the bidirectional 
Negr1 lncRNAs on gene expression. Since Negr1 is highly expressed in 
neurons and is a determinant of neurite outgrowth [77,78], characterization of 
the lncRNAs regulating it was carried out in primary mouse neurons. First and 
foremost, the abundance of the 2 lncRNAs was measured in mature, Day 8 
primary cortical neuronal cultures (Table 5.6). Quantitative real-time PCR was 
used to measure the abundance of the Negr1 mRNA and lncRNAs.  The mean 
threshold cycle (CT) value of Negr1 mRNA was 20.37 ± 0.10 which was 
comparable to that of the 2 lncRNAs of 22.39 ± 0.04 (L_AK083124) and 
22.67 ± 0.07 (L_BC048612) (Table 5.6). The high abundance and similar 
expression level of lncRNAs and mRNA associated with a common gene 




Table 5.6: Expression level of Negr1 associated mRNA and lncRNAs in 
Day 8 primary cortical neuronal cultures. Threshold cycle (CT) values of 
Negr1 mRNA and Negr1 lncRNAs (AK083124, BC048612) detected in 
mouse primary neuronal cultures. Data are presented as mean ± SD, n=3. 
 
Mouse Primary 
Neuron Day 8 
Negr1 mRNA L_AK083124 L_BC048612 









5.3.3 Regulation of Negr1 mRNA expression and neurite outgrowth by 
bidirectional lncRNA transcription  
The role of the Negr1 bidirectional lncRNAs was determined by modulation 
of expression of the lncRNAs. Knockdown of each lncRNA was performed 
using LNA™ longRNA GapmeRs. LNA™ longRNA GapmeRs are antisense 
oligonucleotides that consist of DNA monomers with LNA™ modified 
nucleotides on either side. The LNA™ modified nucleotides increase affinity 
for their target whereas nuclease resistance of the oligo and the DNA gap 
activates RNase H cleavage of the target lncRNA upon binding. LncRNAs can 
be localized in both the cytoplasm and nucleus [97]. Since RNase H is present 
in both cellular components, LNA™ Gapmers mediate significantly better 
knockdown of nuclear targets than siRNA mediated silencing. Therefore, 
LNA™ Gapmers serve as the best tool for lncRNA knockdown studies.  
 
A dose-dependent increase in gapmer concentration against each lncRNA was 
transfected into primary neuronal cultures on Day 6. Five nM, 10 nM, 25 nM 
and 50 nM of gapmer against AK083124 (AK_gap) and BC048612 (BC_gap) 
resulted in a dose-dependent decrease in expression of both lncRNAs, 
AK083124 and BC048612 (Figures 5.23, 5.24). Transfecting cells with a 
concentration above 50 nM resulted in complete death of the neurons.  Dose-
dependent reduction in the BC048612 lncRNA resulted in a dose-dependent 
reduction in expression of the Negr1 mRNA (Figure 5.23) but no change in 
Negr1 mRNA expression was observed upon knockdown of the AK083124 
lncRNA (Figure 5.24). The effect of knockdown of the BC048612 lncRNA on 
neurite outgrowth was then investigated. MAP2 staining of the cultures 




corresponding reduction in Negr1 mRNA expression, there was a dose-
dependent reduction in neurite outgrowth with maximum reduction at 50 nM 
gapmer concentration (Figure 5.25).  
 
 
Figure 5.23: Quantitation of Negr1 mRNA in primary neuronal cultures 
transfected with increasing dose of LNA™ Gapmers against BC048612 
lncRNA. Total cellular RNA was used to quantify Negr1 mRNA and lncRNA 
expression levels. Expression was normalized to Day 2 and GAPDH was used 
as a control/housekeeping gene to normalize mRNA and lncRNA expression. 
Data are presented as mean ± SD, n=3.  
 
 
Figure 5.24: Quantitation of Negr1 mRNA in primary neuronal cultures 
transfected with increasing dose of LNA™ Gapmers against AK083124 
lncRNA. Total cellular RNA was used to quantify Negr1 mRNA and lncRNA 
expression levels. Expression was normalized to Day 2 and GAPDH was used 
as a control/housekeeping gene to normalize mRNA and lncRNA expression. 






Figure 5.25: Quantitation of neurite outgrowth in primary neuronal cultures transfected with increasing dose of LNA™ Gapmers 
against BC048612 lncRNA. Primary neuronal cultures on Day 6 were transfected with gapmer against the lncRNA and fixed 48 hours later. 
Immunostaining with MAP2 antibody was used to determine neurite outgrowth. Average neurite outgrowth per neuron was quantitated using 
NeuriteTracer
® 
plugin. Average neurite outgrowth was normalized to respective negative controls. Representative MAP2 stained images for each 
treatment are shown. Data are presented as mean ± SD, n=3. Statistical significance was tested using the Student’s t-test and p-value is indicated 









Knockdown of the BC048612 bidirectional lncRNAs, but not AK083124 
lncRNA displayed down-regulation of Negr1 mRNA expression and neurite 
outgrowth. To determine why only BC048612 showed a regulatory effect on 
Negr1 mRNA expression but not AK083124, the Negr1 gene promoter region 
was further analyzed. Further interrogation of the promoter region showed that 
the first exon of L_BC048612 was longer than that of L_AK083124 and 
covered a larger region of the promoter (Figure 5.26). L_BC048612 was 
transcribed 59 bp closer to the Negr1 gene as compared to L_AK083124 
(Figure 5.26). Bellizzi et al. (2006) reported that the Sp1 transcription factor 
plays a critical role in regulating transcription from bidirectional promoters 
[305]. To determine if the Negr1 promoter possessed putative Sp1 binding 
sites, prediction of Sp1 binding was carried out using RegRNA [306]. Two 
Sp1 binding sites were predicted to target the promoter region between the 
Negr1 mRNA transcription start site and L_AK083124 bidirectional lncRNA 
transcription start site (Figure 5.26). Interestingly, the putative Sp1 binding 
site overlapped exactly with the transcription start site of L_BC048612 (Figure 
5.26). This suggested that transcription of L_BC048612 but not L_AK083124 
could have a direct effect on Negr1 gene transcription. Hence, the study was 
taken further to evaluate the effect of over-expression of lncRNA, BC048612 







Figure 5.26: Mapping of putative Sp1 binding site on Negr1 bidirectional promoter between Negr1 mRNA and lncRNA. UCSC genome 
browser showing Negr1 lncRNA transcribed in an opposite direction to the Negr1 gene.  L_ prefix denotes lncRNA; m_ prefix denotes mRNA; 









To over-express BC048612 in mouse primary neurons, the lncRNA was 
inserted downstream of a mammalian promoter which would permit 
transcription of the gene of interest. To achieve this, the lncRNA, BC048612, 




 vector (Figure 5.8) and verified by 
sequencing. Positive clones containing the lncRNA were used as templates to 
re-amplify the lncRNA with Hind III and Xba I restriction sites at each end. A 
Hind III site was added to the forward primer and a Xba I site was added to the 
reverse primer (Table 5.7). The fragment containing the restriction enzyme 




 vector and the sequence confirmed 
by DNA sequencing. Thereafter, the lncRNA was excised with Hind III and 
Xba I enzymes for sub-cloning into the mammalian expression vector, 




Table 5.7: Primer design to amplify fragments of mouse Negr1 lncRNA, 
BC048612. RE sites are underlined. 
 
Primer RE site Sequence (5’ → 3’) 
Forward - AGGGATGGAGGACCAGGCAGG 
Reverse - TTTCATCCGCAAATGACTAACA 
Forward with RE site Hind III TAGCAAGCTTAGGGATGGAGG 

















Figure 5.27: Map of the pcDNA™4/TO/myc-HisA mammalian expression 
vector. The vector contains the Human cytomegalovirus (CMV) immediate 
early promoter which permits high-level expression of the gene of interest 





 vector was excised using the appropriate restriction enzymes. 
The same enzymes were also employed to linearize the pcDNA™4/TO/myc-
HisA vector. The purified vector and insert fragments were ligated at an insert 






To determine the effect of BC048612 over-expression on Negr1 expression 
and neurite outgrowth in primary neurons, BC048612 was cloned downstream 
of a mammalian promoter in pcDNA™4/TO/myc-HisA mammalian 
expression vector. The plasmid was transfected into murine primary cortical 
neurons on Day 6 and harvested after 48 hours. Successful over-expression of 
BC048612 in the primary neurons was determined by quantitative real-time 
PCR (Table 5.8). BC048612 expression was 432 ± 23 fold higher than in 
control cells. This resulted in significantly increased expression of Negr1 
mRNA (1.42 ± 0.08, p=0.001) (Figure 5.28). The effect of over-expression on 
neurite outgrowth was also determined. MAP2 staining of these cultures 
revealed markedly increased neurite outgrowth of 167 ± 4 % upon over-
expression of the BC048612 lncRNA (Figure 5.29).  
 
Thus far, knockdown and over-expression of bidirectional lncRNAs to the 
Negr1 gene correspondingly reduced or increased Negr1 mRNA expression in 
primary neurons. This had a direct correlation to neurite outgrowth. Hence, the 
bidirectional lncRNAs serve as positive regulators of Negr1 expression.  
 
Table 5.8: Relative expression of lncRNA, BC048612 in murine primary 
cortical neuronal cultures transfected with mammalian expression 











Figure 5.28: Relative Negr1 mRNA expression in murine primary cortical 
neuronal cultures transfected with mammalian expression plasmid 
containing BC048612 (pcNegr1 L_BC048612) on Day 6 and harvested 48 
hours after transfection. Expression was normalized to cells transfected with 
empty vector. Data are presented as mean ± SD, n=3. Statistical significance 




Figure 5.29: LncRNA BC048612 regulates neurite outgrowth in murine 
primary cortical neuronal cultures. Primary neuronal cultures on Day 6 
were transfected with mammalian expression plasmid containing BC048612 
(pcNegr1 L_BC048612) on Day 6. Cells were fixed 48 hours later and 
immunostained with MAP2 antibody. Average neurite outgrowth per neuron 
was determined using NeuriteTracer
® 
plugin. Average neurite outgrowth was 
normalized to control cells transfected with empty vector. Representative 
MAP2 stained images for each treatment are shown. Data are presented as 
mean ± SD, n=3. Statistical significance was tested using the Student’s t-test 
and p-value is indicated next to the average neurite outgrowth. Scale bar 




5.4 Mechanism of regulation of Negr1 mRNA expression by its 
bidirectional lncRNAs and miR-203  
The first part of this chapter investigated the regulation of Negr1 mRNA 
expression by miR-203. It was found that miR-203 directly regulates the 
mouse and human Negr1 3’UTR (Section 5.2.3). Functional studies in primary 
neurons further showed that modulation of miR-203 expression could 
inversely regulate Negr1 mRNA expression and neurite outgrowth (Section 
5.2.4, Figure 5.30). This accounted for the miR-203 mediated down-regulation 
of Negr1 mRNA expression during ischemic injury (Section 5.2.5). Exploiting 
the miR-203:Negr1 mRNA interaction in an in vitro ischemic conditions 
showed that inhibition of miR-203 expression could successfully increase 
neuronal cell viability by enhancing Negr1 mRNA expression (Section 5.2.5). 
Hence, inhibition of miR-203 could serve as a potential neuroprotectant in 
stroke therapy.  
 
In addition to miRNAs, the BC048612 lncRNA, bidirectional to the Negr1 
gene, was also characterized and identified as a possible regulator of Negr1 
gene expression (Section 5.3.3). Knockdown of the BC048612 lncRNA but 
not AK083124 lncRNA resulted in significant down-regulation of Negr1 
mRNA expression and neurite outgrowth. Over-expression of BC048612, 
which overlaps with the binding site for the transcription factor Sp1, enhanced 
Negr1 mRNA expression and neurite outgrowth. This implied that the 
bidirectional lncRNAs act as activators of the Negr1 gene. In the liver or heart, 
mRNA and bidirectional lncRNA expression were absent along with reduced 
DNA hypomethylation and H3K27m3 histone modification (Figure 5.30). In 




observed with increased DNA hypomethylation and active H3K4m3 histone 
signature (Figure 5.30). It was postulated that transcription of the 
L_BC048612 lncRNA in neurons promotes DNA hypomethylation at the CpG 
islands as well as active histone signatures (H3K4m3) [298] which could 
allow binding of the Sp1 transcription factor [305,307] and hence activate 
transcription of the Negr1 gene (Figure 5.30).  
 
These observations suggested that the Negr1 lncRNA is a positive regulator of 
Negr1 mRNA expression whereas miR-203 negatively regulates Negr1 
mRNA expression and hence neurite outgrowth (Figure 5.30). Thus, 
expression of Negr1 mRNA and neurite outgrowth is enhanced by its 
bidirectional lncRNAs and fine-tuned by miR-203 for maintenance of the 







Figure 5.30: A model for bidirectional lncRNA and miR-203 mediated 
regulation of Negr1 mRNA expression by transcriptional and 
translational regulation respectively.  Negr1 gene transcription is indicated 
by blue arrows and bidirectional lncRNA transcription is indicated by black 
arrows in the opposite direction in the nucleus. Activation signatures (DNA 
hypomethylation and H3K4m3) in neurons at the Negr1 gene promoter region 
could be mediated by transcription of the bidirectional lncRNA. This could 
allow binding of the Sp1 transcription factor to facilitate transcription of the 
Negr1 gene. In the cytoplasm, miR-203 acts as a negative modulator of Negr1 
mRNA translation. In combination, increased Negr1 expression mediates 
neurite outgrowth and survival whereas decreased Negr1 expression reduces 




6 MICRORNA-MEDIATED REGULATION OF TRKB T1 
EXPRESSION BY TRANSLATIONAL INHIBITION AND 
ALTERNATIVE SPLICING 
6.1 Introduction 
The study thus far has identified several neuron-specific genes and their 
associated non-coding that are crucial to neuronal maturation. This was further 
supported with their dysregulation during ischemia accounting for neuronal 
death (Chapter 4). The cell adhesion molecules and neurotrophin signalling 
pathway (Table 4.1), were found to be implicated in neuronal survival. Hence, 
following up regulatory ncRNAs in each of these pathways could pinpoint 
promising neuroprotectants in ischemic injury. Amongst the cell adhesion 
molecules, Negr1 was identified as a promising target for modulation.  
Regulation of Negr1 by miRNAs and lncRNAs was characterized and the 
neuroprotective potential of miR-203 inhibitor in ischemic injury was 
demonstrated (Chapter 5). Having identified a neuroprotectant from the cell 
adhesion molecules, this chapter was aimed at identifying potential 
neuroprotectants from the neurotrophin signalling pathway. Ntrk2 
(neurotrophic tyrosine kinase receptor, type 2), which encodes for the TrkB 
protein and is a receptor for brain-derived neurotrophic factor (BDNF), was 
identified as a promising target for modulation in the neurotrophin signalling 
pathway (Table 4.1). This BDNF:TrkB signalling is crucial for neurite 
outgrowth, neuronal differentiation, survival and plasticity [49-51] in both the 
embryonic and adult brain [308].  
 
BDNF mediates its biological effects by binding to the full length TrkB 




tyrosine residues in the cytoplasmic kinase domains [56]. These activate 
mitogen-activated protein kinase/extracellular signal-regulated protein kinase 
(MAPK/ERK), phospholipase Cγ (PLCγ), and phosphoinositide 3-kinase 
(PI3K) pathways [57] that promote differentiation, neuronal survival as well 
as regulate neuronal structure and function in developing and mature nervous 
systems [58].  
 
In addition to the full-length isoform (TrkB FL) encoding the active receptor, 
alternative splicing of the neurotrophic tyrosine kinase receptor, type 2 (Ntrk2) 
gene yields a truncated receptor, TrkB T1. TrkB T1 lacks the kinase domain 
and negatively modulates the activity of TrkB FL [59]. TrkB FL is present 
only in neuronal cells while TrkB T1 is present in both neuronal as well as 
non-neuronal cells such as astrocytes and oligodendrocytes [60,61]. The 
expression of each isoform is also specifically regulated during development 
[52,62,63]. TrkB FL is expressed from the early development period of the 
central nervous system and is maintained into adulthood. On the other hand, 
TrkB T1 is expressed at a very low level in the early and mid developmental 
stages but increases drastically during late development [52,62,63]. The high 
TrkB T1 level then remains constant throughout adulthood. Interestingly, the 
increased expression of TrkB T1 takes place with down-regulation of BDNF 
expression and correlates with axonal and synaptic pruning [52].  
 
The homeostasis of the TrkB FL and TrkB T1 isoforms is crucial to neuronal 
survival [62]. During ischemic injury, excitotoxicity perturbs this balance by 




neuronal death [64,65]. TrkB T1 therefore acts as a dominant inhibitor of the 
neuroprotective TrkB FL-BDNF signalling cascade [64,65]. Thus, blocking 
the induced expression of TrkB T1 during ischemic injury could serve 
neuroprotective potential. 
 
Since no lncRNAs were found to be conclusively associated with Ntrk2 in 
chapter 4, this part of the study aimed to determine miRNAs as regulators of 
TrkB T1 expression both at the level of post-transcriptional regulation and 
alternative splicing. Specific assays were employed to study putative miRNAs 
and their mode of action. This was followed up with studies in primary 
neuronal cultures to determine if the interaction could be replicated in vitro.  
 
6.2 Expression of TrkB T1 in neuronal maturation and ischemic 
injury 
To determine if the neuronal maturation and ischemic injury model established 
in this study was consistent with the literature, it was necessary to first validate 
the expression of TrkB T1 during neuronal maturation and ischemic injury. To 
determine the profile of TrkB T1 expression during maturation and how it is 
affected upon exposure to ischemic injury, TrkB T1 expression was 
determined in Day 2 and Day 6 maturing neurons as well as Day 6 neurons 
subjected to 4 hours OGD. The expression was normalized to Day 2 (Figure 
6.1). TrkB T1 was found to be up-regulated 1.85 ± 0.05 fold from Day 2 to 
Day 6 and exposure to 4 hours OGD drastically increased this expression to 




It was speculated that the drastic increase in expression upon ischemic injury 
could perturb the TrkB FL/TrkB T1 balance in the neurons, resulting in cell 
death [64]. Hence, modulation of TrkB T1 expression could prevent this 









Figure 6.1: Change in TrkB T1 mRNA expression during murine 
neuronal maturation and ischemic injury. Expression of TrkB T1 mRNA 
was measured in Day 6 neurons as well as Day 6 neurons subjected to 4 hours 
OGD and normalized to Day 2 neurons. Expression of GAPDH was used as a 
control/housekeeping gene to normalize mRNA expression. Data are 
presented as mean ± SD, n=3. Statistical significance was tested using the 




6.3 microRNA mediated regulation of TrkB T1 expression 
6.3.1 Bioinformatics prediction of miRNAs binding to 3’UTR of    
TrkB T1 
To directly modulate TrkB T1 expression, miRNA mediated gene regulation 
by targeting the 3’UTR was exploited. miRNAs predicted to target the mouse 
(NM_008745.3) and human (NM_001007097.2) 3’UTR were identified using 
the 3 bioinformatics prediction databases, TargetScan [309], microRNA.org 
[310] and miRWalk [311]. As mentioned earlier, only miRNAs that had 
selectively conserved binding sites on both the mouse and human TrkB T1 
3’UTR were shortlisted for further studies [283]. The mouse and human TrkB 
T1 3’UTR were aligned and the miRNAs were mapped onto it (Figure 6.2). 
Eighteen miRNAs (miR-129-5p, -143, -149, -15a, -15b, -16, -195, -214, -22, -
223, -29a, -29b, -29c, -448, -497, -544, -760-3p and -9) were found to have 
conserved binding sites between the mouse and human TrkB T1 3’UTR 












Figure 6.2: Schematic representation of miRNAs predicted to target the human TrkB T1 3’UTR with conserved binding sites in the 
mouse TrkB T1 3’UTR. The solid black line represents the 3’UTR region of human TrkB T1 (not drawn to scale). The first nucleotide of the 












6.3.2 Selection of miRNAs for further interaction studies 
From the shortlisted miRNAs (Figure 6.2), screening for the possible 
modulators of TrkB T1 was carried out. Co-expression of the target gene and 
miRNAs regulating it is an important point to consider for miRNA based gene 
regulation. Expression validation of TrkB T1 in primary neurons (Figure 6.1) 
showed the presence of this molecule in primary neurons on Day 6. The 
abundance of the shortlisted miRNAs was obtained from the microRNA 
microarray data obtained in Chapter 3. The average signal intensity for each 
miRNA was determined (Table 6.1). The use of the mean signal intensity of 
300 as a background filtering criteria resulted in the exclusion of 6 miRNAs 
from the list, leaving 12 miRNAs (underlined in Table 6.1) as potential 
regulators of TrkB T1 3’UTR.  
 
To further shortlist miRNAs that could regulate the expression of TrkB T1, the 
expression profile of the remaining 12 miRNAs was determined in these 
neurons relative to Day 2 (Table 6.2). Since TrkB T1 was upregulated by 1.85 
± 0.05 fold during maturation (Figure 6.1), miRNAs showing a differential 
expression of more than 1.5 fold were chosen for further validation studies 
(underlined in Table 6.2). This brought the list of potential regulators of TrkB 









Table 6.1: Abundance of miRNAs predicted to target TrkB T1 3’UTR 
with conserved binding sites as determined by microarray. The signal 
intensity of each miRNA was averaged across Day 2, 4, 6 and 8 from the 
miRNA microarray data obtained in Chapter 3. miRNAs with average signal 
intensity less than 300 were filtered off as background, leaving 12 miRNAs to 
be present (underlined).  
 




















Table 6.2: Relative miRNA expression of 12 miRNAs expressed above 
background in neurons. Expression of selected miRNAs as determined by 
microarray in Day 6 neurons was normalized to Day 2 neurons and presented 
as fold change. miRNAs showing a differential expression of more than 1.5 
fold are underlined. 
















Having shortlisted 7 miRNAs that could possibly target and regulate 
expression of TrkB T1, the next logical move was to compare the expression 
profile of TrkB T1 and these putative regulatory RNAs during neuronal 
maturation (Day 6 relative to Day 2) and ischemic injury (4 hours OGD 
relative to Day 2). This would provide insights into the expression of these 
molecules during maturation and how it is affected upon exposure to ischemic 
injury. Up-regulation of TrkB T1 expression during neuronal maturation was 
accompanied by up-regulation of miR-129-5p, -22, -29a, -29b and -29c 
expression but down-regulation of miR-195 and -9 expression (Figure 6.3). 
Upon exposure to OGD, the expression of TrkB T1, miR-129-5p, -195, -29a, -
29b, -29c and -9 increased relative to maturation (Figure 6.3). However, 
expression of miR-22 decreased as compared to its expression at maturation 
(Figure 6.3). Since miRNAs mediate translational repression of mRNA 
expression by binding to the 3’UTR of the target mRNA [282,283], miRNAs 
regulating TrkB T1 would be expected to display an opposite profile to the 
expression of TrkB T1. miR-195 and miR-9 showed an opposite expression to 
TrkB T1 during maturation whereas miR-22 showed an opposite expression to 
TrkB T1 during OGD. Hence, these miRNAs could be potential regulators of 
TrkB T1 mRNA expression. The predicted interaction sites of these 3 
miRNAs were mapped to the aligned mouse and human TrkB T1 3’UTR 







Figure 6.3: Quantification of TrkB T1 mRNA and miRNA expression during murine cortical neuron maturation and ischemic injury as 
determined by qPCR. Expression of TrkB T1 mRNA and miRNAs predicted to target both the mouse and human TrkB T1 3’UTR were 
measured in Day 2 neurons, Day 6 neurons (maturation) as well as Day 6 neurons subjected to 4 hours OGD (ischemic). Expression was 
normalized to Day 2. Expression of GAPDH was used as a control/housekeeping gene to normalize mRNA and miRNA expression. Data are 









Mmu  CTGA-GATAAAGGAAAGACAAAGGCTGGGGCTGTGGTGCTTGTTGCCTG---ACGCCCTG 56 
Hsa  CTGAAATAAAGGAAAAGACAGAGAAAGGGGCTGTGGTGCTTGTTGGTTGATGCTGCCATG 60 
     ****    ** * ******* **   *******************  **     *** ** 
 
                     miR-195  3’  CGGUUAUAAAGACACGACGAU  5’ 
                                               ||||||| 
Mmu  TGAGCTGAACT-CTGGGACTGCTG-TTGCCTATCCCAGGAAGTGCTGCTTATTTGAGGGT 114 
Hsa  TAAGCTGGACTCCTGGGACTGCTGTTGGCTTATCCCGGGAAGTGCTGCTTATCTGGGGTT 120 
     * ***** *** ************ * ** ****** *************** ** ** * 
 
Mmu  GTCTGGTGGAAATGGGTAATCTCCGAGG--------ATGTCTGCAGCCTGCTTGTTGTGA 166 
Hsa  TTCTGGTAGATGTGGGCGGTGTTTGGAGGCTGTACTATATGAAGCCTGCATATACTGTGA 180 
      ****** **  ****   * *  *  *        ** *            *  ***** 
 
                 miR-22  3’  UGUCAAGAAGUUGACCGUCGAA  5’ 
                                           ||||||| 
Mmu  GCTGTGACTGGGGAACCCCAAGGCAGAGGCAGGGGTCAGGCAGCTGAGAAGCAGCAGAAG 226 
Hsa  GCTGTGATTGGGGAACACCAATGCAGAGGTAACTCTCAGGCAGCTAAGCAGCACCTCAAG 240 
     ******* ******** **** ******* *    ********** ** **** *  *** 
 
Mmu  AACAC--ACTTAGATTCACCTTCTGTTCTTACAATAGTTCAAATATAGAATCGAAGTGAA 284 
Hsa  AAAACATGTTAAATTAATGCTTCTCTTCTTACAGTAGTTCAAATACAAAACTGAAATGAA 300 
     ** **    * *  *    ***** ******** *********** * **  *** **** 
 
Mmu  ATCTCATTGGATTATGCCTCTCTAATGAAAAGCGAGCTGTTTGACTATACGGAAAATGTG 344 
Hsa  ATCCCATTGGATTGTACTTCTCTTCTGAAAAGTGTGCTTTTTGACCCTACTGGACATTTA 360 
     *** ********* * * *****  ******* * *** ******  *** * * ** *  
 
Mmu  CTGACATTAATTGCTTCTGTTTATTAAAGGTGATTTGCAAATTAAAAACTCTGCATCTAT 404 
Hsa  TTGACTT-AATTGCTTCTGTTTATTAAAATTGACCTGCAAAGTTAAAAAAAAATTAAAGT 419 
      **** * ********************  ***  ****** * ****           * 
 
Mmu  CATCTATCCATCTATCTGTTTGTCTATCATATCTATCTGTCTGTCTATCTGTCTATCATC 464 
Hsa  TGAGAACAGGTATAAGTGCACACTGAATAGTCT--------AATCTACATGTAACACATA 471 
          *    * **  **       *  *              ****  ***    ***  
 
Mmu  TATCTACCTACCTCTCTATCATATCTATCTGTCTGTCTATCTATCTATCTATCTATCTAT 524 
Hsa  TTTTAGTGTGATTTTCTATACTCTAATCAGCACTGAATTCAGAGGGTTTGACTTTTTCAT 531 
     * *     *   * *****  * *        ***  *    *    *  *  * *  ** 
 
Mmu  CTATCTATCTATCTATCTATCTATCTATCATCTATCTACCTATCATCGATCTACTTATCT 584 
Hsa  CTATAACACAGTGAC----TAAAAGAGTTAAGGGTATATATACCATCACTTTGGGACTTG 587 
     ****    *  *       *  *    * *    * **  ** ****  * *     *   
 
Mmu  ATCA------------TCTATCTATCTACCTATCA-TCGATTTACT—TATCTATCATCT 629 
Hsa  GTAGTATTATTAAAAGGTTATTTCCTTCACTGTCAATAAAAGTCCAAATGTTTAGCTTAG 647 
      *                *** *   *  ** *** *  *  * *   * * ** * *   
 
Mmu  ATCTATCTATCTATCTATCTATCTATCTATTTATCTATCTATCTATCTATCTGTCATCTA 689 
Hsa  GTCTGAGAGTCAA----ACAATGTTAAGGATTGTCTTAAAGTTCCTTAGCCAGCAAAACA 703 
      ***     ** *     * ** *      ** ***     *   *    * *  *   * 
 
Mmu  TCTAAAGTCATAGC-TAGGTCTAAGTGCACACTAAAAGTCTAATCCACACATAACACCTA 748 
Hsa  AAACAAAACAAAACAAACAAATGAAAAACGTTTAAAAAGAAGAAGAAGAAAAAAAACAAG 763 
         **  ** * *  *    * *        *****     *   * * * ** **    
 
Mmu  TTTCAGCAACATCTTCTGTTCTCTAACCTTTGCTAACTTCTGTGA----TTTCCACCTAC 804 
Hsa  AACAAGCAGCAACAGCTGTTTTGTTGGGGCTATAGATTTAAGTTAGGCATAGTCAATTTC 823 
         **** ** *  ***** * *      *    * **  ** *    *   **  * * 
 
Mmu  AACCCTGCGACTGATAGACTTAAAGGCACATTGGTGGTGTCATTAGTAGGTTCTTTGTTT 864 
Hsa  AGAATAAC---T--AAGAGTGGAATATATGCATATGGTGAAATTATAACCTTGCCCTT-- 876 
     *      *   *   *** *  **   *      *****  ****  *  **     *   
 
Mmu  TGCTGGCAGCAAAGACCCAAACTCTTCGCTAACGATTGCTTTCAAAGTCCACCCGGCAGG 924 
Hsa  ------------------------------------------------------------ 876 




Mmu  TAGAACGGAGCAGCACCAGGGACTGTGTGGCCAGGAGTATGGACCTGAATTAACCACAGC 984 
Hsa  ------------------------------------------------------------ 876 
                                                                      
 
Mmu  CTGAGAATAAATAATGGTAGGGTATATGCATATAGGGAATTAAAATCTTGTCCCTTTCCA 1044 
Hsa  ------------------------------------------------------TTTTAT 882 
                                                           ***    
 
Mmu  TTGCCCTCTGCTAACCACCTGCCCTTTAGAGGTTTGCCTAGCGAGAGCACC-TCAGATCT 1103 
Hsa  TTGCCCTCTGCGATCCACCTGCTTTTTAGAAGTCTGCCGAGTGAGAAGGCCACAGTATCT 942 
     *********** * ********  ****** ** **** ** ****   **     **** 
 
Mmu  CATGCTGTTTGAATTACAGAGCTGCAGT-TCTCTAGTGTGAATAGGCCTGCAAGCTGAGC 1162 
Hsa  CATGCTGTTTGCATTACAGAACTGCAGCTTTTCTACTCTGAAAAGGCCTGGGAGCAGAAT 1002 
     *********** ******** ******  * **** * **** *******  *** **   
 
Mmu  TGCTGGCCTGCTGTGAGCGGGAGAGCATGTCTAAGGACAGTCCC-------TGGAGCATG 1215 
Hsa  GGCTGGCCTGCTGTGAGCAGGAGAGGAGATTCTAAGAAGGATAGTCCCCCCTACAACATA 1062 
      ***************** ****** *  *   * **  *           *  * ***  
 
Mmu  CTGCCCTACTGCTG-----------------------CGTCCTGACCCAGCAGCAGAGAG 1252 
Hsa  CTGTCATACTGCTGGGTTTTCATGGGTAGGAAAGCTTGTCCTGACCCCAGCAGCAAAGAG 1122 
     *** * ********                          *    ********** **** 
 
Mmu  GTGGCCAGCTGCTAATGAATGTGGGCT----------------CCTTGCTGAAAGAACAG 1296 
Hsa  GTGGCAGGTCGCTAATGAATATATGCTTTATAATGTCCTTCTTCATTGCTGAGAGGGCAG 1182 
     *****  *  ********** *  ***                * ******* **  *** 
 
Mmu  TCTCCCAGCTACCAATTCCTGTAGCCCCCAACCACTCCCCACCTGACCCGTCCCTGTACC 1356 
Hsa  CCTTAGAGCTGTGGATTTCTGCATCCCCCCTGAGTCT---------GACCCATGGACACC 1233 
      **   ****    *** *** * *****                   *        *** 
 
Mmu  CCTCTCATTCACTTTGTCATGGCAGTGGCCTTTGTGGGATCCATCCCATCTGCACCAGGC 1416 
Hsa  TGTTTCATTCACTTTAGCATCACAGTGACCTTTGTATGCTCTGTTCAGTCTGTGTCAGGC 1293 
       * ***********  ***  ***** *******  * **  * *  ****   ***** 
 
Mmu  AGC-------------------------------------------AACTTTGTCTGTCC 1433 
Hsa  AGTATGCTTGTCCTGAAGAGAGGTTTGGCTATCCCCACCCCACCCCACCCCACCCTGTTC 1353 
     **                                            * *     **** * 
 
Mmu  CTCCATTCTCACTTGAGGTCCCCTTCAGAGCCAGGCTGGGATATTTCATTTAAAAACCAC 1493 
Hsa  CTT-----TTTTATCAGGAGGACTTCAGAGCCAGGCCTGCAGCATTTTGTTTGAAAACAC 1408 
     **      *    * ***    **************  * *   **   **  *** *** 
 
Mmu  ACTCAGCTCTATTATA----CACTCACACACAGAGCATAGCTTGAGAGGAAACTTATTA- 1548 
Hsa  AATCAGCTCTGACAGTTAGACATGCACACAGACGCCATAGCTGGATTGGAAACATTGATG 1468 
     * ********   *      **  ****** *   ******* **  ****** *      
 
Mmu  ------AC-ATTCCTTTTTTA-----------------AAAGGTAGTTTATCTTTAAGGA 1584 
Hsa  TTTTAAAAATTTATTTTTTTTGGAAATAGTTGCACAAATGCTGCAATTTAGCTTTAAGGT 1528 
           *   **  ******                      * * **** ********  
 
Mmu  TTTTTAGGTTTTTCTCTTAACAATCCCAGCATGTTTGGGAACTATTTTGAATCCTCTGTA 1644 
Hsa  TCTATAGATTTTTAACTAGTCCA---ACACAGTCAGAAACATTGTTTTGAATCCTCTGTA 1585 
     * * *** *****  **   * *      **         * * **************** 
 
Mmu  AGCATGTCCATCAATCTTAATAAACCAGAACCCGTTTAGGCCCCACTTGACATCAGGGGA 1704 
Hsa  AACCAAGGCATTAATCTTAATAAACCAGGATCCATTTAGGTACCACTTGATATAAAAAGG 1645 
     * *     *** **************** * ** ******  ******** ** *   *  
 
Mmu  ATACTGTAGTATT-----TTATACTGAGCCACT-----------------ACAGTATGGC 1742 
Hsa  ATATCCATAATGAATATTTTATACTGCATCCTTTACATTAGCCACTAAATACGTTATTGC 1705 
     ***               ********   *  *                 **  *** ** 
 
Mmu  TCAATTCCGGTCTTTTTGTGAGTCCGTGGATTAGAGTGTTTGCACTGGCCAACCACA--- 1799 
Hsa  TTGATGAAGACCTTTCACAGAATCCTATGGATTGCAGCATTTCACTTGGCTACTTCATAC 1765 





Mmu  --TTGTGCCTGAGAGGGCCAGTCACTTCCACAGACCTCTC-----------AGAGGCTTT 1846 
Hsa  CCATGCCTTAAAGAGGGGCAGTTTCTCAAAAGCAGAAACATGCCGCCAGTTCTCAAGTTT 1825 
        **      ****** ****  **   *   *                       *** 
 
Mmu  GTCTCCAGGTGCACAGTGGGTCTCAGCACAGAAGGCTCCGTGT--CCTGAA------CAC 1898 
Hsa  TCCTCCTAACTCCATTTGAATGTAAGGGCAGCTGGCCCCCAATGTGGGGAGGTCCGAACA 1885 
       ****     *    **  * * **  ***  *** **   *     **           
 
Mmu  CCCCACTGCCCAGCACTGCCCCCACTGCAGCTAAGTGACAGCTCCTGTCACCACTGAGAT 1958 
Hsa  TTTTCTGAATTCCCATTTTCTTGTTCGCGGCTAAATGACAGTTTCTGTCATTACTTAGAT 1945 
                  ** *  *      ** ***** ****** * ******  *** **** 
UAGAUUCCGAUCUUUCCCAAAGG  5’  miR-9 
                |||||| 
Mmu  CTCTGTCTTTCCCAAAGGTGTTGACTTACCCAGAGGCCAGCTAATAGCAGAAATCTTGAC 2018 
Hsa  TCCGATCTTTCCCAAAGGTGTTGATTTACAAAGAGGCCAGCTAATAGCAGAAATCATGAC 2005 
       *  ******************* ****  ************************ **** 
 
Figure 6.4: Alignment of 3’UTR sequence of murine (Mmu: 
NM_008745.3) and human (Hsa: NM_001007097.2) TrkB T1. The 
predicted conserved binding sites of selected miRNAs (miR-195, -22, -9) are 
mapped in blue in this figure and the miRNA seed regions are underlined.  
 
 
6.3.3 Cloning of TrkB T1 3’UTR 
To determine miRNA:mRNA interaction between the 3’UTR of TrkB T1 and 
the shortlisted miRNAs with conserved binding sites, the TrkB T1 3’UTR was 
inserted downstream of a reporter gene, luciferase, in the pMIR-REPORT 
luciferase vector (Figure 5.9). In the previous chapter, comparable results were 
obtained for the luciferase assays carried out on the human and mouse Negr1 
3’UTR construct for miR-203 which had a conserved binding site between the 
species (Chapter 5). Furthermore, functional studies in the mouse and human 
cell culture models for miR-203 also showed similar results. This indicated 
that interaction and functional studies for miRNAs with conserved binding 
sites between 2 species show similar results when conducted in each species 
separately. Similarly, in this study, the binding sites for miR-195, -22 and -9 




TrkB T1 was chosen for interaction studies to affirm that the miRNA:mRNA 
interaction could be exploited for translation into human studies later.  
 
Primers were designed such that a 2244 bp fragment of the human TrkB T1 
was obtained containing binding sites for miR-195, -22 and -9 (Table 6.3, 




 vector (Figure 5.8) 
and verified by sequencing followed by re-amplification with Mlu I restriction 
sites on either end (Table 6.3). The fragment containing the restriction enzyme 




 vector and the sequence confirmed 
by DNA sequencing. Thereafter, the 3’UTR was excised with Mlu I enzyme 
for sub-cloning into the pMIR-REPORT luciferase vector (Figure 5.9). 
Positive clones were identified by sequencing. 
 
Table 6.3: Primer design to amplify the human TrkB T1 3’UTR with 
binding sites for miR-195, -22 and -9. RE sites are underlined. 
 
Primer RE site Sequence (5’ → 3’) 
Forward - TGGATGGGTAGCTGAAATAAA 
Reverse - GCAATCCTTCTAGCTGTTGGG 
Forward with RE site Mlu I ATCAACGCGTTGGATGGGTAG 












Figure 6.5: Schematic representation of fragment of the human TrkB T1 3’UTR that was cloned. The solid black line represents the 
3’UTR region of human TrkB T1 (not drawn to scale). The first nucleotide of the 3’UTR region has been re-numbered as 1. PCR amplification 











6.3.4 miRNA interaction studies on TrkB T1 3’UTR 
HeLa cells were used for the miRNA:mRNA interaction studies. Cells were 
co-transfected with the pMIR-REPORT
TM
 plasmid containing the human 
TrkB T1 3’UTR and miR-195, -22 or -9 inhibitor or mimic. Cells co-
transfected with miR-195 inhibitor showed no significant change in relative 
luminescence but miR-195 mimic showed an increase in relative luminescence 
(Figure 6.6). This shows that there was no direct interaction between miR-195 
and the TrkB T1 3’UTR. miR-22 inhibitor showed a significant increase in 
relative luminescence to 1.10 ± 0.03 (p=0.03) and miR-22 mimic showed a 
significant reduction in relative luminescence to 0.78 ± 0.06 (p=0.02) (Figure 
6.6). This indicated that miR-22 negatively regulates the TrkB T1 3’UTR. 
miR-9 showed similar results to that of miR-195, indicating no interaction 
with the human TrkB T1 3’UTR (Figure 6.6). These results show that only 
miR-22 directly regulates the TrkB T1 3’UTR. 
 
 
Figure 6.6: Relative luminescence of luciferase assay carried out on 
human TrkB T1 3’UTR construct for miR-195, -22 and -9. Luciferase 
reporter construct containing the human TrkB T1 3’UTR fragment was co-
transfected with miR-195, -22 or -9 inhibitor or mimic into HeLa cells. 
Luminescence for luciferase gene activity was obtained 48 hours post-
transfection. The relative luciferase activity was normalized to respective 
negative controls. Data are presented as mean ± SD, n=3. Statistical 
significance was tested using the Student’s t-test and p-value is indicated next 




6.3.5   Affirmation of interaction between miR-22 and TrkB T1 
To re-affirm the interaction observed between miR-22 and TrkB T1, 
mutational studies were carried out. The seed region of the miR-22 binding 
site on the TrkB T1 3’UTR was mutated using PCR primers. For this, primers 
were designed which included nucleotide changes in the seed region of the 
miR-22 binding site (Table 6.4). The cloning was carried out to first amplify 
the 3’UTR using the forward (F) and mutated miR-22 site reverse (mutR) 
primers (Table 6.4, Figure 6.7). Similarly, another fragment was amplified 
using the mutated miR-22 site forward primer (mutF) and the reverse primer 
(R) (Table 6.4, Figure 6.7). The 2 fragments were then joined together to 





 vector (Figure 6.7). Following verification by sequencing, 
the fragment was re-amplified with Spe I/Hind III restriction sites (Table 6.4). 





 vector and the sequence confirmed by DNA sequencing. 
Thereafter, the 3’UTR was excised with Spe I and Hind III enzymes for sub-
cloning into the pMIR-REPORT luciferase vector. Positive clones were 
identified by sequencing. 
 
The human TrkB T1 construct with mutated miR-22 binding site was co-
transfected with miR-22 inhibitor or mimic into HeLa cells for interaction 
studies. Site-directed mutagenesis of the miR-22 seed region abolished the 
interaction between miR-22 and the 3’UTR as no change in relative 
luminescence was observed (Figure 6.8). These results indicated that miR-22 







Table 6.4: Primer design to amplify fragment of human TrkB T1 3’UTR with mutated miR-22 binding sites. Mutation design on seed 
region of miR-22 on TrkB T1 3’UTR is indicated by *. The miR-22 seed region is shown in red while the mutation in shown in blue. The 
mutated miR-22 seed region on the primer is indicated in blue. RE sites are underlined. 
 
                  miR-22  3’  UGUCAAGAAGUUGACCGUCGAA  5’ 
                              | || |      | *******        
      Hsa TrkB T1 3’UTR   5’  AGAGGTAACTCTCAAATGATCA  3’ 
Primer RE site Sequence (5’ → 3’) 
Forward (F) - TGGATGGGTAGCTGAAATAAA 
Reverse (R) - AATGTCCAGTAGGGTCAAAAA 
Mutated miR-22 site 
forward (mutF) 
- CTCTCAAATGATCAAGCAG 
Mutated miR-22 site 
reverse (mutR) 
- CTGCTTGATCATTTGAGAG 
Forward with RE site Spe I ATCAACTAGTTGGATGGGTAG 














Figure 6.7: Schematic representation of fragment of the human TrkB T1 3’UTR with mutated miR-22 binding site. The solid black line 
represents the 3’UTR region of human TrkB T1 (not drawn to scale). The first nucleotide of the 3’UTR region has been re-numbered as 1. PCR 












Figure 6.8: Relative luminescence of luciferase assay carried out on 
human TrkB T1 3’UTR construct with mutated miR-22 binding site 
(Figure 6.7). Luciferase reporter construct containing the human TrkB T1 
3’UTR fragment was co-transfected with miR-22 inhibitor or mimic into HeLa 
cells. Luminescence for luciferase gene activity was obtained 48 hours post-
transfection. The relative luciferase activity was normalized to respective 
negative controls. Data are presented as mean ± SD, n=3. Statistical 
significance was tested using the Student’s t-test and p-value is indicated next 
to the relative luminescence.  
 
6.3.6 miR-22 modulates TrkB T1 mRNA expression in primary 
neurons 
Luciferase reporter assay showed a direct interaction between miR-22 and the 
TrkB T1 3’UTR. The interaction was confirmed with no interaction observed 
upon mutation of the miR-22 binding site. The next step was to determine if 
modulating miR-22 levels in primary neurons could modulate the endogenous 
TrkB T1 expression. To modulate miR-22 levels, primary cortical neuronal 
cultures on Day 6 were transfected with miR-22 inhibitor and mimic 
independently. This was followed by measurement of changes in the TrkB T1 
mRNA levels (Figure 6.9). Transfection of miR-22 inhibitor significantly 
decreased miR-22 expression to 0.007 ± 0.003 (Table 6.5) which increased the 
TrkB T1 expression to 1.24 ± 0.04 (p=0.016) (Figure 6.9). Transfection with 




6.5) which resulted in a decrease in the TrkB T1 expression to 0.58 ± 0.01 
(p=0.001) (Figure 6.9). Hence, modulation of miR-22 using its inhibitors or 
mimics resulted in a corresponding regulation of TrkB T1 mRNA expression 
in primary neuronal cultures (Figure 6.9).  
 
Table 6.5: Relative expression of miR-22 in murine primary cortical 
neuronal cultures transfected with either miR-22 inhibitor or mimic at a 
concentration of 30 nM on Day 6 and harvested 24 hours after 
transfection. 
 
Treatment Relative expression of miR-203 
miR-22 inhibitor 0.007 ± 0.003 





Figure 6.9: Relative TrkB T1 mRNA expression in murine primary 
cortical neuronal cultures transfected with either miR-22 inhibitor or 
mimic at a concentration of 30 nM on Day 6. Cells were harvested 24 hours 
after transfection and expression was normalized to respective negative 
controls. Data are presented as mean ± SD, n=3. Statistical significance was 







6.3.7 Modulation of TrkB T1 in OGD conditions 
Having observed in vitro modulation of TrkB T1 by miR-22 under normal 
conditions, it was necessary to investigate if modulation of miR-22 during 
ischemic conditions could control TrkB T1 expression levels and neuronal 
viability. Day 6 neurons were subjected to 4 hours of oxygen and glucose 
deprivation (OGD) and transfected with miR-22 inhibitor or mimic during the 
reperfusion phase. Expression analysis showed that TrkB T1 expression was 
up-regulated to 1.28 ± 0.09 after 4 hours OGD (Figure 6.10). Treatment with 
miR-22 inhibitor after OGD significantly increased TrkB T1 expression to 
1.41 ± 0.03 (p=0.020) whereas transfection with miR-22 mimic significantly 
reduced TrkB T1 expression to 0.90 ± 0.07 (p=0.003) (Figure 6.10). To assess 
the effect of miR-22 and TrkB T1 modulation on neuronal cell viability, 
colorimetric MTT assay was used. Exposure to 4 hours OGD showed                      
65.2 ± 11.0 % viability as compared to control cells (Figure 6.11). Treatment 
with miR-22 inhibitor did not show a significant change in cell viability. 
However, miR-22 mimic significantly increased cell viability to 85.4 ± 6.8 % 
(Figure 6.11). Hence, increasing miR-22 levels could reduce TrkB T1 mRNA 
expression which could in turn increase cell viability in neurons subjected to 
OGD.  
 
Thus far, it has been shown that miR-22 binds and regulates TrkB T1 3’UTR. 
Modulation of miR-22 expression could therefore inversely regulate TrkB T1 
mRNA expression in primary neuronal cultures. Further utilizing this 




of miR-22 could successfully increase neuronal cell viability by reducing 
TrkB T1 expression. 
 
 
Figure 6.10: Relative TrkB T1 expression in primary neurons transfected 
with miR-22 inhibitor or mimic and subjected to 4 hours OGD. Neuronal 
cultures subjected to 4 hours OGD were transfected with miR-22 inhibitor or 
mimic after exposure to OGD and allowed to undergo reperfusion for 24 
hours. Total cellular RNA was used to quantify TrkB T1 mRNA levels. The 
changes in expression were compared against control cultures not subjected to 
OGD. Data are presented as mean ± SD, n=3. Statistical significance was 




Figure 6.11: Percentage cell viability of primary neuronal cultures treated 
with miR-22 inhibitor or mimic after OGD. Cell viability was measured 
using Annexin V/Ethidium homodimer III/Hoechst nuclear staining and 
expressed as a percentage of control cultures not subjected to OGD. Data are 
presented as mean ± SD, n=3. Statistical significance was tested using the 




6.4 microRNA mediated regulation of Ntrk2 splicing 
The previous section investigated the regulation of TrkB T1 expression by 
miRNAs that target the 3’UTR. In addition to mediating translational silencing 
in the cytoplasm, recent reports have shown that miRNAs can regulate gene 
expression at the transcriptional level in the nucleus [127,130,131,312]. It was 
hypothesized that presence of miRNAs in the nucleus could possibly regulate 
splicing as well. Since TrkB T1 is derived as a splice variant of the Ntrk2 
gene, it was hypothesized that miRNAs binding to exon-intron or intron-exon 
junctions could possibly regulate splicing of the TrkB T1 isoform in the 
nucleus. Such a mechanism has not been reported earlier, hence, this study 
was undertaken to determine if miRNAs could regulate splicing.   
 
6.4.1 Bioinformatics prediction of miRNAs binding to intron-exon 
junction of alternative exon 
In the mouse, alternative splicing of the pre-messenger RNA derived from the 
Ntrk2 gene gives rise to 2 isoforms, TrkB FL and TrkB T1. TrkB FL is 
comprised of 18 exons which are formed by skipping exon 14 (Figure 6.12). A 
stop codon (denoted by * in red) in the last exon, exon 20, gives rise to the full 
length protein with a protein kinase domain (Figure 6.12). For TrkB T1, the 
alternative exon (exon 14) is incorporated, resulting in an alternative 
polyadenylation signal and translational stop codon that gives rise to a C-
terminal truncated protein (Figure 6.12). As skipping or incorporation of exon 
14 would determine which TrkB isoform is formed, it was hypothesized that 
regulation of the region encompassed by intron 13 (Figure 6.13) and the start 







Figure 6.12: Structure of the mouse Ntrk2 gene, splice variants and protein domains of isoforms. Schematic representation of all TrkB 
exons (numbers are shown in boxes) and introns. Exons are shown as boxes and introns are shown as lines (not drawn to scale). Names of 
alternative splice variants and protein isoforms are shown on the left. * - Translation stop codon; S -  Signal sequence; LRRNT - Leucine Rich 
Repeat N-Terminal domain; LRR - Leucine-rich Repeats; LRRCT - Leucine Rich Repeat C-Terminal domain; IG like 1 – Immunoglobulin-like 











For miRNAs to act as regulators of exon inclusion/exclusion, it was 
hypothesized that they would have to target the intron 13-exon 14 junction of 
the mouse Ntrk2 gene (Figure 6.13). Furthermore, as mentioned earlier, 
conservation of binding sites between different species implies these sites are 
under selective pressure and are biologically important [283]. To determine 
this, the mouse and human intron-exon junction were aligned. 
 
In humans, the alternative exon is exon 16 (Figure 6.13). Hence, the intron 13-
exon 14 junction of the mouse Ntrk2 gene was aligned to the intron 15-exon 
16 junction of the human NTRK2 gene (Figure 6.13). Alignment showed high 
conservation at this intron-exon junction (Figure 6.13), suggestive of 
importance of this region for regulation of exon inclusion or exclusion. To 
determine miRNAs that could bind to this intron-exon junction, the RegRNA 
database was used. miRNAs overlapping the intron-exon junction with 
conserved binding sites and displaying a score of more than 100 as determined 
by RegRNA were selected. Using these criteria, 25 miRNAs were predicted to 
bind the intron 13-exon 14 junction of the mouse Ntrk2 and intron 15-exon 16 






Figure 6.13: Comparison of the structure of the mouse and human TrkB gene and splice variants. Schematic representation of all TrkB 
exons (numbers are shown in boxes) and introns. Exons are shown as boxes and introns are shown as lines (not drawn to scale). Names of 
alternative splice variants and protein isoforms are shown on the left. The alternative exon that gives rise to the TrkB T1 isoform is in red and the 
conservation in sequence at this intron-exon junction is shown by *. Intron sequence is in lower case letters and exon sequence is capitalized. 














Table 6.6: miRNAs predicted to bind conserved regions of intron 13-exon 
14 of mouse Ntrk2 and intron 15-exon 16 of human NTRK2. RegRNA was 
used to predict putative miRNA binding sites and the RegRNA score is 
indicated for each miRNA for the mouse and human gene. 
 
miRNA 
Mouse intron 13-exon 
14 (RegRNA score) 
Human intron 15-exon 
16 (RegRNA score) 
miR-143-3p 108 108 
miR-150-3p 105 105 
miR-15a-5p 116 116 
miR-15b-5p 108 108 
miR-16-5p 106 115 
miR-191-5p 140 140 
miR-195-5p 113 119 
miR-19a-3p 100 100 
miR-203-3p 117 117 
miR-208a-3p 115 115 
miR-208b-3p 115 115 
miR-330-3p 137 137 
miR-374-5p 103 111 
miR-423-5p 116 104 
miR-483-5p 100 100 
miR-490-3p 126 125 
miR-491-3p 115 115 
miR-494-3p 123 123 
miR-551b-5p 133 124 
miR-652-5p 124 128 
miR-671-5p 102 102 
miR-761 100 100 
miR-875-3p 107 104 
miR-877-5p 119 119 










6.4.2 Selection of miRNAs for further interaction studies 
From the list of 25 conserved miRNAs, screening for the possible modulators 
of Ntrk2 splicing was carried out. Co-expression of TrkB T1 and miRNAs 
regulating it would indicate miRNA based gene regulation. The presence of 
TrkB T1 in primary neurons was established earlier (Figure 6.1). The 
abundance of the shortlisted miRNAs was obtained from the microRNA 
microarray data obtained in Chapter 3. The average signal intensity for each 
miRNA during maturation was determined (Figure 6.14). Only miRNAs with 
a mean signal intensity of more than 300 (log2 transformed value of 8.22) for 
all the days were considered as present. Using this criterion, 11 miRNAs 
(miR-143-3p, -150-3p, -203-3p, -208a-3p, -208b-3p, 330-3p, -483-5p, -494-
3p, -652-5p, -671-5p -761) had a mean signal intensity less than this cut-off 
and were excluded from the list. Hence, 14 miRNAs were determined to be 
potential regulators of the alternative exon of Ntrk2 in both mouse and human 
(Figure 6.14).  
 
Since TrkB T1 expression was differentially expressed from Day 2 to Day 8 
with fold change more than 1.5 on 2 days (Days 6 and 8) (Figure 6.15), 
miRNAs regulating its expression would be expected to show altered 
expression on at least 2 days as well. Of these 14 miRNAs, only 4 miRNAs, 
miR-191-5p, -195-5p, -19a-3p and -877-5p, showed differential expression of 
more than 1.5 fold on at least 2 days (indicated in dotted lines in Figure 6.15).  
 
Of these 4 miRNAs, miR-191-5p showed the highest binding score for both 




Mapping of miR-191-5p to the intron-exon junction of the alternative exon for 
both the mouse and human showed its predicted binding site crossed the 
intron-exon junction (Figure 6.16) and hence, it was speculated that miR-191-









Figure 6.14: Abundance of miRNAs predicted to bind conserved regions of intron 13-exon 14 of mouse Ntrk2 and intron 15-exon 16 of 
human NTRK2 as determined by microarray. The average signal intensity of each miRNA on Days 2, 4, 6 and 8 from the miRNA microarray 
data obtained in Chapter 3 was log2 transformed and averaged. miRNAs with average signal intensity less than 300 (log2 transformed value of 










Figure 6.15: Relative expression of TrkB T1 and shortlisted miRNAs 
predicted to target intron-exon junction of Ntrk2 alternative exon in 
primary mouse neurons. Expression of selected miRNAs as determined by 
microarray in Day 4, 6 and 8 neurons was normalized to Day 2 neurons and 
presented as fold change. miRNAs showing differential expression of more 








miR-191-5p   3' GUCGACGAAAACCCUAAGGCAAC 5' 
                  |:| ||||| || ||::|||  
 Mmu I13 tcgttttgtgtttcttttagG-TTTTGTTTTGTTTCATAAG E14 125447  
 Hsa I15 ttattttgtgtttcttttagG-TTTTGTTTTGTTTCATAAG E16 142011  
         *  ****************** ******************* 
 
Figure 6.16: Alignment of intron-exon junction sequence of murine 
(Mmu) and human (Hsa) Ntrk2 gene and mapping of miR-191-5p. Gene 
sequence of mouse intron 13 (I13) – exon 14 (E14) and human intron 15 (I15) 
– exon 16 (E16) were aligned. Intron sequence is in lower case letters and 
exon sequence is capitalized. The predicted conserved binding site for miR-








6.4.3 Expression analysis of miRNAs predicted to target TrkB T1 
In silico analysis suggested a possible regulatory role of miR-191 on the 
intron-exon junction of the Ntrk2 alternative exon, and hence splicing. This 
was followed up with determination of the expression profile of TrkB T1 and 
miR-191 in neuronal maturation and how it is altered upon ischemic injury.  
The expression of TrkB T1 increased to 1.52 ± 0.01 (p=0.001) from Day 2 to 
Day 6 during neuronal maturation (Figure 6.17). Exposure to 4 hours OGD 
drastically increased TrkB T1 expression to 2.20 ± 0.09 (p=0.001) (Figure 
6.17). This was compared to the expression profile of miR-191. Similar to the 
expression of TrkB T1, expression of miR-191 increased during neuronal 
maturation to 2.17 ± 0.03 (p=0.001) and further increased to 4.02 ± 0.15 
(p=0.001) upon exposure to ischemic injury (Figure 6.17). The similar 
expression pattern of TrkB T1 and miR-191 predicted to regulate its splicing, 




Figure 6.17: Change in TrkB T1 and miR-191 expression during murine 
neuronal maturation and ischemic injury. Expression was measured in Day 
6 neurons as well as Day 6 neurons subjected to 4 hours OGD and normalized 
to Day 2 neurons. Data are presented as mean ± SD, n=3. Statistical 
significance was tested using the Student’s t-test and p-value is indicated next 




6.4.4 Construction of NTRK2 minigene  
Minigene splicing assays are used to identify and perform analysis of cis- and 
trans-acting regulatory elements that determine alternative splicing [314]. The 
minigene comprises of a genomic segment of the alternatively spliced region 
and genomic regions preceding and succeeding it [314]. Also, it would contain 
the motif of the predicted regulatory factor under study to determine if the 
modulation of the cis-acting regulatory factor alters exon usage. The minigene 
construct is inserted downstream of the cytomegalovirus (CMV) promoter to 
ensure high expression of the minigene pre-mRNAs upon transient 
transfection [314,315]. The expression of the alternatively spliced products is 
then determined by quantitative real-time PCR. Therefore, the minigene 
splicing assay serves as a rapid assay to determine the role of cis- and trans-
acting factors in regulation of splicing [314].  
 
In order to evaluate the effect of the miR-191 binding site on usage of the 
Ntrk2 alternative exon in splicing, the segments of the exon and intron 
preceding and succeeding the alternative exon were cloned into an expression 
vector with a CMV promoter, pcDNA™4/TO/myc-HisA (Figure 5.29). Since 
the human and mouse intron-exon junction of the alternative exon is 
conserved, and to affirm that the regulatory mechanism in study is applicable 
to humans as well, the minigene splicing construct was generated from the 
human genome. To achieve this, 4 fragments were amplified from the exon 
15-intron 15-exon 16-intron 16-exon 17 region of the human NTRK2 gene 
(Figure 6.18). Each fragment was amplified from the DNA extracted from 




fragment was then joined to the next fragment using primers that overlapped 
adjacent fragments (Table 6.7). Finally, all the fragments were joined together 
to obtain a 953 bp fragment with Hind III and Xba I restriction enzymes sites 





 vector and verified by sequencing. Excision of the fragment 
with Hind III and Xba I enzymes was followed by sub-cloning into the 
mammalian expression vector, pcDNA™4/TO/myc-HisA. Positive clones 







Figure 6.18: Schematic representation of NTRK2 minigene splicing construct designed from the genomic region flanking human NTRK2 
alternative exon, exon 16. The NTRK2 minigene splicing construct was designed by amplifying the exon 15-intron 15 junction (fragment 1), 
intron 15-exon 16 junction (fragment 2), exon 16-intron 16 junction (fragment 3) and intron 16-exon 17 (fragment 4) using the primers indicated 
in Table 6.7. Overlapping primers to join the fragments yielded a 953 bp fragment with Hind III and Xba I restriction enzyme sites for sub-














Table 6.7: Primer design for generation of human NTRK2 minigene 
splicing construct. Primers indicated were used to amplify fragments of the 
genomic region flanking the alternative exon of human NTRK2 gene. Primers 
used to join adjacent fragments and for addition of restriction enzyme sites are 
also indicated. RE sites are underlined. 
 




























Fragment 2 – 
Fragment 3 
- GATGGGTAGCTGAAACCATCTTTTCCACAT 
Fragment 3 – 
Fragment 4 
- TTGGTTGTGTTCAGAGGGGGGAGTTTGTTG  
Hind III – 
Fragment 1 
Hind III TAGCAAGCTTATGGTCTATG 
Xba I – 
Fragment 4 









6.4.5 miRNA interaction studies on NTRK2 minigene  
The human NTRK2 minigene was cloned into the pcDNA™4/TO/myc-HisA 
expression vector. This vector contains 2 tetracycline operator 2 (TetO2) sites 
inserted into the human CMV promoter to allow tetracycline-regulated 
expression of the downstream gene [238]. Four Tet repressor molecules 
(consisting of 2 Tet repressor homodimers) bind to the TetO2 sequences such 
that the downstream gene is responsive to tetracycline. The Tet repressor is 
expressed from the pcDNA™6/TR plasmid (Figure 6.19) which is co-
transfected with pcDNA™4/TO/myc-HisA. In the absence of tetracycline, Tet 
repressor binding to the TetO2 sequences represses the expression of the 
NTRK2 minigene. With the introduction of tetracycline, the CMV/TetO2 
promoter of pcDNA™4/TO/myc-HisA is derepressed and the NTRK2 
minigene is expressed.  
 
To carry out the minigene splicing assay, human SH-SY5Y neuroblastoma 
cells were co-transfected with pcDNA™4/TO/myc-HisA and pcDNA™6/TR 
in a ratio of 1:6. The cells were subjected to retinoic acid induced 
differentiation for 4 days and transfected with either miR-191 inhibitor or 
mimic or negative control followed by addition of tetracycline to express the 
NTRK2 minigene. The cells were harvested 24 hours later and the splice 
variants from the minigene quantified using quantitative real-time PCR. The 
splice variants that were expected to result from differential splicing of the 
NTRK2 minigene were denoted as pc FL and pc T1 (Figure 6.20). Skipping of 
exon 16 would result in the pc FL isoform whereas inclusion of exon 16 would 




determine the level of pc T1, the expression of pc T1 was determined upon 







Figure 6.19: Map of the pcDNA™6/TR vector. The vector expresses the Tet 
repressor under the control of the human CMV promoter. This vector is co-
transfected with pcDNA™4/TO/myc-HisA. The Tet repressor from 
pcDNA
TM
6/TR binds to the tetracycline operator 2 (TetO2) site in the 
promoter of the pcDNA™4/TO/myc-HisA vector to repress expression of the 
gene cloned down-stream of it. The pcDNA™4/TO/myc-HisA promoter is 
therefore responsive to tetracycline [238]. In the absence of tetracycline, Tet 
repressor binding to the TetO2 sequences represses the expression of the 
NTRK2 minigene. With the introduction of tetracycline, the CMV/TetO2 
promoter of pcDNA™4/TO/myc-HisA is derepressed and the NTRK2 








Figure 6.20: Splice variants derived from NTRK2 minigene splicing 
construct and putative miR-191 binding site. The splice variants that were 
expected to result from differential splicing of the NTRK2 minigene were 
denoted as pc FL and pc T1. Similar to the NTRK2 gene, skipping of exon 16 
would result in the pc FL isoform whereas inclusion of exon 16 would result 




Cells co-transfected with the NTRK2 minigene and miR-191 inhibitor showed 
a significant reduction in pc T1 expression of 0.71 ± 0.06 (p=0.007) (Figure 
6.21). Co-transfection of the NTRK2 minigene with miR-191 mimic 
significantly increased pc T1 expression to 1.25 ± 0.04 (p=0.003) (Figure 
6.21). These results showed that miR-191 directly regulates inclusion of the 
NTRK2 alternative exon of the NTRK2 gene, resulting in splicing in favour of 
























Figure 6.21: Relative expression of pc T1 splice variant in NTRK2 splicing 
minigene assay. To carry out the minigene splicing assay, human SH-SY5Y 
neuroblastoma cells were co-transfected with pcDNA™4/TO/myc-HisA and 
pcDNA™6/TR in a ratio of 1:6. Cells were subjected to retinoic acid induced 
differentiation for 4 days and transfected with either miR-191 inhibitor or 
mimic or negative control followed by addition of tetracycline to express the 
NTRK2 minigene. The cells were harvested 24 hours later and pc T1 splice 
variant quantified using quantitative real-time PCR. Data are presented as 
mean ± SD, n=3. Statistical significance was tested using the Student’s t-test 






6.4.6 miR-191 modulates Ntrk2 exon 14 inclusion in mouse primary 
neurons 
The NTRK2 minigene splicing assay showed a direct role of miR-191 in 
inclusion of the NTRK2 alternative exon of the NTRK2, which forms the 
truncated isoform of the receptor. The next step was to determine if 
modulating miR-191 levels in primary neurons could modulate the 
endogenous TrkB T1 expression. 
 
To modulate miR-191 levels, primary cortical neuronal cultures on Day 6 
were transfected with miR-191 inhibitor and mimic independently. This was 
followed by measurement of changes in the miR-191 and TrkB T1 mRNA 
levels 24 hours later (Figure 6.22). Transfection of miR-191 inhibitor 
significantly decreased miR-191 expression to 0.169 ± 0.001 (Table 6.8). This 
resulted in a corresponding reduction in TrkB T1 expression to 0.75 ± 0.07 
(p=0.007) (Figure 6.22). miR-191 mimic, on the other hand, significantly 
increased miR-191 levels to 595 ± 5 (Table 6.8). This significantly increased 
TrkB T1 mRNA expression by 1.13 ± 0.05 (p=0.013) fold (Figure 6.22). 
Hence, modulation of miR-191 levels could regulate Ntrk2 splicing in favour 
of the TrkB T1 truncated isoform in primary neuronal cultures by inclusion of 













Table 6.8: Relative expression of miR-191 in murine primary cortical 
neuronal cultures transfected with either miR-22 inhibitor or mimic at a 
concentration of 30 nM on Day 6 and harvested 24 hours after 
transfection. 
 
Treatment Relative expression of miR-203 
miR-191 inhibitor 0.169 ± 0.001 









Figure 6.22: Relative TrkB T1 mRNA expression in murine primary 
cortical neuronal cultures transfected with either miR-191 inhibitor or 
mimic at a concentration of 30 nM on Day 6. Cells were harvested 24 hours 
after transfection and expression was normalized to respective negative 
controls. Data are presented as mean ± SD, n=3. Statistical significance was 





6.4.7 Model of miR-191 mediated regulation of Ntrk2 alternative 
splicing 
 
This section has shown that miR-191 can directly regulate splicing of Ntrk2 in 
favour of splicing of the truncated TrkB T1 isoform. Splicing decisions are 
based on multiple antagonistic and synergistic influences of regulatory 
proteins whereby activator proteins bind to splicing enhancers which are in 
contact with numerous other splicing factors and RNA [316]. Repressor 
proteins bind to splicing silencers and have RNA-binding domains as well. 
This complex assembly of proteins defines the exons on the pre-mRNA at an 
early stage to form the spliceosome assembly. Interestingly, the splicing 
repressor polypyrimidine tract-binding protein (PTB) has been shown to target 
the interactions involved in exon and intron definition [317,318] by binding to 
pyrimidine rich regions in the  polypyrimidine tract at the 3′ splice site [316]. 
It has been suggested that PTB competes with the splicing factor U2AF for 
binding to the regulated polypyrimidine tract [319,320]. With this knowledge, 
PTB binding sites in the intron-exon junction preceding the Ntrk2 alternative 
exon were determined. Prediction using RegRNA showed a PTB binding site 
just proximal to the intron-exon junction and overlapping with the binding site 
for miR-191 (Figure 6.23). Hence, it was postulated that in the absence of 
miR-191, binding of PTB would prevent U2AF from binding and hence, 
prevent exon inclusion. Upon binding of miR-191, the PTB binding site could 
be blocked and PTB binding ablated. This could result in displacement of PTB 
and binding by U2AF, thereby allowing splicing that favours the exon (Figure 
6.23) [318]. This is but one of several possible mechanisms [121], hence, this 





Figure 6.23: Model of miR-191 mediated regulation of Ntrk2 alternative exon inclusion. Prediction using RegRNA showed a PTB binding 
site (underlined sequence) just proximal to the intron-exon junction and overlapping with the binding site for miR-191. It was postulated that in 
the absence of miR-191, binding of PTB would prevent the U2AF splicing factor from binding and hence, prevent exon inclusion. Upon binding 
of miR-191, the PTB binding site could be blocked and PTB binding ablated. This could result in displacement of PTB and binding by U2AF, 









6.5 Mechanism of microRNA mediated regulation of TrkB T1 
expression by splicing and translational inhibition 
The first part of this chapter investigated the translational regulation of TrkB 
T1 mRNA expression by miR-22. It was found that miR-22 directly regulates 
the TrkB T1 3’UTR (Section 6.3.4). Functional studies in primary neurons 
further showed that modulation of miR-22 could inversely regulate TrkB T1 
mRNA expression (Section 6.3.6). This showed that down-regulation of miR-
22 levels during ischemia accounted for the increase in TrkB T1 levels and 
hence contributed to neuronal cell death (Figures 6.3 and 6.24). Hence, the 
miR-22:TrkB T1 mRNA interaction was exploited in an in vitro ischemic 
condition which showed that over-expression of miR-22 could successfully 
increase neuronal cell viability by reducing TrkB T1 mRNA expression 
(Section 6.3.7). Over-expression of miR-22 could therefore serve as a 
potential neuroprotectant in stroke therapy.  
 
In addition to translational repression, it was found that splicing, a crucial 
determinant of TrkB T1 expression, could be regulated by miRNAs as well. 
Minigene splicing assays showed that miR-191 could directly enhance 
splicing of NTRK2 to favour splicing of the truncated TrkB T1 isoform 
(Section 6.4.5). Similar results were obtained when miR-191 levels were 
modulated in primary neuronal cultures (Section 6.4.6). This implied that up-
regulation of TrkB T1 levels during neuronal maturation and ischemic injury 
was attributed to increased miR-191 levels (Figure 6.17). These 2 studies 
showed that during ischemic injury, up-regulation of miR-191 favours splicing 




in miR-22 further increases TrkB T1 levels. These 2 mechanisms culminate in 
a drastic spike in TrkB T1 levels which acts as a dominant negative inhibitor 
to the full length isoform and also sequesters RhoGDI1 which activates RhoA, 
p38MAPK and stress signalling pathways [51], resulting in extensive neuronal 





Figure 6.24: A model for regulation of TrkB T1 expression by miRNA 
mediated regulation of splicing and translational repression during 
ischemic injury. In normal neurons, BDNF binds to the TrkB FL isoform for 
cell survival signalling. Upon ischemia, stabilization of the hypoxia-inducible 
factor 1 protein, a transcription factor, increases transcription of NTRK2. An 
increase in miR-191 expression favours the splicing of the truncated isoform. 
A simultaneous reduction in miR-22 levels, which represses TrkB T1 






7.1 Characterization of pure maturing primary cortical neuronal 
cultures 
Non-coding RNAs (ncRNAs) are fast rising as controllers of neuron 
development and disease, biomarkers as well as potential therapeutic targets in 
disease [84,85,92,142-144]. These are endogenously produced molecules 
which regulate gene expression by mechanisms ranging from transcriptional 
regulation to posttranscriptional processing, translation and even chromatin 
remodeling [86-88]. Several studies demonstrated that ncRNAs that direct 
neuronal gene expression are dysregulated in ischemia [34,40,96]. It has also 
been reported that modulation of certain miRNAs can confer neuroprotection 
in cerebral ischemic models [145-147]. In addition, the ability of one ncRNA 
to modulate multiple genes simultaneously means that identification of a 
neuroprotective ncRNA that favours neuronal survival at several fronts could 
serve as a better therapeutic approach as compared to targeting a single mRNA 
[123,321]. Unlike miRNAs, elucidation of the role of lncRNAs in neuron 
development and disease is still in its infancy. However, once established, this 
knowledge will reveal valuable information about molecular targets and tools 
that can be used as therapy in diseases like their micro counterparts [322-324]. 
Furthermore, being endogenously produced regulators of gene expression, the 
likelihood of side effects from these ncRNAs will be significantly reduced as 
compared to synthetic drugs. 
 
The main objective of this study was therefore to identify and characterize 




injury by comparing their expression between neuronal maturation and 
ischemic injury. To identify neuroprotective ncRNAs, it was necessary to 
carry out the study in pure neuronal cultures. Neurogenesis begins at 
embryonic day 11 (E11) in mice and peaks at E15 [325], with glial cells 
appearing from E17 onwards. Hence, primary cultures of cortical neurons 
were established from E15 embryos as well as an earlier (E14) and a later 
(E16) embryonic day to determine the optimal embryonic day that yields pure 
neuronal cultures to study neuronal maturation. Cultures were maintained for 
8 days in Neurobasal medium supplemented with B27 to ensure selective 
growth of cortical neurons [241,326] which resulted in > 99% neuronal 
cultures. This was in line with reports by Valerio et al [262] and Yamasaki et 
al [263]. Intense staining for MAP2, a dendritic and neuronal maturation 
marker [264,269,270], and NeuN, a marker of post-mitotic neurons, indicated 
establishment of a mature neuronal network comprising purely post-mitotic 
neurons. This was further validated with absence of staining for the neuronal 
progenitor marker, Sox2, microglial marker, CD11b, oligodendrocyte marker, 
O4 and astrocyte marker, GFAP (Chapter 3). These results were confirmed by 
quantification of abundance of cell-type specific miRNAs, neuron-specific 
miR-124, astrocyte-enriched miR-143 and glia-enriched miR-223 using stem-
loop quantitative real-time PCR [271]. Finally, the functionality of the neurons 
was tested with synapsin I staining, an indicator of synapse formation.  
 
E14 derived primary cortical neuronal cultures gave rise to pure maturing 
neurons but showed presence of neuronal progenitor cells on the first few days 




Also, the appearance of astrocytes on Days 6 and 8 in E16 derived cultures 
showed that glial cells had started to form at E16 [254]. Hence, E15 derived 
pure cortical neuronal cultures were utilized for expression studies in maturing 
neurons and neurons subjected to OGD, similar to studies carried out by 
Valerio et al [262] and Chen et al [327].  
 
7.2 Importance of lncRNAs and miRNAs in neuronal maturation and 
prevention of their dysregulation during ischemic injury 
The long term survival of post-mitotic neurons in the developed nervous 
system is crucial to ensure proper function throughout an organism’s life.  
Also, since neurons cannot proliferate, they cannot afford to be vulnerable to 
apoptosis. To counter this, several anti-apoptotic mechanisms, such as 
reducing the availability of pro-apoptotic proteins, are put in place to inhibit 
the cell death pathway during neuronal maturation [42-46]. However, during 
ischemic injury, aberrant expression of genes essential to neuronal survival or 
function results in lose in restriction of these apoptotic mechanisms or triggers 
apoptosis [34,42,47,279,328,329]. For instance, the gene silencing 
transcription factor neuronal repressor element-1 (RE1) silencing transcription 
factor/neuron-restrictive silencer factor (REST/NRSF) is downregulated 
during differentiation of neural progenitors, giving rise to induction and 
maintenance of the neural phenotype [330]. However, exposure to ischemia 
induces the expression of REST which triggers apoptosis. Preventing the 
induced expression of REST could rescue post-ischemic neurons from 
ischemia-induced apoptosis [47]. Similarly, it was hypothesized that 




be achieved by identifying genes important for neuronal maturation or 
survival, but dysregulated during ischemic injury and possibly reversing or 
preventing their dysregulation to reduce cell death. This approach was applied 
to mRNA as well as ncRNAs (miRNAs and lncRNAs), the endogenously 
produced regulators of gene expression which could serve as tools to modulate 
potential therapeutic targets [280].  
 
To study these, mRNA, miRNA and lncRNA expression levels were 
quantitated using hybridization based microarray technology that can 
determine the expression levels of all known genes, miRNAs and putative 
lncRNAs in a sample [331]. RNA expression profiling of the mRNAs, 
lncRNAs and miRNAs in maturing neurons obtained from E15 mouse 
embryos revealed extensive regulation of genes by ncRNAs during neuronal 
differentiation. The RNA expression profiles reflected changes in gene 
expression associated with dendritic, axonal and synaptic processes (Chapter 
5). Genes that were differentially expressed as well as had altered lncRNA 
expression associated with their locus were mapped to proliferation and 
differentiation associated pathways that are involved in cell cycle processes, 
cell adhesion molecules and neurotrophin signalling (Table 4.1). Of these 
genes, 23 were predicted targets of the differentially expressed miRNAs. Only 
11 genes (Axin2, Igf1r, Ikbkb, Prkcb, Ralgds, Cntn1, Ncam1, Negr1, Nrxn1, 
Ntrk2 and Sh2b3) out of these 23 were found to be differentially expressed on 






Exit from the cell cycle, controlled by several integrated processes, is the first 
determinant of neurogenesis before differentiation of neural stem cells [332]. 
Igf1r, Ikbkb and Prkcb were found to be regulated by lncRNAs and miRNAs 
during maturation to activate PI3K, ERK and NFκB cascades for survival 
function, axonogenesis, as well as neural cell development and migration 
[333-335]. Axin2 is a critical regulator of Wnt signalling that controls cell 
growth and differentiation during central nervous system development 
[336,337] whereas Ralgds inhibits neurite outgrowth [338]. Cell adhesion 
molecules are trans-synaptically interacting cellular proteins that play a key 
role in synapse formation, maturation, intercellular communication, activity-
dependent validation, and network connectivity in the brain [20,70,339]. 
Differentially expressed neurogenesis associated miR-124, was predicted to 
target the cell adhesion molecules, Cntn1 and Negr1 [340]. Another pathway 
essential to neuronal survival and function is the neurotrophin pathway. It 
activates the PI3K and ERK cascades for neurite outgrowth, neuronal 
differentiation, survival and plasticity [49-51]. Upregulation of Ntrk2 (TrkB 
receptor) was observed, correlating to long term potentiation and plasticity 
during maturation. Further modulation of growth factor signalling could be 
provided by the growth factor induced-antagonist, Sh2b3, which was 
upregulated during maturation, to suppress proliferation [341]. Increased pro-
survival signaling was also conferred by elevated expression of Ikbkb [334]. 
Hence, the shortlisted genes, being crucial controllers of neuronal 
development, were postulated to be under tight regulatory control of the 





Interestingly, a large number of the genes identified in these pathways showed 
similar expression profiles between the miRNAs and their respective target 
mRNAs. This is unusual as miRNAs, being translational inhibitors, are 
expected to show an inverse expression profile with their target mRNAs [283]. 
Therefore, it was speculated that the associated lncRNAs could be providing 
another level of modulation. The function of miRNAs is well-established, 
however, the mechanisms by which lncRNAs regulate gene expression are 
more diverse and not fully elucidated. Therefore, to decipher the relation 
between the mRNAs and lncRNAs associated with specific genes, the 
expression of the 11 mRNA-lncRNA pairs (Axin2, Igf1r, Ikbkb, Prkcb, 
Ralgds, Cntn1, Ncam1, Negr1, Nrxn1, Ntrk2 and Sh2b3) altered during 
neuronal maturation was determined in a neuronal ischemic injury model. 
Comparison of the mRNA and lncRNA expression profiles between a survival 
(neuronal maturation) model and an ischemic injury (OGD) model was used to 
elucidate the role of the lncRNAs in regulating the expression pattern of their 
respective mRNAs. Using this approach, the potential relationship between 7 
out of the 11 mRNA-lncRNA pairs was determined (Axin2, Prkcb, Cntn1, 
Ncam1, Negr1, Nrxn1 and Sh2b3). An inversion of expression of these genes 
(Axin2, Prkcb, Cntn1, Ncam1, Negr1, Nrxn1, Sh2b3) was observed upon 
ischemic insult. Such inversion of expression upon ischemic injury has also 
been observed for NB-3, a cell adhesion molecule expressed in neurons for 
axonal extension and neuronal survival [279]. Downregulation of Axin2 during 
neuronal differentiation and upregulation upon ischemic injury has also been 
reported [336,337]. This implies that such opposite expression of these genes 




mRNA microarray data showed similar results to those from rodent ischemic 
stroke models (middle cerebral artery occlusion, MCAo), indicating our in 
vitro model of ischemic injury is reflective of the gene expression changes 
taking place in an in vivo ischemic injury model (Table 7.1) [34]. The 
observations in this study on the inverse regulation of genes crucial to 
neuronal function upon ischemic injury are hence consistent with previous 
reports [34,279].  
 
Table 7.1: Comparison of mRNA expression profile of selected genes in 
primary neurons subjected to 4 hours OGD and rodent ischemic stroke 
models (middle cerebral artery occlusion, MCAo). Expression of selected 
genes described by Jeyaseelan et al. [34] as determined by DNA microarray 
was extracted from mRNA microarray data of primary neurons subjected to 4 
hours OGD.  Expression is indicated in signal log ratio (SLR).  
Gene  
Mmu neurons 4hrs OGD 
vs 0hr OGD (SLR) 
MCAo Brain vs Sham 
(SLR) 
Akap6 -0.76 −1.19 
Bmpr2 0.20 4.92 
Dhcr24 -1.13 −1.06 
Sept3 -0.07 −2.28 
Gad1 -0.23 −3.21 
Gnb1 0.17 1.54 
Golph3 -0.16 −1.63 
Madd -0.908 −2.29 
Mapk1 -0.72 −2.45 
Mapre1 -0.66 −0.97 
Neurod1 -0.07 −1.03 
Nr4a1 -1.12 −0.96 
Ssr3 -1.16 −2.28 
Stx1a -0.59 −2.46 
Syt4 -0.63 −0.81 
Tpm1 1.50 2.39 
Vim 0.09 2.74 
  
An inverse relationship was inferred between the Axin2, Cntn1, Ncam1, 
Negr1, Nrxn1 and Sh2b3 mRNA-lncRNA pairs while Prkcb showed a 




distinct relationship between the lncRNA-mRNA pairs suggests a 
transcriptional or posttranscriptional regulatory function for lncRNAs in 
neuronal development. Except for the Negr1 lncRNAs that have been found to 
be expressed in a bidirectional manner, lncRNAs associated with the other 
selected genes overlapped with intronic or exonic regions in either a sense or 
antisense manner. Ling et al. [160] also observed several sense and natural 
antisense transcripts at the Nrgn and Camk2n1 loci. They postulated these 
transcripts functioned to increase the diversity of posttranscriptional regulation 
and result in cell- and time-specific regulation of their gene products during 
cerebral corticogenesis and function [160]. Nuclear localized antisense and 
bidirectional transcripts are also known to activate gene expression of their 
partner protein-coding genes by associating with chromatin-modifying 
complexes [139,342]. The numerous types of lncRNAs and their varying 
expression patterns observed in this study could possibly be modulators of 
gene expression for precise control of neuronal development. However, the 
exact role of each lncRNA in regulating gene expression can only be 
determined after elucidating its localization in the cell and its interacting 
molecules.  
 
In addition to regulation by lncRNAs, the 7 genes (Axin2, Cntn1, Ncam1, 
Negr1, Nrxn1, Prkcb, Sh2b3) were also regulated post-transcriptionally by 
miR-124, -128, -129-5p, -203, -218, -290-5p, -326, -329, -377 and miR-495. 
Amongst these, miR-124, -128, -129-5p, -218, -326, -329, -377 and -495 have 
been reported to exhibit brain specific or brain-enriched expression patterns 




cluster that modulates activity-dependent dendritogenesis and miR-495 also 
regulates expression of brain-derived neurotrophic factor (BDNF) [290,343]. 
Interestingly, the cell adhesion molecules (Cntn1, Ncam1, Negr1, Nrxn1) were 
targeted by all these miRNAs with miR-377 specifically targeting only the 4 
cell adhesion molecules (Figure 4.14).  
 
Of these cell adhesion molecules, Ncam1 and Negr1, implicated in neurite 
outgrowth and neuronal maturation [78,79,344-346], were constitutively up-
regulated during maturation with down-regulation of the associated lncRNAs 
(Table 4.6). These observations were further supported by a drastic increase in 
NEGR1 and NCAM1 protein levels in synaptosomes during neuronal 
maturation in another study [79]. Increased expression of the cell adhesion 
molecules also coincided with extensive up-regulation of neuronal-enriched 
miR-377 predicted to target these mRNAs (Table 4.4). This observation is 
consistent with another study which suggested that miRNAs could be involved 
in neuronal homeostasis [347]. Interestingly, miR-377 is derived from the 
neuron-enriched miR-379-410 cluster. In response to increased neuronal 
activity, transcription of miR-134, another member of miR-379-410 cluster, is 
induced to promote neurite outgrowth [290]. Being in the same cluster, it is 
likely that miR-377 shares a similar function. Therefore, in addition to 
lncRNAs, neuron-specific miRNAs could also co-regulate expression of the 
neuron-specific genes. 
 
Identification of a network of neuron-specific transcriptomes in the first part 




neuronal development and survival. It was hypothesized that the expression of 
genes important in neuronal maturation was under transcriptional or 
posttranscriptional control of the lncRNAs and further fine-tuned at the 
translational level by miRNAs. Therefore, this coordinated regulatory network 
could be the key to modulating neuronal homeostasis for precise neuronal 
development. Dysregulation of this delicate lncRNA-mRNA-miRNA network 
during ischemic insult could therefore to be a contributing factor to neuronal 
cell death. This has led to the identification of putative targets and molecules 
for neuroprotection in ischemic disease. 
 
7.3 Importance of co-regulation of Negr1 mRNA expression by miR-
203 and Negr1 bidirectional lncRNAs  
In chapter 4, expression profiling of RNA transcripts during neuronal 
maturation and ischemic injury highlighted two pathways crucial to neuronal 
survival, the cell adhesion molecules and the neurotrophin signalling pathway 
(Table 4.1). Shortlisted genes in each of these pathways were found to be 
regulated by both lncRNAs and miRNAs (Figure 4.14). To determine 
promising neuroprotectants, ncRNAs regulating a gene from each pathway 
(Figure 4.14) were characterized and their effects on neurite outgrowth and 
neuronal survival were evaluated.  
 
Cell adhesion molecules mediate connections between presynaptic and 
postsynaptic neurons for axonal extension, neuronal pathfinding as well as the 
assembly and stability of the synapse [70,71]. The synapse enables neurons to 




Proteins found on the synapse are responsible for both its structure and 
function, with them possessing an inter-dependent relationship [348,349]. 
Synaptic function also determines neuronal survival via synapse-to-nucleus 
signalling [74] whereas synaptic dysfunction results in cell death [350]. 
Likewise, the synapse is also vulnerable to ischemic injury [351,352] as the 
large energy requirement of the neuron means several mitochondria have to be 
localized close to the synapse bouton [353]. Cerebral ischemia causes a drastic 
reduction in synaptic vesicle content and increases the number of damaged 
mitochondria [75,353]. Hypoxic stress and excitotoxicity also trigger severe 
but reversible changes in dendritic spine structure and morphology 
[75,352,354-356]. Dysregulation in synaptic adhesion subsequently results in 
neuronal cell death [353] showing the importance of the synapse as a 
determinant of neuronal fate in ischemia [75]. Signals at the synapse after 
ischemia travel to the cell body and nucleus to result in delayed cell death, 
also known as synaptic apoptosis [355]. This signified the importance of the 
cell adhesion molecules in not only neurite outgrowth but also as mediators of 
cell survival signalling [74,357].  
 
Of the numerous cell adhesion molecules, Costain et al. [75] reported that the 
synaptosomal NEGR1 protein levels as well as Negr1 mRNA levels in the 
mouse were altered after cerebral ischemia suggesting this dysregulation could 
have a part to play in triggering post-ischemic events. These changes were 
similarly observed in the current study whereby Negr1 expression showed the 
most drastic increase during neuronal maturation but the most drastic 




reduced expression of Negr1 mRNA in primary neurons 24 hours after 
exposure to OGD correlated with the expression observed in mouse brain 20 
hours post-ischemia [75]. Its role in synapse function could therefore be an 
important contributor to precise neuronal function but its dysregulation could 
indeed be the mediator of neuronal death during ischemia [74,357]. Hence, 
prevention of its dysregulation during ischemia could serve as a potential 
neuroprotective approach. 
 
This study further identified and characterized miRNAs and lncRNAs 
associated with Negr1 that could possibly regulate Negr1 expression. miR-203 
was determined to directly bind to and inhibit the Negr1 murine and human 
3’UTR. This could also effectively reduce neurite outgrowth. Furthermore, 
upon exposure to ischemic injury miR-203 expression was observed to be up-
regulated which downregulated the expression of Negr1 mRNA. Exploiting 
the miR-203:Negr1 mRNA interaction in an in vitro ischemic conditions could 
successfully increase Negr1 mRNA expression and neuronal cell viability by 
inhibiting miR-203 expression.  
 
Another known target of miR-203 is c-Jun [358], a component of the AP-1 
transcription factor that is activated in response to external stimuli as well as 
in cerebral ischemia [359]. Tripathi et al. [360] showed that miR-203 targeted 
downregulation of c-Jun after exposure to OGD could increase cell survival 
and hence serve as a neuroprotectant. However, in the current study, 
administration of miR-203 mimic after exposure to OGD did not show any 




miR-203:c-Jun interaction was not conserved between humans and mice and 
hence, the miR-203:c-Jun interaction could be absent in mice, accounting for 
the difference in results. The current study, however, showed conservation of 
the miR-203:Negr1 interaction across different species. The protective role of 
miR-203 modulation hence needs to be validated in other models such as SH-
SY5Y cells. 
 
In addition to miRNAs, bidirectional lncRNAs to the Negr1 CG-rich 
promoter, AK083124 and BC048612, were also identified and then 
characterized as transcriptional activators of Negr1 expression. Of these, 
knockdown of the BC048612 lncRNA resulted in significant down-regulation 
of Negr1 mRNA expression and neurite outgrowth whereas over-expression 
enhanced Negr1 mRNA expression and neurite outgrowth. This was in line 
with reports of nuclear localized bidirectional lncRNAs acting as activators of 
gene transcription [296,361]. The mechanism of regulation of bidirectional 
lncRNA induced gene expression is not fully known but is being slowly 
elucidated. The cis-acting effect of bidirectional lncRNAs was also observed 
for antisense non-coding RNAs associated with the CG-rich Vim, Nefl and 
Sphk1 gene promoter [298,362]. Examination of the DNA methylation status 
upon lncRNA manipulation showed that lncRNA transcription induced 
sequence-specific DNA demethylation in the promoter which pointed towards 
epigenetic mediated control of gene regulation [298,362].  Furthermore, the 
repressive H3K9 methylation chromatin mark was replaced by activating 
H3K4 methylation in the vicinity of the gene, thereby favouring gene 




Recently, Bellizzi et al. [305] determined that Sp1 transcription factor binding 
sites are responsible for bidirectional transcription from GC-rich promoters. 
This mechanism was explored in the current study as well and interestingly, 
two Sp1 binding sites were predicted to target the promoter region between the 
Negr1 mRNA transcription start site and Negr1 bidirectional lncRNAs’ 
transcription start site. It has also been reported that Sp1 binding is inhibited 
by CpG methylation [307]. A further study by Kurihara et al. [301] showed 
that transcription of lncRNA-Tcam1 from its CG-rich promoter coincided with 
DNA hypomethylation and active chromatin marks (H3K9 acetylation, H3K4 
mono- and tri-methylation) coupled with expression of its bidirectional 
Smarcd2 transcript that possessed an Sp1 binding site upstream of its 
transcription start site. From these studies, it was postulated that transcription 
of the Negr1 bidirectional lncRNAs in neurons promoted DNA 
hypomethylation at the CpG islands as well as H3K4m3 active histone 
modification. This could allow binding of the Sp1 transcription factor and 
hence activate transcription of the Negr1 gene (Figure 5.30).  
 
These studies therefore showed that the Negr1 bidirectional lncRNAs act as 
transcriptional activators of Negr1 mRNA expression whereas miR-203 
negatively regulates Negr1 mRNA expression and hence neurite outgrowth. 
Thus, expression of the synaptic cell adhesion molecule, Negr1 is enhanced by 
its bidirectional lncRNAs and fine-tuned by miR-203 to ensure optimal 
synapse-to-nucleus signaling that mediates neuronal survival. Exposure to 
ischemia can trigger apoptotic signals at the synapse that upon reaching the 




the fate of the neuron post-ischemia. Thus, manipulation of the pro-survival 
Negr1 molecule by its regulatory ncRNAs could possibly mediate 
neuroprotection. 
 
7.4 microRNA mediated regulation of TrkB T1 expression by splicing 
and expression 
The second pathway found to be altered during neuronal maturation and 
ischemic injury was the neurotrophin signalling pathway, which comprises 
neurotrophins (growth factors) and their receptors that mediate neuronal 
survival and development. With neurotrophins being one of the most 
important determinants of neuronal differentiation and survival [58], it is 
intuitive that these growth factors be used as neuroprotectants to activate pro-
survival pathways post injury. Hence, to salvage cortical neurons post-
ischemia, activation of the BDNF-TrkB signaling cascade, the most highly 
expressed growth factor molecules in the cortex [52], was carried out. 
Interestingly, administration of BDNF immediately or days after ischemia 
could confer neuroprotection [53] and inhibition of BDNF activity 
exacerbated the ischemia [54]. However, systemic administration requires 
very large amounts of BDNF due to low amounts entering the brain due to the 
blood-brain barrier [55]. Therefore, an alternative approach to trigger this 
pathway is to increase the endogenous receptor level for the BDNF ligand, 
TrkB, so that any available BDNF in circulation can activate the pathway.  
 
However, there are 2 splice isoforms of this receptor, the full length (TrkB FL) 




negative inhibitor of TrkB FL [59,66]. After transient cerebral ischemia in 
rats, TrkB FL protein levels are dramatically downregulated in the ischemic 
region but present at high levels in the contralateral neocortex [64]. On the 
other hand, TrkB T1 protein is highly upregulated in the ischemic region but 
low levels are observed in the contralateral neocortex [64]. The TrkB T1 
protein was found to be specifically up-regulated in neurons in the ischemic 
region and interestingly, these same neurons were found to be undergoing 
degeneration, as indicated by Fluoro-Jade B-labeling, a compound that 
specifically binds to degenerating neurons [64]. This pointed towards neuronal 
cell death during ischemia being caused by dramatic upregulation of TrkB T1 
[64,65]. Other studies also showed that transgenic mice overexpressing TrkB 
T1 in neurons showed significantly larger infarct upon ischemic injury [67]. 
Similarly, in the primary neuronal cultures exposed to OGD in this study, a 
significant upregulation of TrkB T1 expression was observed with increased 
neuronal apoptosis (Chapter 6). Profiling data also showed differential 
expression of the TrkB gene, Ntrk2, during neuronal maturation (Figure 4.14). 
Thus, blocking the induced expression of TrkB T1 during ischemic injury 
could be a therapeutic approach to mediate neuroprotection by facilitating 
BDNF:TrkB FL pro-survival signaling.  
 
Hence, studies were undertaken to identify regulators of TrkB T1 at the level 
of post-transcriptional regulation and alternative splicing in primary neuronal 
cultures. It was found that miR-22 directly regulates the TrkB T1 3’UTR to 
inhibit TrkB T1 translation. This suggested that down-regulation of miR-22 




increased TrkB T1 would heterodimerize with TrkB FL to sequester 
neuroprotective BDNF in circulation, thereby inhibiting prosurvival signalling 
[51]. Moreover, homodimerization of TrkB T1 would sequester RhoGDI1, 
allowing activation of RhoA signalling that could in turn activate p38MAPK 
and stress signalling pathways, hence contributing to neuronal cell death [51]. 
Therefore, preventing the upregulation of TrkB T1 by exploiting the         
miR-22:TrkB T1 mRNA interaction to confer neuroprotection was tested in an 
in vitro ischemic condition. Interestingly, it was observed that over-expression 
of miR-22 could successfully increase neuronal cell viability by reducing 
TrkB T1 mRNA expression. The reduced TrkB T1 levels would increase the 
proportion of TrkB FL protein, allowing TrkB FL homodimerization and pro-
survival signalling upon binding by neuroprotective BDNF protein as well as 
prevent sequestration of RhoGDI1, also favouring cell survival. The 
neuroprotective effect of TrkB T1 interference and increased TrkB FL 
expression in excitotoxicity induced death, one of the pathways triggered by 
ischemia, was also reported by Vidaurre et al. [64].  
 
The neuroprotective effect of miR-22 over-expression could also be conferred 
through down-regulation of the pro-apoptotic activities of mitogen-activated 
protein kinase 14/p38 (MAPK14/p38) and tumor protein p53-inducible 
nuclear protein 1 (Tp53inp1) to result in decreased caspase activation [363]. 
This was observed in the context of Huntington’s disease but could still be 
applicable to the ischemic condition. Hence, over-expression of miR-22 could 
serve as a neuroprotectant by targeting the TrkB T1 receptor as well as by 




The present study was carried out such that miRNAs under study were 
conserved from rodents to humans to allow translation of the data from 
animals to humans. Likewise, the miR-22 binding site was found to be 
conserved in mouse, rat and human. Hence, the miR-22 targets and 
mechanism of action could be conserved in these species suggesting that miR-
22 over-expression acting as a neuroprotectant in an in vitro ischemic stroke 
model could possibly be applicable to human stroke patients as well.  
 
Since the TrkB T1 is derived from as a splice variant of the Ntrk2 gene, it was 
further hypothesized that miRNAs regulating inclusion of the alternative exon 
could be implicated in splicing in favour of the TrkB T1 isoform during 
ischemia. It was found the miR-191 could directly regulate splicing of Ntrk2 
in favour of splicing of the truncated TrkB T1 isoform (Chapter 6). 
Furthermore, this suggested that up-regulation of TrkB T1 levels during 
neuronal maturation and ischemic injury was attributed to increased miR-191 
levels. miRNAs regulating alternative splicing by targeting splicing factors 
such as PTBP1 [166] have been previously described. siRNAs have been 
shown to influence alternate splicing decisions at specific exons possibly by 
inducing a compacted chromatin structure that slows down polymerase II 
procession, resulting in exon inclusion [121,129,364]. However, no 
microRNAs have been reported to directly influence exon inclusion/exclusion.  
 
Splicing decisions are based on multiple antagonistic and synergistic 
influences of regulatory proteins whereby activator proteins bind to splicing 




[316]. Interestingly, prediction using RegRNA showed a PTB binding site just 
proximal to the intron-exon junction and overlapping with the binding site for 
miR-191 (Figure 6.23). Hence, it was postulated that in the absence of miR-
191, binding of PTB would prevent U2AF from binding and hence, prevent 
exon inclusion. Upon binding of miR-191, the PTB binding site could be 
blocked and PTB binding ablated. This could result in displacement of PTB 
and binding by U2AF, thereby allowing splicing that favours the exon (Figure 
6.23) [318]. This is but one of several possible mechanisms [121], hence, this 
and other probable mechanisms of splicing also need to be explored in future.  
 
miR-191 has been shown to be upregulated during neuronal maturation [286], 
is induced with NDMA-receptor dependent plasticity [365] and directly 
targets BDNF [366]. It is also highly up-regulated in brains of rats subjected to 
middle cerebral artery occlusion after 24 hours [34]. Hence, this study shows 
that pathogenesis during cerebral ischemia could be brought about by miR-191 
mediated inclusion of the Ntrk2 alternative exon to favour expression of TrkB 
T1 as well as down-regulation of pro-survival BDNF.  
 
All in all, studies on TrkB T1 showed that during ischemic injury, up-
regulation of miR-191 favours splicing of the Ntrk2 gene to form the TrkB T1 
isoform and a simultaneous reduction in miR-22 further increases TrkB T1 
levels. These 2 mechanisms culminate in a drastic spike in TrkB T1 levels 
which acts as a dominant negative inhibitor to the full length isoform and 
sequesters RhoGDI1, activating RhoA, p38MAPK and stress signalling 




down-regulation of BDNF by miR-191 and up-regulation of pro-apoptotic 
proteins due to down-regulation of miR-22 could be contributing to the 
pathology of ischemia in neuron. Furthermore, miR-22 mimic proved to be a 





7.5 Conclusions and future studies 
In this study, non-coding RNAs regulating neuronal maturation and their 
alteration in ischemic injury that confers toxicity were studied. After having 
established a primary neuronal culture comprising pure post-mitotic neurons, 
expression profiling of maturing neurons and those subjected to ischemic 
insult was carried out. This identified 7 neuron-specific genes (Axin2, Prkcb, 
Cntn1, Ncam1, Negr1, Nrxn1 and Sh2b3), each regulated by a set of ncRNAs, 
to be crucial to neuronal pro-survival signaling and their dysregulation 
contributed to ischemic induced cell death. Of the 7 genes, Negr1 was 
followed-up to characterize the associated lncRNAs and miRNAs and 
determine their effects on gene expression as well as neuronal structure and 
function. Inhibition of miR-203, found to regulate Negr1, was also found to be 
neuroprotective in ischemic injury. Such molecular studies could be replicated 
for the remaining 6 genes to identify the ncRNA-gene pair that is the strongest 
determinant of neuronal survival as well as confer maximum neuroprotective 
potential during ischemia.   
 
Negr1 expression was found to be directly inhibited by miR-203 at the 
posttranscriptional level which could reduce neurite outgrowth. miR-203 was 
correlated to Negr1 mRNA expression and changes in neurite outgrowth. 
These studies can be complemented with measurements of synaptic markers 
such as synapsin I to enhance the functional validation and add further insight 
into the molecular nature of miR-203:Negr1-regulated morphological changes 





Inhibition of miR-203 could also confer neuroprotection to neurons during 
ischemia by up-regulation of the pro-survival, Negr1. The neuroprotective 
potential of miR-203 inhibition needs to be followed-up in human SH-SY5Y 
neuron-like cells as well as in animal models of stroke to determine if it can 
serve as a therapeutic molecule in stroke patients. 
 
Two bidirectional lncRNAs were also found to induce Negr1 transcription 
which was determined by knockdown as well as over-expression studies. It 
was speculated that lncRNA transcription promoted DNA hypomethylation 
and active histone signatures which allowed binding of the Sp1 transcription 
factor to activate transcription of Negr1. To validate this hypothesis, the DNA 
methylation status of the Negr1 bidirectional promoter needs to be determined 
using bisulfite sequencing analysis of the genomic DNA after Negr1 lncRNA 
knockdown or over-expression. The histone modification status at this loci 
also need to be determined by chromatin immunoprecipitation (ChIP) with 
H3K4m3 antibody using the neuronal nuclei. This could be followed by real 
time PCR amplication using promoter specific primers of the DNA purified 
from the bound fraction. Detection of Sp1 in the bound fraction by western 
blot could also elucidate the if Sp1 binding is involved in the bidirectional 
activity as postulated. 
 
This bidirectional function of the Negr1 promoter can be further validated by 
inserting the promoter directly upstream of the luciferase gene in the forward 
as well as reverse direction and determining the luciferase activity. The Sp1 




to determine the effects on gene expression which would further determine the 
importance of Sp1 in gene transcription. 
 
Although it was determined that lncRNA transcription mediated 
transcriptional activation of Negr1 in cis, the final location of the lncRNAs in 
the cell could point at other functions of the lncRNAs. For instance, nuclear 
localized lncRNAs could regulate gene expression at other loci in the nucleus 
by regulating chromatin-modifying complexes [107,164,367] and transcription 
factors [175]. A cytoplasmic location could point at posttranscriptional 
regulation such as regulation of mRNA stability and translation or acting as 
sponges for miRNAs [368]. The trans-acting effects of the lncRNAs can be 
determined by mRNA profiling of neurons in which the lncRNAs have been 
knocked-down or over-expressed.  
 
Unlike miRNAs which show high sequence conservation between species, 
only few lncRNAs show this characteristic. However, recent reports indicate 
some evolutionary constraint within lncRNA loci [369,370] which is not 
confined to conservation in sequence but could also encompass conservation 
in structure, function or expression. Determination of conservation in structure 
or other characteristics of the Negr1 lncRNAs or even promoter could help 
determine the human orthologues of these lncRNAs which could ultimately be 
characterized and used as neuroprotectants.  
 
Another neuroprotective miRNA was identified to be miR-22 which down-




This binding could effectively salvage primary neurons after exposure to 
ischemia injury. In addition to in vitro studies, the neuroprotective potential of 
miR-22 needs to be confirmed in human SH-SY5Y cells as well as in animal 
models of stroke. 
 
Other than miR-22 mediated regulation of TrkB T1 translation, miR-191 was 
found to act earlier in the cascade by favouring splicing towards the TrkB T1 
isoform. The mechanism of action of miR-191 on alternative exon inclusion 
can be determined by RNA-ChIP assay using PTB and U2AF antibodies 
followed by assaying for miR-191 and the intron-exon junction of interest in 
the bound fraction. Furthermore, studies on the minigene splicing assay can be 
carried further by combination constructs in which the PTB binding site has 
been mutated to determine the effects on splicing with miR-191 modulation. 
This would confirm the competitive binding between the two. The ability of 
reduced miR-191 expression to increase neuronal cell survival post-ischemia 
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